NCT Id,Brief Title,Official Title,Overall Status,Conditions,Interventions,Study First Post Date,Last Update Post Date,Phases,Study Type,sex,minimumAge,maximumAge
NCT04134260,Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer,Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Salvage Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*) *INtensifying Treatment for NOde Positive Prostate Cancer by VArying the Hormonal ThErapy,RECRUITING,Prostate Adenocarcinoma|Stage I Prostate Cancer AJCC v8|Stage II Prostate Cancer AJCC v8|Stage IIA Prostate Cancer AJCC v8|Stage IIB Prostate Cancer AJCC v8|Stage IIC Prostate Cancer AJCC v8|Stage III Prostate Cancer AJCC v8|Stage IIIA Prostate Cancer AJCC v8|Stage IIIB Prostate Cancer AJCC v8|Stage IIIC Prostate Cancer AJCC v8|Stage IVA Prostate Cancer AJCC v8,Drug: Hormone Therapy|Drug: Apalutamide,2019-10-22,2024-02-07,PHASE3,INTERVENTIONAL,MALE,18 Years,
NCT01142427,Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL),COMPLETED,Acute Lymphoblastic Leukemia,Other: Cytology Specimen Collection Procedure,2010-06-11,2023-10-03,,OBSERVATIONAL,ALL,,30 Years
NCT00898365,Study of Kidney Tumors in Younger Patients,"Renal Tumors Classification, Biology, and Banking Study",RECRUITING,Adult Cystic Nephroma|Anaplastic Kidney Wilms Tumor|Angiolipoma|Cellular Congenital Mesoblastic Nephroma|Classic Congenital Mesoblastic Nephroma|Clear Cell Sarcoma of the Kidney|Congenital Mesoblastic Nephroma|Cystic Partially Differentiated Kidney Nephroblastoma|Diffuse Hyperplastic Perilobar Nephroblastomatosis|Extrarenal Rhabdoid Tumor|Kidney Medullary Carcinoma|Kidney Neoplasm|Kidney Oncocytoma|Kidney Wilms Tumor|Metanephric Adenofibroma|Metanephric Adenoma|Metanephric Stromal Tumor|Metanephric Tumor|Mixed Congenital Mesoblastic Nephroma|Ossifying Renal Tumor of Infancy|Papillary Renal Cell Carcinoma|Renal Cell Carcinoma|Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions|Rhabdoid Tumor of the Kidney|Wilms Tumor,Other: Cytology Specimen Collection Procedure,2009-05-12,2024-08-09,,OBSERVATIONAL,ALL,,29 Years
NCT01119560,Genetic Susceptibility Biomarkers in Children With Neuroblastoma (Also Known as Neuroblastoma Epidemiology in North America [NENA]),Genetic Susceptibility Factors in the Etiology of Neuroblastoma Also Known as Neuroblastoma Epidemiology in North America (NENA),COMPLETED,Neuroblastoma,Other: Cytology Specimen Collection Procedure,2010-05-07,2019-01-08,,OBSERVATIONAL,ALL,,
NCT04917640,Registry for Accelerated Partial Breast Irradiation With (SBRT) or (IMRT),Accelerated Partial Breast Irradiation (PBI) With Stereotactic Body Radiation Therapy (SBRT) or Intensity Modulated Radiation Therapy (IMRT),WITHDRAWN,Breast Cancer,Radiation: Radiation Therapy|Radiation: Radiation Therapy,2021-06-08,2021-09-08,,OBSERVATIONAL,FEMALE,50 Years,100 Years
NCT00760266,Blood Pressure Lowering of Aliskiren HCTZ Compared to HCTZ in Stage 2 Systolic Hypertension in Older Population,"An 8-week Randomized, Double-blind, Parallel-group, Multi-center, Active-controlled Dose Escalation Study to Evaluate the Efficacy and Safety of Aliskiren HCTZ (300/25 mg) Compared to HCTZ (25 mg) in Older Patients With Stage 2 Systolic Hypertension",COMPLETED,Hypertension,Drug: Aliskiren|Drug: Hydrochlorothiazide,2008-09-26,2011-04-04,PHASE4,INTERVENTIONAL,ALL,55 Years,
NCT06015282,The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older,"A Phase 3, Randomized, Observer-Blind, Controlled, Multicenter, Clinical Study to Evaluate Immunogenicity and Safety of a MF59-Adjuvanted Quadrivalent Subunit Cell-derived Influenza Vaccine (aQIVc) in Comparison With Quadrivalent Influenza Vaccines, in Adults Aged 50 Years and Older.",ACTIVE_NOT_RECRUITING,"Influenza, Human",Biological: Investigational aQIVc|Biological: licensed QIV1|Biological: licensed QIV2,2023-08-29,2024-09-20,PHASE3,INTERVENTIONAL,ALL,50 Years,
NCT00942331,Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,"A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients With Advanced Transitional Cell Carcinoma",COMPLETED,Advanced Urothelial Carcinoma|Metastatic Bladder Urothelial Carcinoma|Metastatic Prostate Carcinoma|Metastatic Renal Pelvis Urothelial Carcinoma|Metastatic Ureter Urothelial Carcinoma|Metastatic Urethral Urothelial Carcinoma|Metastatic Urothelial Carcinoma|Stage IV Bladder Urothelial Carcinoma AJCC v7|Stage IV Prostate Cancer AJCC v7|Stage IV Renal Pelvis Cancer AJCC v7|Stage IV Ureter Cancer AJCC v7|Stage IV Urethral Cancer AJCC v7|Unresectable Urothelial Carcinoma,Drug: Cisplatin|Biological: Bevacizumab,2009-07-20,2023-10-16,PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT03375320,Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors,"Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)",ACTIVE_NOT_RECRUITING,Carcinoid Tumor|Functioning Pancreatic Neuroendocrine Tumor|Intermediate Grade Lung Neuroendocrine Neoplasm|Locally Advanced Digestive System Neuroendocrine Neoplasm|Locally Advanced Digestive System Neuroendocrine Tumor G1|Locally Advanced Lung Neuroendocrine Neoplasm|Locally Advanced Pancreatic Neuroendocrine Tumor|Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm|Low Grade Lung Neuroendocrine Neoplasm|Lung Neuroendocrine Tumor|Lung Neuroendocrine Tumor G2|Metastatic Digestive System Neuroendocrine Neoplasm|Metastatic Digestive System Neuroendocrine Tumor G1|Metastatic Lung Neuroendocrine Neoplasm|Metastatic Lung Neuroendocrine Tumor|Metastatic Pancreatic Neuroendocrine Neoplasm|Metastatic Pancreatic Neuroendocrine Tumor|Metastatic Thymic Neuroendocrine Neoplasm|Neuroendocrine Neoplasm|Neuroendocrine Tumor G2|Non-Functioning Pancreatic Neuroendocrine Tumor|Pancreatic Serotonin-Producing Neuroendocrine Tumor|Thymic Neuroendocrine Tumor|Unresectable Digestive System Neuroendocrine Neoplasm|Unresectable Digestive System Neuroendocrine Tumor G1|Unresectable Lung Neuroendocrine Neoplasm|Unresectable Pancreatic Neuroendocrine Neoplasm|Unresectable Thymic Neuroendocrine Neoplasm,Drug: Cabozantinib S-malate|Procedure: Computed Tomography,2017-12-18,2024-07-03,PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT04540120,Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome,"A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Orally Administered Dapansutrile Capsules for the Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome",TERMINATED,Covid19|Cytokine Release Syndrome,Drug: dapansutrile capsules|Drug: placebo capsules,2020-09-07,2023-04-13,PHASE2,INTERVENTIONAL,ALL,18 Years,
NCT02933866,Phase III Clinical Study in Patients With Mild to Severe Scalp Psoriasis,"A Randomized, Double-Blind, Vehicle-Controlled, Parallel-Design, Multiple-Site, Phase III Clinical Study to Evaluate the Efficacy and Safety of DSXS Topical Product in Patients With Mild to Severe Scalp Psoriasis",COMPLETED,Scalp Psoriasis,Drug: DSXS topical|Drug: Vehicle topical,2016-10-14,2018-12-06,PHASE3,INTERVENTIONAL,ALL,18 Years,65 Years
NCT03058666,Comparison of Aerosol Delivery of Infasurf to Usual Care in Spontaneously Breathing RDS Patients,Comparison of Aerosol Delivery of Infasurf to Usual Care in Spontaneously Breathing RDS Patients,COMPLETED,Respiratory Distress Syndrome,Drug: Aerosolized Calfactant|,2017-02-23,2024-05-29,PHASE3,INTERVENTIONAL,ALL,1 Hour,24 Hours
NCT03997266,NICU Antibiotics and Outcomes Trial,NICU Antibiotics and Outcomes Trial,RECRUITING,Microbial Colonization|Extreme Prematurity|Early-Onset Neonatal Sepsis|Late-Onset Neonatal Sepsis|Necrotizing Enterocolitis of Newborn|Death; Neonatal,Drug: Ampicillin|Drug: Normal saline,2019-06-25,2024-01-17,PHASE4,INTERVENTIONAL,ALL,,4 Hours
NCT05040360,Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors,Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors,RECRUITING,Metastatic Malignant Neoplasm in the Liver|Pancreatic Neuroendocrine Tumor|Stage I Pancreatic Neuroendocrine Tumor AJCC v8|Stage II Pancreatic Neuroendocrine Tumor AJCC v8|Stage III Pancreatic Neuroendocrine Tumor AJCC v8,Drug: Capecitabine|,2021-09-10,2024-08-16,PHASE2,INTERVENTIONAL,ALL,18 Years,
NCT03936660,A 12 Month Site Randomized Trial in Adults With Type 2 Diabetes Mellitus and History of Cardiovascular Disease,COOrdinating CaRDIology CliNics RAndomized Trial of Interventions to Improve OutcomEs (COORDINATE) - Diabetes,ACTIVE_NOT_RECRUITING,"Diabetes Mellitus, Type 2|Cardiovascular Diseases",|Other: Intense Education Intervention,2019-05-03,2023-01-20,NA,INTERVENTIONAL,ALL,18 Years,
NCT04527991,Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread,A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Subjects With Metastatic or Locally Advanced Unresectable Urothelial Cancer,ACTIVE_NOT_RECRUITING,Locally Advanced or Metastatic Unresectable Urothelial Cancer,Drug: Sacituzumab Govitecan-hziy|Drug: Paclitaxel,2020-08-27,2024-09-20,PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT06178991,"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.","A PHASE 3, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID-19 AND INFLUENZA IN HEALTHY INDIVIDUALS",ACTIVE_NOT_RECRUITING,Influenza|COVID-19,Biological: Influenza and COVID-19 Combination A|Biological: Licensed influenza vaccine|Biological: Influenza and COVID-19 Combination B|Biological: Licensed influenza vaccine|Biological: Influenza and COVID-19 Combination B|Biological: COVID-19 Vaccine|Biological: Licensed influenza vaccine|Biological: Investigational influenza vaccine,2023-12-21,2024-08-23,PHASE3,INTERVENTIONAL,ALL,18 Years,64 Years
NCT04214262,Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer,"A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC",ACTIVE_NOT_RECRUITING,Lung Non-Small Cell Carcinoma|Stage I Lung Cancer AJCC v8|Stage II Lung Cancer AJCC v8,Drug: Atezolizumab|Procedure: Biospecimen Collection,2020-01-02,2024-09-19,PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT05235165,Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma,A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma,RECRUITING,Metastatic Malignant Neoplasm in the Lung|Metastatic Osteosarcoma|Osteosarcoma,Procedure: Biospecimen Collection|Procedure: Biospecimen Collection,2022-02-11,2024-09-23,PHASE3,INTERVENTIONAL,ALL,,50 Years
NCT03701282,Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia,A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL),ACTIVE_NOT_RECRUITING,Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma,Procedure: Biospecimen Collection|Procedure: Biospecimen Collection,2018-10-10,2024-09-26,PHASE3,INTERVENTIONAL,ALL,18 Years,69 Years
NCT02193282,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC),ACTIVE_NOT_RECRUITING,Lung Non-Squamous Non-Small Cell Carcinoma|Stage IB Lung Non-Small Cell Carcinoma AJCC v7|Stage II Lung Non-Small Cell Cancer AJCC v7|Stage IIA Lung Non-Small Cell Carcinoma AJCC v7|Stage IIB Lung Non-Small Cell Carcinoma AJCC v7|Stage IIIA Lung Non-Small Cell Cancer AJCC v7,Drug: Erlotinib Hydrochloride|Other: Laboratory Biomarker Analysis|Drug: Erlotinib Hydrochloride|Other: Clinical Observation,2014-07-17,2024-09-26,PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT03954574,Pulmonary Hemodynamics During Exercise - Research Network,Pulmonary Hemodynamics During Exercise - Research Network,RECRUITING,Pulmonary Circulation Diseases,Diagnostic Test: assessment of pulmonary hemodynamics during exercise by right heart catheterization|Diagnostic Test: assessment of pulmonary hemodynamics during exercise by right heart catheterization,2019-05-17,2024-01-03,,OBSERVATIONAL,ALL,18 Years,
NCT05647265,Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma,Official Title Neoadjuvant Immunotherapy in Sarcomatoid Mesothelioma,RECRUITING,Pleural Biphasic Mesothelioma|Pleural Sarcomatoid Mesothelioma,Biological: Nivolumab,2022-12-12,2024-05-23,PHASE2,INTERVENTIONAL,ALL,18 Years,
NCT00824720,Safety and Efficacy of a Glaucoma Drug Delivery System,,COMPLETED,"Glaucoma, Open-Angle|Ocular Hypertension",Drug: High Dose Device|Drug: Low Dose Device|Device: Placebo Device,2009-01-19,2015-03-06,PHASE2,INTERVENTIONAL,ALL,21 Years,
NCT03996265,Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors,Randomized Placebo-Controlled Trial of Bupropion for Cancer Related Fatigue,RECRUITING,Be Diagnosed With Cancer and Have Completed Systemic Therapy,Drug: Bupropion Hydrochloride Controlled-release|Other: Placebo Administration,2019-06-24,2024-04-23,PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT02595073,Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Moderate to Severe Atopic Dermatitis.",COMPLETED,Atopic Dermatitis,Drug: DSXS|Drug: Placebo,2015-11-03,2018-12-07,PHASE3,INTERVENTIONAL,ALL,6 Months,
NCT05705531,A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma,Assessment of Clonal Hematopoiesis and Its Relationship to Cardiovascular Disease in Hodgkin Lymphoma Survivors,RECRUITING,Cardiovascular Disorder|Clonal Hematopoiesis|Hodgkin Lymphoma,Procedure: Biospecimen Collection,2023-01-30,2024-09-23,,OBSERVATIONAL,ALL,7 Years,40 Years
NCT05642182,Study of SFA002 in Patients With Mild to Moderate Psoriasis Plaques,A Study of Improvement in Psoriasis Symptoms Associated With Combinations of Biologically Active Natural Substances (SFA-002) With Known Safety Profile,RECRUITING,Psoriasis,"Drug: Drug (SFA002) Vitamin D, Magnesium|Drug: Drug (SFA002) Vitamin D, Magnesium and Propionate",2022-12-08,2024-05-21,PHASE1,INTERVENTIONAL,ALL,18 Years,
NCT04725682,Bioequivalence Study of Tacrolimus in Healthy Volunteers,"A Single Dose, Open-Label, Randomized, Four-Way Crossover, Fully Replicate, Bioequivalence Study of Generic Tacrolimus and Prograf® Capsules in Healthy Volunteers Under Fasting Conditions",COMPLETED,Healthy Volunteers,Drug: Tacrolimus|Drug: Tacrolimus,2021-01-27,2023-09-21,PHASE1,INTERVENTIONAL,ALL,18 Years,59 Years
NCT03866382,Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors,"A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)",RECRUITING,Bladder Adenocarcinoma|Bladder Clear Cell Adenocarcinoma|Bladder Mixed Adenocarcinoma|Bladder Neuroendocrine Carcinoma|Bladder Small Cell Neuroendocrine Carcinoma|Bladder Squamous Cell Carcinoma|Chromophobe Renal Cell Carcinoma|Collecting Duct Carcinoma|Invasive Bladder Giant Cell Urothelial Carcinoma|Invasive Bladder Lymphoepithelioma-Like Carcinoma|Invasive Bladder Nested Urothelial Carcinoma|Invasive Bladder Plasmacytoid Urothelial Carcinoma|Invasive Bladder Sarcomatoid Urothelial Carcinoma|Invasive Bladder Urothelial Carcinoma|Kidney Medullary Carcinoma|Large Cell Neuroendocrine Carcinoma|Malignant Testicular Leydig Cell Tumor|Malignant Testicular Sertoli Cell Tumor|Metastatic Bladder Carcinoma|Metastatic Bladder Clear Cell (Glycogen-Rich) Urothelial Carcinoma|Metastatic Bladder Giant Cell Urothelial Carcinoma|Metastatic Bladder Large Cell Neuroendocrine Carcinoma|Metastatic Bladder Lipid-Rich Urothelial Carcinoma|Metastatic Bladder Micropapillary Urothelial Carcinoma|Metastatic Bladder Plasmacytoid Urothelial Carcinoma|Metastatic Bladder Sarcomatoid Urothelial Carcinoma|Metastatic Bladder Small Cell Neuroendocrine Carcinoma|Metastatic Bladder Squamous Cell Carcinoma|Metastatic Chromophobe Renal Cell Carcinoma|Metastatic Kidney Medullary Carcinoma|Metastatic Malignant Genitourinary System Neoplasm|Metastatic Papillary Renal Cell Carcinoma|Metastatic Penile Carcinoma|Metastatic Prostate Small Cell Neuroendocrine Carcinoma|Metastatic Sarcomatoid Renal Cell Carcinoma|Metastatic Urethral Carcinoma|Papillary Renal Cell Carcinoma|Sarcomatoid Renal Cell Carcinoma|Stage IV Bladder Cancer AJCC v8|Stage IV Penile Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8|Stage IV Urethral Cancer AJCC v8|Stage IVB Prostate Cancer AJCC v8|Urachal Adenocarcinoma|Urethral Clear Cell Adenocarcinoma,Procedure: Bone Scan,2019-03-07,2024-09-26,PHASE2,INTERVENTIONAL,ALL,18 Years,
NCT00812565,Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's Disease,"Prospective 24-week, Double-blind, Randomised, Placebo-controlled, Multicenter Study Evaluating Safety and Change in Efficacy-related Surrogate Parameters in Patients With Dementia of the Alzheimer's Type Under Treatment With Increasing Dosages of Intravenous Immunoglobulin (Octagam 10%)",COMPLETED,Alzheimer's Disease,Drug: Placebo|Biological: octagam 10%|Biological: octagam 10%|Biological: octagam 10%|Drug: Placebo|Biological: octagam 10%|Biological: octagam 10%|Biological: octagam 10%,2008-12-22,2014-05-05,PHASE2,INTERVENTIONAL,ALL,50 Years,85 Years
NCT01298648,Special Investigation in Patients With Crohn's Disease (All Patients Investigation),Special Investigation (All Cases Investigation in Patients With Crohn's Disease),COMPLETED,Crohn's Disease,,2011-02-18,2018-07-02,,OBSERVATIONAL,ALL,16 Years,99 Years
NCT01575548,Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery,"Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy",ACTIVE_NOT_RECRUITING,Clear Cell Renal Cell Carcinoma|Stage IV Renal Cell Cancer AJCC v7,Procedure: Computed Tomography|Procedure: Computed Tomography,2012-04-11,2024-08-16,PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT04071457,"S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration","S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients With Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)",RECRUITING,Multiple Myeloma,|Drug: Lenalidomide|Drug: Lenalidomide|Drug: Lenalidomide||Drug: Lenalidomide|,2019-08-28,2024-08-23,PHASE3,INTERVENTIONAL,ALL,18 Years,75 Years
NCT04267848,"Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial",Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO),RECRUITING,Lung Non-Small Cell Carcinoma|Lung Non-Small Cell Squamous Carcinoma|Lung Non-Squamous Non-Small Cell Carcinoma|Stage II Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8,Procedure: Biospecimen Collection|Procedure: Biospecimen Collection|Procedure: Biospecimen Collection,2020-02-13,2024-09-27,PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT05641857,Lumbar Spine on MRI and Low Back Pain in Elite Cross-country Skiers,Lumbar Spine on MRI and Low Back Pain in Elite Cross-country Skiers,COMPLETED,Disc Degeneration,|,2022-12-08,2023-11-02,,OBSERVATIONAL,ALL,16 Years,35 Years
NCT05879926,"Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25","A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET)",RECRUITING,Breast Cancer,Drug: Ovarian Function Suppression + Aromatase Inhibitor|Drug: Ovarian Function Suppression + Aromatase Inhibitor,2023-05-30,2024-09-04,PHASE3,INTERVENTIONAL,FEMALE,18 Years,60 Years
NCT01751126,Double-Masked Trial of NOVA22007 (1mg/mL Ciclosporin/Cyclosporine) Versus Vehicle in Pediatric Patients With Active Severe Vernal Keratoconjunctivitis,"A Multicenter, Randomized, Double-Masked, 3 Parallel Arms, Placebo Controlled Study to Assess the Efficacy and Safety of NOVA22007 1mg/mL (Ciclosporin/Cyclosporine) Eye Drops, Emulsion Administered in Paediatric Patients With Active Severe Vernal Keratoconjunctivitis With Severe Keratitis",COMPLETED,Vernal Keratoconjunctivitis,Drug: NOVA22007 ''Ciclosporin''|Drug: NOVA22007 ''Ciclosporin''|Drug: Placebo,2012-12-17,2022-03-28,PHASE3,INTERVENTIONAL,ALL,4 Years,18 Years
NCT03660826,"Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone","A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer.: A Platform Trial for Women With Recurrent or Persistent Endometrial Cancer",ACTIVE_NOT_RECRUITING,Endometrial Adenocarcinoma|Endometrial Mixed Cell Adenocarcinoma|Endometrial Serous Adenocarcinoma|Endometrial Undifferentiated Carcinoma|Endometrioid Adenocarcinoma|Stage IV Uterine Corpus Cancer AJCC v8,Procedure: Biospecimen Collection|Procedure: Biospecimen Collection|Procedure: Biospecimen Collection|Procedure: Biospecimen Collection|Procedure: Biospecimen Collection|Procedure: Biospecimen Collection,2018-09-07,2024-09-26,PHASE2,INTERVENTIONAL,FEMALE,18 Years,
NCT01190930,Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma,Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy),ACTIVE_NOT_RECRUITING,Acute Lymphoblastic Leukemia|Adult B Lymphoblastic Lymphoma|Ann Arbor Stage I B Lymphoblastic Lymphoma|Ann Arbor Stage II B Lymphoblastic Lymphoma|Childhood B Acute Lymphoblastic Leukemia|Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|Childhood B Lymphoblastic Lymphoma|Down Syndrome|Hypodiploid B Acute Lymphoblastic Leukemia|Philadelphia Chromosome Positive,Drug: Dexamethasone|Drug: Dexamethasone|Drug: Cyclophosphamide|Drug: Dexamethasone|Drug: Dexamethasone|Drug: Cyclophosphamide|Drug: Dexamethasone|Drug: Cyclophosphamide,2010-08-30,2024-02-08,PHASE3,INTERVENTIONAL,ALL,1 Year,30 Years
NCT03588130,A Study to Evaluate the Safety and the Efficacy of EscharEx (EX-02 Formulation) in Debridement of Venous Leg Ulcers,"A Multicenter , Prospective, Randomized, Placebo Controlled, Adaptive Design Study Performed to Evaluate the Safety and the Efficacy of EscharEx (EX-02 Formulation) in Debridement of Venous Leg Ulcers",COMPLETED,Venous Leg Ulcer,Drug: EscharEx (5% EX-02 formulation)|Drug: Gel Vehicle|Drug: Non-surgical standard of care (NSSOC),2018-07-17,2022-11-14,PHASE2,INTERVENTIONAL,ALL,18 Years,90 Years
NCT00206830,SHORTness of Breath In the Emergency Department (SHORTIE),SHORTness of Breath In the Emergency Department (SHORTIE),COMPLETED,Acute Myocardial Infarction|Heart Failure|Pulmonary Embolism,|Device: Triage Profiler S.O.B. Panel,2005-09-21,2015-07-27,PHASE2|PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT03793166,"Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study",PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE],ACTIVE_NOT_RECRUITING,Clear Cell Renal Cell Carcinoma|Metastatic Malignant Neoplasm in the Bone|Metastatic Malignant Neoplasm in the Lymph Nodes|Metastatic Malignant Neoplasm in the Soft Tissues|Metastatic Malignant Neoplasm in the Viscera|Sarcomatoid Renal Cell Carcinoma|Stage III Renal Cell Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8,Procedure: Biospecimen Collection|Procedure: Biospecimen Collection,2019-01-04,2024-09-26,PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT05805826,To Understand the Safety and Effects of a C. Difficile Vaccine With New Adds-Ons That Will Be Given to Healthy Adults,"A PHASE 1/2 RANDOMIZED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED WITH NOVEL ADJUVANTS IN HEALTHY ADULTS",ACTIVE_NOT_RECRUITING,Clostridoides Difficile Associated Disease,Biological: C. difficile vaccine formulation 1.|Biological: C. difficile vaccine formulation 2.|Biological: C. difficile vaccine formulation 3.|Other: Saline Placebo.|Biological: C. difficile vaccine formulation 2.|Biological: C. difficile vaccine formulation 3.|Biological: C. difficile vaccine (previously studied formulation).|Biological: C. difficile vaccine formulation 2.|Biological: C. difficile vaccine formulation 2.|Biological: C. difficile vaccine formulation 2.|Biological: C. difficile vaccine formulation 2.|Biological: C. difficile vaccine (previously studied formulation).|Biological: C. difficile vaccine formulation 2.,2023-04-10,2024-09-25,PHASE1|PHASE2,INTERVENTIONAL,ALL,65 Years,
NCT04233866,"Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread","A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients With Treatment Naïve Metastatic Pancreatic Cancer (GIANT)",ACTIVE_NOT_RECRUITING,Metastatic Pancreatic Adenocarcinoma|Stage IV Pancreatic Cancer AJCC v8,Drug: Gemcitabine|Drug: Fluorouracil,2020-01-18,2023-12-28,PHASE2,INTERVENTIONAL,ALL,70 Years,
NCT04985630,The Mitopure Challenge to Detect Levels of Urolithin A in Dried Blood Spots,Open-labelled Study to Validate Home-based Use of a Health and Wellness Kit (The Mitopure Challenge) to Detect Levels of Urolithin A in Dried Blood Spots After Intake of Mitopure (Proprietary Urolithin A),RECRUITING,Healthy Aging|Healthy|Healthy Diet,Dietary Supplement: Mitopure,2021-08-02,2024-08-06,NA,INTERVENTIONAL,ALL,18 Years,80 Years
NCT05540522,A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older,"A PHASE 3, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER",COMPLETED,"Influenza, Human",Biological: Quadrivalent influenza modRNA vaccine|Biological: Quadrivalent influenza vaccine|Biological: Quadrivalent influenza modRNA vaccine|Biological: Quadrivalent influenza vaccine,2022-09-14,2024-04-03,PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT04821622,Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC,"TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER",ACTIVE_NOT_RECRUITING,Prostate Cancer,Drug: talazoparib plus enzalutamide|Drug: Placebo plus enzalutamide,2021-03-29,2024-09-19,PHASE3,INTERVENTIONAL,MALE,18 Years,
NCT05245422,Acceptance of a Partially Hydrolyzed Formula,Parent And Infant Relief (PAIR): Acceptance of a Partially Hydrolyzed Formula,COMPLETED,Fussy Infant (Baby),Other: Infant Formula - Intact protein|Other: Infant Formula - Partially hydrolyzed protein,2022-02-18,2023-07-27,NA,INTERVENTIONAL,ALL,15 Days,75 Days
NCT03422822,Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis,"A PHASE 3 MULTI-CENTER, LONG-TERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB, WITH OR WITHOUT TOPICAL MEDICATIONS, ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS",ACTIVE_NOT_RECRUITING,"Dermatitis, Atopic",Drug: Abrocitinib 100 mg|Drug: Abrocitinib 200 mg,2018-02-06,2024-08-09,PHASE3,INTERVENTIONAL,ALL,12 Years,
NCT05128825,"A Study of ZN-c3 in Subjects With High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer","A Phase 2 Open-Label, Multicenter Study To Evaluate Efficacy And Safety Of ZN-c3 In Subjects With High-Grade Serous Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer (ZN-c3-005/GOG-3066/DENALI)",ACTIVE_NOT_RECRUITING,"High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer",Drug: ZN-c3,2021-11-22,2024-06-25,PHASE2,INTERVENTIONAL,ALL,18 Years,
NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754),ACTIVE_NOT_RECRUITING,Alveolar Soft Part Sarcoma|Angiomatoid Fibrous Histiocytoma|Atypical Fibroxanthoma|Clear Cell Sarcoma of Soft Tissue|Epithelioid Malignant Peripheral Nerve Sheath Tumor|Epithelioid Sarcoma|Extraskeletal Myxoid Chondrosarcoma|Extraskeletal Osteosarcoma|Fibrohistiocytic Neoplasm|Fibrosarcoma|Inflammatory Myofibroblastic Tumor|Intimal Sarcoma|Leiomyosarcoma|Liposarcoma|Liver Embryonal Sarcoma|Low Grade Fibromyxoid Sarcoma|Low Grade Myofibroblastic Sarcoma|Malignant Peripheral Nerve Sheath Tumor|Malignant Skin Granular Cell Tumor|Malignant Triton Tumor|Mesenchymal Chondrosarcoma|Myxofibrosarcoma|Myxoid Chondrosarcoma|Myxoinflammatory Fibroblastic Sarcoma|Nerve Sheath Neoplasm|PEComa|Pericytic Neoplasm|Plexiform Fibrohistiocytic Tumor|Sclerosing Epithelioid Fibrosarcoma|Skin Glomus Tumor|Stage IB Soft Tissue Sarcoma AJCC v7|Stage IIB Soft Tissue Sarcoma AJCC v7|Stage III Soft Tissue Sarcoma AJCC v7|Stage IV Soft Tissue Sarcoma AJCC v7|Synovial Sarcoma|Undifferentiated High Grade Pleomorphic Sarcoma of Bone,Drug: Doxorubicin|Drug: Doxorubicin|Drug: Pazopanib|Radiation: Radiation Therapy,2014-07-03,2024-09-26,PHASE2|PHASE3,INTERVENTIONAL,ALL,2 Years,
NCT04214067,"Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer",A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer,ACTIVE_NOT_RECRUITING,Endometrial Endometrioid Adenocarcinoma|Stage I Uterine Corpus Cancer AJCC v8|Stage II Uterine Corpus Cancer AJCC v8,Procedure: Biospecimen Collection|Procedure: Biospecimen Collection,2019-12-30,2024-08-06,PHASE3,INTERVENTIONAL,FEMALE,18 Years,
NCT00887146,Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma,Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma,ACTIVE_NOT_RECRUITING,Brain and Central Nervous System Tumors,Radiation: radiotherapy|Drug: concomitant temozolomide (TMZ),2009-04-23,2024-08-02,PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT01901094,Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy,A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy,ACTIVE_NOT_RECRUITING,Stage II Breast Cancer|Stage IIIA Breast Cancer,Procedure: Axillary Lymph Node Dissection (ALND)|Radiation: Nodal Radiation Therapy,2013-07-17,2024-02-26,PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT00927394,Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus,"An 8 Week Randomized, Double-Blind, Parallel Group, Multi-Center, Active Controlled Study to Evaluate the Antihypertensive Efficacy and Safety of Aliskiren Administered in Combination With Valsartan Versus Valsartan Alone in Patients With Stage 2 Systolic Hypertension and Type 2 Diabetes Mellitus",COMPLETED,Hypertension,Drug: Aliskiren|Drug: Valsartan,2009-06-25,2012-12-06,PHASE4,INTERVENTIONAL,ALL,18 Years,
NCT05552976,A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2),"A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-2",RECRUITING,Relapsed or Refractory Multiple Myeloma,Drug: Mezigdomide|Drug: Carfilzomib,2022-09-23,2024-09-23,PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT04593927,Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients,Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients (Prevention of Relapses and Delay of Progression of Physical Disability in Secondary Progressive Multiple Sclerosis),COMPLETED,Secondary Progressive Multiple Sclerosis (SPMS),Drug: Mayzent,2020-10-20,2024-02-12,,OBSERVATIONAL,ALL,,99 Years
NCT06267560,Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD,"A Randomized Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Pelacarsen (TQJ230) in US Black/African American & Hispanic Patient Populations With Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease",RECRUITING,Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease,Drug: TQJ230|Drug: Placebo,2024-02-20,2024-08-09,PHASE3,INTERVENTIONAL,ALL,18 Years,80 Years
NCT00980460,Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer,Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment,ACTIVE_NOT_RECRUITING,PRETEXT I Hepatoblastoma|PRETEXT II Hepatoblastoma|PRETEXT III Hepatoblastoma|PRETEXT IV Hepatoblastoma,Drug: Cisplatin|Drug: Cisplatin|Drug: Cisplatin|Drug: Cisplatin|Other: Laboratory Biomarker Analysis,2009-09-21,2024-08-06,PHASE3,INTERVENTIONAL,ALL,,21 Years
NCT01975376,The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,"Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.",TERMINATED,Cardiovascular Disease,Drug: bococizumab (PF-04950615)|Drug: Placebo,2013-11-03,2018-07-11,PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT02437201,Study of Liberty Program on Women's Health and Intimate Partner Violence,"Study of Liberty Program on Women's Health and Intimate Partner Violence: Multinational, Open, Randomised, Controlled Clinical Study",UNKNOWN,Violence Against Women,Behavioral: Liberty Program|,2015-05-07,2015-09-29,NA,INTERVENTIONAL,FEMALE,18 Years,60 Years
NCT01838512,Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE),Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE),RECRUITING,Multiple Myeloma,|,2013-04-24,2024-08-09,,OBSERVATIONAL,ALL,18 Years,
NCT04828681,Angio-IMR and Cardiac MR-derived MVO in STEMI Patients,Functional Coronary Angiography-Derived Index of Microcirculatory Resistance and Microvascular Obstruction in Cardiac Magnetic Resonance Imaging After ST-segment Elevation Myocardial Infarction,UNKNOWN,ST-segment Elevation Myocardial Infarction (STEMI),Diagnostic Test: Cardiac magnetic resonance imaging|Diagnostic Test: Cardiac magnetic resonance imaging,2021-04-02,2022-09-08,,OBSERVATIONAL,ALL,,
NCT06118281,ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack,ARTEMIS - Effects of Ziltivekimab Versus Placebo on Cardiovascular Outcomes in Patients With Acute Myocardial Infarction,NOT_YET_RECRUITING,Cardiovascular Risk|Acute Myocardial Infarction (AMI),Drug: Ziltivekimab|Drug: Placebo,2023-11-07,2024-04-02,PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT05675410,"A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab",A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy With Immuno-oncology Therapy for Children and Adults With Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma,RECRUITING,Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8,Procedure: Biospecimen Collection|Procedure: Biospecimen Collection|Procedure: Biospecimen Collection|Procedure: Biospecimen Collection|Procedure: Biospecimen Collection|Procedure: Biospecimen Collection|Procedure: Biospecimen Collection|Procedure: Biospecimen Collection,2023-01-09,2024-09-25,PHASE3,INTERVENTIONAL,ALL,5 Years,60 Years
NCT03908229,Trainee Participation Increases Colon Adenoma Detection Rate,Trainee Participation Increases Colon Adenoma Detection Rate: a Randomized Controlled Trial,COMPLETED,Colonic Polyp,Procedure: Trainee colonoscopy|Procedure: Experienced physician colonoscopy,2019-04-09,2020-03-03,NA,INTERVENTIONAL,ALL,18 Years,
NCT05602194,Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma,A Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents and Young Adults Receiving Acute Lymphoblastic Leukemia Therapy,RECRUITING,"B Acute Lymphoblastic Leukemia|B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|B Acute Lymphoblastic Leukemia, BCR-ABL1-Like|Lymphoblastic Lymphoma|Mixed Phenotype Acute Leukemia|T Acute Lymphoblastic Leukemia",Procedure: Biospecimen Collection|Procedure: Biospecimen Collection|Dietary Supplement: Levocarnitine,2022-11-02,2024-09-23,PHASE3,INTERVENTIONAL,ALL,15 Years,40 Years
NCT00435162,Dose Response of Valsartan on Sitting Systolic Blood Pressure in Children 6 Months - 5 Years of Age With High Blood Pressure,"A Randomized, Multicenter, Double-blind, 6 Week Study to Evaluate the Dose Response of Valsartan on Blood Pressure Reduction in Children 6 Months - 5 Years Old With Hypertension, Followed by a 2 Week Placebo Withdrawal Period.",COMPLETED,Hypertension,Drug: Valsartan 0.25 mg/kg|Drug: Valsartan 1.0 mg/kg|Drug: Valsartan 4.0 mg/kg,2007-02-14,2011-05-09,PHASE3,INTERVENTIONAL,ALL,6 Months,5 Years
NCT03604991,Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery,A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma,SUSPENDED,Clinical Stage II Esophageal Adenocarcinoma AJCC v8|Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage III Esophageal Adenocarcinoma AJCC v8|Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8|Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Esophageal Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma,Procedure: Biospecimen Collection|Procedure: Biospecimen Collection|Procedure: Biospecimen Collection|Procedure: Biospecimen Collection,2018-07-30,2024-09-19,PHASE2|PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT04293562,A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations,"A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations",ACTIVE_NOT_RECRUITING,Acute Myeloid Leukemia,Procedure: Allogeneic Hematopoietic Stem Cell Transplantation|Drug: Asparaginase|Drug: Asparaginase|Procedure: Allogeneic Hematopoietic Stem Cell Transplantation|Drug: Asparaginase|Procedure: Allogeneic Hematopoietic Stem Cell Transplantation|Drug: Asparaginase|Procedure: Allogeneic Hematopoietic Stem Cell Transplantation|Drug: Asparaginase|Drug: Asparaginase|Procedure: Allogeneic Hematopoietic Stem Cell Transplantation|Drug: Asparaginase|Procedure: Allogeneic Hematopoietic Stem Cell Transplantation|Drug: Asparaginase,2020-03-03,2024-09-23,PHASE3,INTERVENTIONAL,ALL,,21 Years
NCT05050162,Comparing High-Dose Cisplatin Every Three Weeks to Low-Dose Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer,Randomized Phase II/III Trial of Radiation With High-Dose Cisplatin (100 mg/m2) Every Three Weeks Versus Radiation With Low-Dose Weekly Cisplatin (40 mg/m2) for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN),RECRUITING,Advanced Head and Neck Squamous Cell Carcinoma|Advanced Hypopharyngeal Squamous Cell Carcinoma|Advanced Laryngeal Squamous Cell Carcinoma|Advanced Oropharyngeal Squamous Cell Carcinoma|Squamous Cell Carcinoma of Unknown Primary,Drug: Cisplatin|Drug: Cisplatin|Drug: Cisplatin|Drug: Cisplatin,2021-09-20,2024-02-07,PHASE2|PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT00741260,Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer,"A Phase 1/2, Open-Label Study Of Neratinib (HKI-272) In Combination With Capecitabine In Subjects With Solid Tumors And ErbB-2 Positive Metastatic Or Locally Advanced Breast Cancer",COMPLETED,Breast Cancer,Drug: Neratinib|Drug: Neratinib|Drug: Neratinib|Drug: Neratinib|Drug: Neratinib|Drug: Neratinib|Drug: Neratinib,2008-08-26,2018-09-05,PHASE1|PHASE2,INTERVENTIONAL,ALL,18 Years,
NCT03737994,Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer,A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol,ACTIVE_NOT_RECRUITING,Lung Non-Squamous Non-Small Cell Carcinoma|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8,Drug: Crizotinib|Drug: Alectinib|Drug: Lorlatinib|Drug: Alectinib|Drug: Brigatinib|Drug: Brigatinib|Drug: Alectinib|Drug: Crizotinib|Drug: Alectinib|Drug: Brigatinib,2018-11-13,2024-08-16,PHASE2,INTERVENTIONAL,ALL,18 Years,
NCT03033576,Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma,A Phase II Randomized Study of Nivolumab (NSC-748726) With Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent,ACTIVE_NOT_RECRUITING,Clinical Stage III Cutaneous Melanoma AJCC v8|Clinical Stage IV Cutaneous Melanoma AJCC v8|Melanoma of Unknown Primary|Mucosal Melanoma|Unresectable Cutaneous Melanoma|Unresectable Melanoma,Biological: Ipilimumab|Biological: Ipilimumab,2017-01-27,2024-09-26,PHASE2,INTERVENTIONAL,ALL,18 Years,
NCT02465060,"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",Molecular Analysis for Therapy Choice (MATCH),ACTIVE_NOT_RECRUITING,Advanced Lymphoma|Advanced Malignant Solid Neoplasm|Bladder Carcinoma|Breast Carcinoma|Cervical Carcinoma|Colon Carcinoma|Colorectal Carcinoma|Endometrial Carcinoma|Esophageal Carcinoma|Exocrine Pancreas Carcinoma|Gastric Carcinoma|Glioma|Head and Neck Carcinoma|Hematopoietic and Lymphoid Cell Neoplasm|Kidney Carcinoma|Liver Carcinoma|Lung Carcinoma|Lymphoma|Malignant Uterine Neoplasm|Melanoma|Multiple Myeloma|Ovarian Carcinoma|Prostate Carcinoma|Rectal Carcinoma|Recurrent Bladder Carcinoma|Recurrent Breast Carcinoma|Recurrent Cervical Carcinoma|Recurrent Colon Carcinoma|Recurrent Colorectal Carcinoma|Recurrent Esophageal Carcinoma|Recurrent Gastric Carcinoma|Recurrent Glioma|Recurrent Head and Neck Carcinoma|Recurrent Liver Carcinoma|Recurrent Lung Carcinoma|Recurrent Lymphoma|Recurrent Malignant Solid Neoplasm|Recurrent Melanoma|Recurrent Multiple Myeloma|Recurrent Ovarian Carcinoma|Recurrent Pancreatic Carcinoma|Recurrent Prostate Carcinoma|Recurrent Rectal Carcinoma|Recurrent Skin Carcinoma|Recurrent Thyroid Gland Carcinoma|Recurrent Uterine Corpus Cancer|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Multiple Myeloma|Skin Carcinoma|Thyroid Gland Carcinoma|Uterine Corpus Cancer,Drug: Afatinib|Drug: Afatinib|Procedure: Biopsy|Procedure: Biopsy|Procedure: Biopsy|Drug: Crizotinib|Drug: Crizotinib|Other: Cytology Specimen Collection Procedure|Other: Cytology Specimen Collection Procedure|Procedure: Biopsy|Procedure: Biopsy|Procedure: Biopsy|Other: Cytology Specimen Collection Procedure|Other: Cytology Specimen Collection Procedure|Other: Cytology Specimen Collection Procedure|Other: Cytology Specimen Collection Procedure|Other: Cytology Specimen Collection Procedure|Other: Cytology Specimen Collection Procedure|Other: Cytology Specimen Collection Procedure|Other: Cytology Specimen Collection Procedure|Procedure: Biopsy|Other: Cytology Specimen Collection Procedure|Procedure: Biopsy|Other: Cytology Specimen Collection Procedure|Other: Cytology Specimen Collection Procedure|Drug: Capivasertib|Drug: Binimetinib|Other: Cytology Specimen Collection Procedure|Other: Cytology Specimen Collection Procedure|Other: Cytology Specimen Collection Procedure|Procedure: Biopsy|Procedure: Biopsy|Drug: Copanlisib|Drug: Copanlisib|Drug: Adavosertib|Other: Cytology Specimen Collection Procedure|Other: Cytology Specimen Collection Procedure|Other: Cytology Specimen Collection Procedure,2015-06-08,2024-09-26,PHASE2,INTERVENTIONAL,ALL,18 Years,
NCT02452476,"A Double Blind, Randomized, Controlled Study to Evaluate CHF 5633 (Synthetic Surfactant) and Poractant Alfa in Neonates With Respiratory Distress Syndrome (RDS) (POC)","A DOUBLE BLIND, RANDOMIZED, CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF SYNTHETIC SURFACTANT (CHF 5633) IN COMPARISON TO PORCINE SURFACTANT (PORACTANT ALFA, CUROSURF®) IN THE TREATMENT OF PRETERM NEONATES WITH RESPIRATORY DISTRESS SYNDROME",COMPLETED,"Respiratory Distress Syndrome, Newborn",Drug: CHF5633|Drug: Poractant alfa,2015-05-22,2021-08-13,PHASE2,INTERVENTIONAL,ALL,1 Hour,24 Hours
NCT02932891,"An Open Label, Safety Study to Assess the Potential for Adrenal Suppression.","An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS Topical Product in Patients With Atopic Dermatitis",COMPLETED,Atopic Dermatitis,Drug: DSXS topical,2016-10-13,2018-12-07,PHASE2,INTERVENTIONAL,ALL,6 Months,17 Years
NCT03348631,Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer,"A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma",ACTIVE_NOT_RECRUITING,Recurrent Endometrial Endometrioid Adenocarcinoma|Recurrent Ovarian Carcinoma|Recurrent Ovarian Clear Cell Adenocarcinoma|Recurrent Ovarian Endometrioid Adenocarcinoma|Recurrent Uterine Corpus Cancer,Procedure: Computed Tomography,2017-11-21,2023-11-08,PHASE2,INTERVENTIONAL,FEMALE,18 Years,
NCT01349322,Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery,A Phase III Trial of Accelerated Whole Breast Irradiation With Hypofractionation Plus Concurrent Boost Versus Standard Whole Breast Irradiation Plus Sequential Boost for Early-Stage Breast Cancer,ACTIVE_NOT_RECRUITING,Breast Cancer,Radiation: Standard fractionation whole breast irradiation|Radiation: Hypofractionated whole breast irradiation,2011-05-06,2024-09-20,PHASE3,INTERVENTIONAL,FEMALE,18 Years,
NCT02003222,Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia,A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults,ACTIVE_NOT_RECRUITING,Acute Lymphoblastic Leukemia,Procedure: Allogeneic Hematopoietic Stem Cell Transplantation|Procedure: Allogeneic Hematopoietic Stem Cell Transplantation,2013-12-06,2024-09-24,PHASE3,INTERVENTIONAL,ALL,30 Years,70 Years
NCT00530686,Pancreatic Islet Cell Transplantation - A Novel Approach to Improve Islet Quality and Engraftment,Pancreatic Islet Cell Transplantation - A Novel Approach to Improve Islet Quality and Engraftment,COMPLETED,Islet Cell Transplantation|Type 1 Diabetes,,2007-09-17,2017-04-24,PHASE1,INTERVENTIONAL,ALL,18 Years,65 Years
NCT04613596,Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7,A Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation,RECRUITING,Advanced Non-Small Cell Lung Cancer|Metastatic Non-Small Cell Lung Cancer,Drug: Adagrasib|Drug: Adagrasib|Drug: Adagrasib|Drug: Adagrasib|Drug: Pembrolizumab,2020-11-03,2024-09-23,PHASE2|PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT04457596,"T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial","The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib",RECRUITING,Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|HER2 Positive Breast Carcinoma|Invasive Breast Carcinoma|Multifocal Breast Carcinoma|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Synchronous Bilateral Breast Carcinoma,Biological: Trastuzumab Emtansine|Biological: Trastuzumab Emtansine,2020-07-07,2024-08-02,PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT01129596,Post-marketing Surveillance of Long-term Administration of Donepezil Hydrochloride -Investigation of the Clinical Condition and Safety in Patients With Alzheimer's Disease-,Post-marketing Surveillance of Long-term Administration of Donepezil Hydrochloride -Investigation of the Clinical Condition and Safety in Patients With Alzheimer's Disease-,COMPLETED,Alzheimer's Disease,Drug: donepezil hydrochloride,2010-05-24,2018-11-05,,OBSERVATIONAL,ALL,,
NCT04424316,A Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy.,"A PHASE 3, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY",COMPLETED,Respiratory Tract Infection,Biological: RSVpreF|Biological: Placebo,2020-06-09,2024-03-04,PHASE3,INTERVENTIONAL,FEMALE,0 Years,49 Years
NCT03843996,Comparison of a Novel Wound Dressing Stratamed Versus Current Clinical Practice After Follicular Unit Extraction Hair Transplantation,Comparison of a Novel Wound Dressing Stratamed Versus Current Clinical Practice After Follicular Unit Extraction Hair Transplantation,COMPLETED,Wounds and Injuries,Device: Treatment - Stratamed|Device: Treatment - Stratamed,2019-02-18,2019-02-18,NA,INTERVENTIONAL,ALL,18 Years,
NCT02828358,Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement,A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene Rearrangement,ACTIVE_NOT_RECRUITING,Acute Leukemia of Ambiguous Lineage|B Acute Lymphoblastic Leukemia|Mixed Phenotype Acute Leukemia,Drug: Azacitidine,2016-07-11,2024-08-09,PHASE2,INTERVENTIONAL,ALL,,364 Days
NCT06132958,Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005),"A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy (MK-2870-005/ENGOT-en23/GOG-3095)",RECRUITING,Endometrial Cancer,Biological: Sacituzumab tirumotecan|Drug: Doxorubicin,2023-11-15,2024-09-19,PHASE3,INTERVENTIONAL,FEMALE,18 Years,
NCT04759586,Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma,A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma,RECRUITING,Primary Mediastinal Large B-Cell Lymphoma,Procedure: Biospecimen Collection|Procedure: Biospecimen Collection|Procedure: Biospecimen Collection|Procedure: Biospecimen Collection|Procedure: Biospecimen Collection|Procedure: Biospecimen Collection,2021-02-18,2024-09-19,PHASE3,INTERVENTIONAL,ALL,2 Years,
NCT03602586,Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer,A Phase II Study of MK-3475 (Pembrolizumab) (NSC #776864) + Epacadostat (NSC #766086) in Recurrent Clear Cell Carcinoma of the Ovary,COMPLETED,Malignant Ovarian Clear Cell Tumor|Recurrent Ovarian Carcinoma,Drug: Epacadostat,2018-07-27,2024-07-26,PHASE2,INTERVENTIONAL,FEMALE,18 Years,
NCT00375063,Study of Unprotected Left Main Stenting Versus Bypass Surgery (LE MANS Study),Prospective Randomized Study of Unprotected Left Main Stenting Versus Bypass Surgery,COMPLETED,Coronary Artery Stenosis|Myocardial Revascularization|Myocardial Ischemia,,2006-09-12,2006-09-12,PHASE4,INTERVENTIONAL,ALL,18 Years,80 Years
NCT02944435,"A Comparative, Pharmacokinetic Study of CB-839 Capsule and Tablet Formulations in Healthy Adults","A Comparative, Randomized, Single-Dose, 2-Way Crossover Pharmacokinetic Comparability Study of CB-839 Administered as Capsule and Tablet Formulations in Healthy Adult Subjects",COMPLETED,Healthy Volunteers,Drug: CB-839 Capsules|Drug: CB-839 Tablets,2016-10-25,2017-01-04,PHASE1,INTERVENTIONAL,ALL,18 Years,55 Years
NCT05204927,177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer,"A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of 177Lu-PSMA-I&T Versus Hormone Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer",ACTIVE_NOT_RECRUITING,Metastasis From Malignant Tumor of Prostate,Drug: Abiraterone with Prednisone or Enzalutamide|Drug: 177Lu-PSMA-I&T,2022-01-24,2024-02-29,PHASE3,INTERVENTIONAL,MALE,18 Years,
NCT06063473,A Study Comparing Trifarotene Cream 0.005% to AKLIEF® Cream in the Treatment of Acne Vulgaris,"A Multi-center, Double-blind, Randomized, Placebo Controlled, Parallel-group Study, Comparing Trifarotene Cream 0.005% (Taro Pharmaceuticals U.S.A, Inc.) and to AKLIEF® Cream (Trifarotene 0.005%,Galderma) and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris",COMPLETED,Acne Vulgaris,"Drug: Trifarotene Cream 0.005%|Drug: AKLIEF® Cream (Trifarotene 0.005%, Galderma Laboratories)|Drug: Placebo",2023-10-02,2023-10-02,PHASE1,INTERVENTIONAL,ALL,12 Years,40 Years
NCT03678025,Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer,Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer,RECRUITING,Castration Levels of Testosterone|Metastatic Prostatic Adenocarcinoma|Stage IV Prostate Cancer AJCC v8|Stage IVA Prostate Cancer AJCC v8|Stage IVB Prostate Cancer AJCC v8,Drug: Abiraterone|Drug: Abiraterone|Drug: Abiraterone,2018-09-19,2024-08-16,PHASE3,INTERVENTIONAL,MALE,18 Years,
NCT03204916,Cancer Care Delivery in Adolescent and Young Adult Patients With Acute Lymphoblastic Leukemia,Documentation and Delivery of Guideline-Consistent Treatment in Adolescent and Young Adult (AYA) Acute Lymphoblastic Leukemia (ALL),ACTIVE_NOT_RECRUITING,Acute Lymphoblastic Leukemia,Behavioral: Discussion,2017-07-02,2023-12-28,,OBSERVATIONAL,ALL,15 Years,39 Years
NCT00346216,Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen,"A Randomized, Double Blind, Parallel-group Study Of Cardiovascular Safety In Osteoarthritis Or Rheumatoid Arthritis Patients With Or At High Risk For Cardiovascular Disease Comparing Celecoxib With Naproxen And Ibuprofen",COMPLETED,"Arthritis, Rheumatoid",Drug: celecoxib|Drug: Ibuprofen|Drug: Naproxen,2006-06-29,2021-03-03,PHASE4,INTERVENTIONAL,ALL,18 Years,
NCT05253157,Change in Pain With Virtual Reality-augmented Remote Rehabilitative Care,Changes in Pain Interference and Severity After an Episode of Virtual Reality-augmented Remote Rehabilitative Care: a Pragmatic Exploratory Descriptive Trial,COMPLETED,Musculoskeletal Pain,,2022-02-23,2022-02-23,,OBSERVATIONAL,ALL,18 Years,
NCT05464069,Safety of Nerivio in Pregnant Women With Migraine,A Retrospective Controlled Survey Study to Assess the Safety of Treating Migraine With Nerivio During Pregnancy and 3 Months Postpartum,COMPLETED,Migraine|Pregnancy Related,Device: Nerivio|,2022-07-19,2022-12-13,,OBSERVATIONAL,FEMALE,18 Years,42 Years
NCT02201992,Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial),A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein,RECRUITING,ALK Gene Rearrangement|ALK Gene Translocation|ALK Positive|Stage IB Non-Small Cell Lung Carcinoma AJCC v7|Stage II Non-Small Cell Lung Cancer AJCC v7|Stage IIA Non-Small Cell Lung Carcinoma AJCC v7|Stage IIB Non-Small Cell Lung Carcinoma AJCC v7|Stage IIIA Non-Small Cell Lung Cancer AJCC v7,Drug: Crizotinib|Other: Clinical Observation,2014-07-28,2024-07-03,PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT04003389,A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause,"A Randomized, Placebo-Controlled, Double-Blind Phase 3 Clinical Study to Investigate the Long-Term Safety of Fezolinetant in Women Suffering From Vasomotor Symptoms (Hot Flashes) Associated With Menopause",COMPLETED,Hot Flashes,Drug: fezolinetant|Drug: fezolinetant|Drug: placebo,2019-07-01,2023-09-21,PHASE3,INTERVENTIONAL,FEMALE,40 Years,65 Years
NCT02973789,Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR),"LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure",ACTIVE_NOT_RECRUITING,Nonsmall Cell Lung Cancer|NSCLC,Device: NovoTTF-200T|Drug: Immune checkpoint inhibitors or docetaxel,2016-11-25,2024-09-26,PHASE3,INTERVENTIONAL,ALL,22 Years,
NCT01226004,Multi-Institutional Registry for Prostate Cancer Radiosurgery,Multi-Institutional Registry for Prostate Cancer Radiosurgery. An IRB Approved Observational Trial,UNKNOWN,Prostate Cancer Early Risk Treated by Radiosurgery|Prostate Cancer Intermediate Risk Treated by Radiosurgery,,2010-10-21,2019-08-06,,OBSERVATIONAL,MALE,18 Years,90 Years
NCT01632904,Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study,"Polycythemia Vera Symptom Study Evaluating Ruxolitinib Versus Hydroxyurea in a Randomized, Multicenter, Double-Blind, Double-Dummy, Phase 3 Efficacy and Safety Study of Patient Reported Outcomes",COMPLETED,Polycythemia Vera,Drug: Ruxolitinib|Drug: Hydroxyurea (HU),2012-07-03,2017-11-14,PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT04032704,A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors,Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors,TERMINATED,"Small Cell Lung Cancer|Non-small Cell Lung Cancer, Squamous|Non-small Cell Lung Cancer, Non-squamous|Head and Neck Squamous Cell Carcinoma|Esophageal Squamous Cell Carcinoma|Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma|Prostate Cancer|Melanoma",Drug: ladiratuzumab vedotin|Drug: ladiratuzumab vedotin|Drug: ladiratuzumab vedotin|Drug: ladiratuzumab vedotin|Drug: ladiratuzumab vedotin,2019-07-25,2024-04-17,PHASE2,INTERVENTIONAL,ALL,18 Years,
NCT05047601,A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection,"A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332/RITONAVIR IN PREVENTING SYMPTOMATIC SARS-COV-2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID-19",COMPLETED,COVID-19,Drug: PF-07321332|Drug: PF-07321332|Drug: Placebo for PF-07321332,2021-09-17,2023-05-06,PHASE2|PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT01856192,Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,"Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma",ACTIVE_NOT_RECRUITING,Ann Arbor Stage II Diffuse Large B-Cell Lymphoma|Ann Arbor Stage III Diffuse Large B-Cell Lymphoma|Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma,Drug: Cyclophosphamide|Drug: Cyclophosphamide,2013-05-17,2024-09-26,PHASE2,INTERVENTIONAL,ALL,18 Years,
NCT01321567,Quality of Life in New Treatable Therapy as Rabeprazole Option for Refractory Reflux Esophagitis,Quality of Life in New Treatable Therapy as Rabeprazole Option for Refractory Reflux Esophagitis,COMPLETED,Refractory Reflux Esophagitis,Drug: rabeprazole sodium,2011-03-23,2023-07-24,,OBSERVATIONAL,ALL,18 Years,
NCT01105767,Methicillin-resistant Staphylococcus Aureus (MRSA) Skin and Soft Tissue Infection (SSTI) Prevention in Military Trainees,Evaluating Strategies to Prevent Methicillin-resistant Staphylococcus Aureus Skin and Soft Tissue Infections in Military Trainees,COMPLETED,Staphylococcus Aureus|MRSA Skin Infections|Staphylococcal Skin Infections,"|Other: Supplemental training, education and hygiene|Drug: Chlorhexidine gluconate",2010-04-16,2023-02-03,NA,INTERVENTIONAL,MALE,18 Years,42 Years
NCT02176967,Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma,Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma,ACTIVE_NOT_RECRUITING,Ganglioneuroblastoma|Localized Resectable Neuroblastoma|Localized Unresectable Neuroblastoma|Neuroblastoma,Other: Clinical Observation|Procedure: Biopsy|Procedure: Biopsy,2014-06-27,2024-09-23,PHASE3,INTERVENTIONAL,ALL,,18 Months
NCT01694667,Omega-3 Fatty Acids for Hyperactivity Treatment in Autism Spectrum Disorder,Effectiveness of Omega-3 Fatty Acids for the Reduction of Hyperactivity in Children With Autism Spectrum Disorder,COMPLETED,Autism Spectrum Disorders|Hyperactivity,Drug: Omega-3 Fatty Acids|Other: Placebo,2012-09-27,2020-08-31,PHASE2,INTERVENTIONAL,ALL,5 Years,8 Years
NCT02339740,Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia,A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid,ACTIVE_NOT_RECRUITING,Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA,Drug: Arsenic Trioxide,2015-01-15,2023-11-22,PHASE3,INTERVENTIONAL,ALL,12 Months,21 Years
NCT00379340,Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor,Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors,ACTIVE_NOT_RECRUITING,Stage III Kidney Wilms Tumor|Stage IV Kidney Wilms Tumor,Radiation: 3-Dimensional Conformal Radiation Therapy,2006-09-21,2024-04-16,PHASE3,INTERVENTIONAL,ALL,,29 Years
NCT02402244,Project: Every Child for Younger Patients With Cancer,"The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study",RECRUITING,Adrenal Gland Pheochromocytoma|Carcinoma In Situ|Central Nervous System Neoplasm|Childhood Immature Teratoma|Childhood Langerhans Cell Histiocytosis|Childhood Mature Teratoma|Congenital Mesoblastic Nephroma|Desmoid Fibromatosis|Ganglioneuroma|Lymphoproliferative Disorder|Malignant Neoplasm|Malignant Solid Neoplasm|Melanocytic Neoplasm|Myeloproliferative Neoplasm|Neoplasm of Uncertain Malignant Potential|Neuroendocrine Neoplasm|Stromal Neoplasm,Other: Cytology Specimen Collection Procedure,2015-03-30,2024-07-25,,OBSERVATIONAL,ALL,,25 Years
NCT02595944,Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial),Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers,ACTIVE_NOT_RECRUITING,Stage IB Lung Non-Small Cell Carcinoma AJCC v7|Stage II Lung Non-Small Cell Cancer AJCC v7|Stage IIIA Lung Non-Small Cell Cancer AJCC v7,Procedure: Biospecimen Collection|Procedure: Biospecimen Collection,2015-11-04,2024-09-26,PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT01975389,The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects,"Phase 3 Multi Center, Double Blind, Randomized, Placebo Controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615), In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects",TERMINATED,Cardiovascular Disease,Drug: bococizumab (PF-04950615)|Drug: Placebo,2013-11-03,2019-05-01,PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT04148729,USG Guided ESP Block in Spinal Surgery,Effect of USG Guided ESP Block in Spinal Surgery,COMPLETED,Postoperative Pain,Drug: ESP block|Drug: Control Group,2019-11-01,2022-06-22,PHASE4,INTERVENTIONAL,ALL,18 Years,65 Years
NCT05705401,Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer,A Phase III Randomized Trial of Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer (HERO),RECRUITING,HER2-positive Breast Cancer,Radiation: Standard of Care Adjuvant Breast Radiation|Drug: Standard of Care HER2-targeted Therapy Without Adjuvant Breast Radiation,2023-01-30,2024-09-04,PHASE3,INTERVENTIONAL,ALL,40 Years,
NCT00567567,Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma,Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma,COMPLETED,Localized Resectable Neuroblastoma|Localized Unresectable Neuroblastoma|Recurrent Neuroblastoma|Regional Neuroblastoma|Stage 4 Neuroblastoma|Stage 4S Neuroblastoma,Procedure: Autologous Hematopoietic Stem Cell Transplantation|Procedure: Autologous Hematopoietic Stem Cell Transplantation,2007-12-05,2022-04-28,PHASE3,INTERVENTIONAL,ALL,,30 Years
NCT05567601,Doxil/Caelyx BE Study,"A Randomized, Multi-center, Cross-over, Comparative Bioavailability Study of DOXIL/CAELYX Manufactured at a New Site in Patients With Advanced or Refractory Ovarian or Breast Cancer",COMPLETED,Ovarian Cancer|AIDS-related Kaposi Sarcoma|Multiple Myeloma|Metastatic Breast Cancer,Drug: DOXIL/CAELYX|Drug: DOXIL/CAELYX,2022-10-05,2024-07-25,PHASE1,INTERVENTIONAL,ALL,18 Years,75 Years
NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,"A Phase III Randomized Trial for Patients With De Novo AML Using Bortezomib and Sorafenib (NSC# 681239, NSC# 724772) for Patients With High Allelic Ratio FLT3/ITD",ACTIVE_NOT_RECRUITING,Acute Myeloid Leukemia|Leukemia Cutis|Myeloid Neoplasm|Myeloid Sarcoma,Drug: Asparaginase|Drug: Asparaginase|Drug: Asparaginase|Drug: Asparaginase|Drug: Asparaginase|Drug: Cytarabine,2011-06-13,2024-08-09,PHASE3,INTERVENTIONAL,ALL,,29 Years
NCT02224781,Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma,"DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial",ACTIVE_NOT_RECRUITING,Clinical Stage III Cutaneous Melanoma AJCC v8|Clinical Stage IV Cutaneous Melanoma AJCC v8|Metastatic Melanoma|Recurrent Melanoma|Unresectable Melanoma,Procedure: Biospecimen Collection|Procedure: Biospecimen Collection|Procedure: Biospecimen Collection|Procedure: Biospecimen Collection,2014-08-25,2024-09-26,PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT05568472,"Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study",A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone to Improve Persistence With Endocrine Therapy in Young Women With Stage I-III Breast Cancer (ASPEN),RECRUITING,Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Hormone Receptor-Positive Breast Carcinoma,Other: Best Practice|Other: Best Practice,2022-10-05,2023-11-13,NA,INTERVENTIONAL,FEMALE,18 Years,
NCT01886872,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (&gt;/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL),ACTIVE_NOT_RECRUITING,Stage I Chronic Lymphocytic Leukemia|Stage II Chronic Lymphocytic Leukemia|Stage III Chronic Lymphocytic Leukemia|Stage IV Chronic Lymphocytic Leukemia,Drug: Bendamustine Hydrochloride|Drug: Ibrutinib|Drug: Ibrutinib,2013-06-26,2024-09-26,PHASE3,INTERVENTIONAL,ALL,65 Years,
NCT03864692,Prediction of Hypotension Using Perfusion Index and Pleth Variability Index After Spinal Anesthesia for C/S,Prediction of Hypotension Using Perfusion Index and Pleth Variability Index After Spinal Anesthesia for Caesarean Section,COMPLETED,Cesarean Section Complications|Hypotension|Spinal Anesthesia|Perfusion Index|Pleth Variability Index,|,2019-03-06,2019-06-18,,OBSERVATIONAL,FEMALE,18 Years,40 Years
NCT03581292,"Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations","A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600 Mutations",ACTIVE_NOT_RECRUITING,Anaplastic Astrocytoma|Glioblastoma|Malignant Glioma,Radiation: Radiation Therapy,2018-07-10,2024-08-09,PHASE2,INTERVENTIONAL,ALL,3 Years,25 Years
NCT00746395,"Randomized, Placebo-controlled Trial of Lubiprostone as a Preparation for Capsule Endoscopy","Randomized, Placebo-controlled Trial of Lubiprostone as a Preparation for Capsule Endoscopy",COMPLETED,Inflammatory Bowel Disease,Drug: Lubiprostone|Drug: Placebo,2008-09-04,2020-10-08,PHASE4,INTERVENTIONAL,ALL,19 Years,90 Years
NCT05799495,A Study to Understand the Effect and Safety of the Study Medicine PF-07817883 in Adults Who Have Symptoms of COVID-19 But Are Not Hospitalized,"A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP, DOSE RANGING STUDY TO EVALUATE VIROLOGICAL RESPONSE AND SAFETY OF ORAL PF-07817883 IN NON-HOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID-19",COMPLETED,SARS-CoV-2 Infection,Drug: PF-07817883|Drug: PF-07817883|Drug: PF-07817883|Drug: Placebo,2023-04-05,2024-01-05,PHASE2,INTERVENTIONAL,ALL,18 Years,64 Years
NCT02629172,Drug Use-results Survey in Patients Infected With Hepatitis C Virus Genotype 1,Drug Use Results Survey in Patients Infected With Hepatitis C Virus Genotype 1,COMPLETED,Chronic Hepatitis C Virus,,2015-12-14,2020-02-24,,OBSERVATIONAL,ALL,,120 Years
NCT03304639,Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma,A Randomized Phase II Study of Anti-PD1 Antibody [MK-3475 (Pembrolizumab)] Alone Versus Anti-PD1 Antibody Plus Stereotactic Body Radiation Therapy in Advanced Merkel Cell Carcinoma,ACTIVE_NOT_RECRUITING,Advanced Merkel Cell Carcinoma|Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8|Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8|Metastatic Merkel Cell Carcinoma|Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8|Pathologic Stage IIIA Cutaneous Merkel Cell Carcinoma AJCC v8|Pathologic Stage IIIB Cutaneous Merkel Cell Carcinoma AJCC v8|Pathologic Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8,Biological: Pembrolizumab|Biological: Pembrolizumab,2017-10-09,2024-07-30,PHASE2,INTERVENTIONAL,ALL,18 Years,
NCT02641639,FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer,"FOCUS: A Multicenter, Multinational, Double-Blind, 2-Arm, Randomized, Phase 2/3, Study of Physician's Choice Chemotherapy ([PCC] Weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) Plus Bevacizumab and CA4P Versus PCC Plus Bevacizumab and Placebo for Subjects With Platinum-Resistant, Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer",TERMINATED,Platinum Resistant Ovarian Cancer,Drug: Fosbretabulin tromethamine|Drug: Placebo,2015-12-29,2018-03-22,PHASE2|PHASE3,INTERVENTIONAL,FEMALE,18 Years,
NCT05243563,Does Steroid Plus CO2 Laser Improve Lichen Sclerosus Symptoms Compared to Steroids Alone?,"A Randomized, Unblinded Trial of Topical Steroids Plus CO2 Laser Compared to Steroids Alone in the Treatment of Vulvovaginal Lichen Sclerosus",TERMINATED,Vulvar Lichen Sclerosus,Device: MonaLisa Touch|Drug: Topical steroid,2022-02-17,2024-09-23,PHASE2|PHASE3,INTERVENTIONAL,FEMALE,18 Years,85 Years
NCT03314935,A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors,"A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors",COMPLETED,Biliary Tract Cancer (BTC)|Colorectal Cancer (CRC)|Endometrial Cancer|Gastroesophageal Cancer (GC)|Ovarian Cancer|Solid Tumors,Drug: INCB001158|Drug: INCB001158|Drug: INCB001158,2017-10-19,2023-12-07,PHASE1|PHASE2,INTERVENTIONAL,ALL,18 Years,
NCT02364557,Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival,A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer,ACTIVE_NOT_RECRUITING,Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8|Metastatic Breast Carcinoma|Metastatic Malignant Neoplasm in the Bone|Metastatic Malignant Neoplasm in the Liver|Metastatic Malignant Neoplasm in the Lung|Metastatic Malignant Neoplasm in the Lymph Nodes|Metastatic Malignant Neoplasm in the Spine|Prognostic Stage IV Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8,|Radiation: Stereotactic Body Radiotherapy,2015-02-18,2024-01-11,PHASE2|PHASE3,INTERVENTIONAL,FEMALE,18 Years,
NCT00075725,Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia,High Risk B-Precursor Acute Lymphoblastic Leukemia (ALL),COMPLETED,Acute Lymphoblastic Leukemia|Adult B Acute Lymphoblastic Leukemia|Childhood B Acute Lymphoblastic Leukemia,Drug: Cyclophosphamide|Drug: Cyclophosphamide|Drug: Cyclophosphamide|Drug: Cyclophosphamide,2004-01-13,2021-04-27,PHASE3,INTERVENTIONAL,ALL,1 Year,30 Years
NCT01173939,Primary Prevention of Major Adverse Cardiac Events (MACE) With Standard and Intensive Statin Treatment in Patients With Diabetes: Survival and Cardiovascular Event Assessments,Primary Prevention of MACE With Standard and Intensive Statin Treatment in Hypercholesterolemia Patients With Concomitant Diabetes and Hypertension,TERMINATED,Hypercholesterolemia|Type 2 Diabetes|Hypertension,Drug: Pravastatin|Drug: Rosuvastatin,2010-08-02,2011-06-01,NA,INTERVENTIONAL,ALL,50 Years,
NCT03574363,Phase 2b Study of KBP-5074 in Subjects With Uncontrolled Hypertension and Advanced Chronic Kidney Disease,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy, Safety, and Pharmacokinetics of KBP-5074 in Patients With Moderate-to-Severe Chronic Kidney Disease and Uncontrolled Hypertension",COMPLETED,Chronic Kidney Diseases|Hypertension,Drug: KBP-5074 0.25 mg tablet|Drug: KBP-5074 0.5 mg tablet|Drug: KBP-5074 0.25 mg tablet,2018-07-02,2024-03-21,PHASE2,INTERVENTIONAL,ALL,18 Years,85 Years
NCT03937635,"Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma",Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM),RECRUITING,Smoldering Plasma Cell Myeloma,Biological: Daratumumab|Drug: Dexamethasone,2019-05-06,2024-08-09,PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT02893930,Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery,A Phase II Study of MLN0128 (TAK-228) in Rapalog-Resistant Advanced Pancreatic Neuroendocrine Tumors (PNET),COMPLETED,Pancreatic Neuroendocrine Tumor G1|Pancreatic Neuroendocrine Tumor G2|Refractory Pancreatic Neuroendocrine Carcinoma,Drug: Sapanisertib,2016-09-09,2023-10-17,PHASE2,INTERVENTIONAL,ALL,18 Years,
NCT05857930,A Study to Assess the Efficacy and Safety of Daily OM-85 in Young Children With Recurrent Wheezing,"A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 2 Study to Assess the Efficacy and Safety of Daily OM-85 Treatment vs. Placebo Given in Children Aged 6 Months to 5 Years With Recurrent Wheezing",RECRUITING,Recurrent Wheezing|Wheezing Lower Respiratory Illness,Drug: OM-85|Drug: Placebo,2023-05-15,2024-08-12,PHASE2,INTERVENTIONAL,ALL,6 Months,72 Months
NCT03956186,Can Right Toe Perfusion Index or Pleth Variability Index Predict Spinal Anesthesia Induced Hypotension?,Can we Predict Predict Spinal Anesthesia Induced Hypotension During Caesarean Section Using Right Toe Perfusion Index or Pleth Variability Index?,COMPLETED,Cesarean Section Complications|Hypotension|Spinal Anesthesia|Perfusion Index|Pleth Variability Index,|,2019-05-20,2019-07-24,,OBSERVATIONAL,ALL,18 Years,45 Years
NCT02268786,Single Embryo TrAnsfeR of Euploid Embryo,"Prospective, Multi-center, Randomized Controlled Trial Comparing Pregnancy Outcomes Following Selection and Single Embryo Transfer (SET) Based on Preimplantation Genetic Screening (PGS) by Next Generation Sequencing (NGS) Versus Standard Morphological Assessment",COMPLETED,Infertility|Aneuploidy,Other: Preimplantation Genetic Screening by NGS|,2014-10-20,2020-05-13,NA,INTERVENTIONAL,FEMALE,25 Years,40 Years
NCT05610163,"Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation",The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing The Efficacy of Triplet Versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients With Locally Advanced Rectal Cancer,RECRUITING,Locally Advanced Rectal Carcinoma|Stage II Rectal Cancer AJCC v8|Stage III Rectal Cancer AJCC v8,Drug: Capecitabine|Drug: Capecitabine,2022-11-09,2024-08-02,PHASE2,INTERVENTIONAL,ALL,18 Years,
NCT00534339,EasyBand GOAL Trial,,WITHDRAWN,Morbid Obesity,,2007-09-24,2014-10-07,NA,INTERVENTIONAL,ALL,18 Years,
NCT03070886,Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery,Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel,ACTIVE_NOT_RECRUITING,Stage I Prostate Adenocarcinoma AJCC v7|Stage II Prostate Adenocarcinoma AJCC v7|Stage III Prostate Adenocarcinoma AJCC v7,Drug: Bicalutamide|Drug: Bicalutamide,2017-03-06,2024-07-15,PHASE2|PHASE3,INTERVENTIONAL,MALE,18 Years,
NCT05154786,The Effects of Early Mobilization and Endurance Training for Patients With Prolonged Mechanical Ventilator,The Effects of Early Mobilization and Endurance Training for Patients With Prolonged Mechanical Ventilator,COMPLETED,Mechanical Ventilation Complication,Other: Early Mobilization and endurance training|Other: Usual Care,2021-12-13,2023-05-03,NA,INTERVENTIONAL,ALL,18 Years,75 Years
NCT02498535,Efficacy and Safety of Inhaled Nitric Oxide (NO) in Cystic Fibrosis (CF) Patients,"Prospective, Randomized, Placebo Controlled Trial of the Efficacy and Safety of Inhaled Nitric Oxide (NO) in Cystic Fibrosis (CF) Patients",TERMINATED,Cystic Fibrosis,Drug: Nitric Oxide 160 ppm|Drug: Nitric Oxide 160 ppm,2015-07-15,2021-03-05,PHASE2,INTERVENTIONAL,ALL,18 Years,
NCT04684524,Dupilumab in Allergic Fungal Rhinosinusitis (AFRS) (LIBERTY-AFRS-AI),A Randomized Double-blind Placebo-controlled Parallel Group Study Assessing the Efficacy and Safety of Dupilumab in Patients With Allergic Fungal Rhinosinusitis (AFRS),ACTIVE_NOT_RECRUITING,Allergic Fungal Rhinosinusitis,Drug: Dupilumab SAR231893|Drug: Placebo,2020-12-24,2024-02-05,PHASE3,INTERVENTIONAL,ALL,6 Years,
NCT02595424,"Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery",Randomized Phase II Study of Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced G3 Non-small Cell Gastroenteropancreatic Neuroendocrine Carcinomas,ACTIVE_NOT_RECRUITING,Gastric Neuroendocrine Carcinoma|Intestinal Neuroendocrine Carcinoma|Pancreatic Neuroendocrine Carcinoma,Drug: Capecitabine|Drug: Carboplatin,2015-11-03,2024-01-10,PHASE2,INTERVENTIONAL,ALL,18 Years,
NCT04089358,"Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors, the StepByStep Study",StepByStep: A Randomized Trial of a Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors,ACTIVE_NOT_RECRUITING,Hematopoietic and Lymphoid Cell Neoplasm|Malignant Solid Neoplasm,Other: Educational Intervention|Other: Educational Intervention,2019-09-13,2024-08-26,PHASE3,INTERVENTIONAL,ALL,15 Years,20 Years
NCT02317796,Adult Subjects With Uncontrolled Type 2 Diabetes,"A Multi-center, Double Blind, Randomized, Placebo-controlled, Parallel Group Phase IIa Study of MLR-1023 in Adult Subjects With Uncontrolled Type 2 Diabetes",COMPLETED,Type 2 Diabetes,Drug: MLR-1023|Drug: MLR-1023|Drug: MLR-1023|Drug: MLR-1023|Drug: MLR-1023,2014-12-16,2016-09-26,PHASE2,INTERVENTIONAL,ALL,18 Years,75 Years
NCT06551324,A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).,"A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF PF-06821497 (MEVROMETOSTAT) IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE (MEVPRO-1)",NOT_YET_RECRUITING,Metastatic Castrate Resistant Prostate Cancer (mCRPC),Drug: PF-06821497|Drug: Docetaxel,2024-08-13,2024-09-19,PHASE3,INTERVENTIONAL,MALE,18 Years,
NCT04315324,Study to Test AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL),A Phase II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL),RECRUITING,Recurrent T Acute Lymphoblastic Leukemia|Refractory T Acute Lymphoblastic Leukemia,Drug: AKR1C3-activated Prodrug OBI-3424,2020-03-19,2024-02-09,PHASE2,INTERVENTIONAL,ALL,18 Years,
NCT02112916,Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma,A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy),ACTIVE_NOT_RECRUITING,Adult T Acute Lymphoblastic Leukemia|Ann Arbor Stage II Adult Lymphoblastic Lymphoma|Ann Arbor Stage II Childhood Lymphoblastic Lymphoma|Ann Arbor Stage III Adult Lymphoblastic Lymphoma|Ann Arbor Stage III Childhood Lymphoblastic Lymphoma|Ann Arbor Stage IV Adult Lymphoblastic Lymphoma|Ann Arbor Stage IV Childhood Lymphoblastic Lymphoma|Childhood T Acute Lymphoblastic Leukemia,Drug: Cyclophosphamide|Drug: Bortezomib,2014-04-14,2024-08-09,PHASE3,INTERVENTIONAL,ALL,1 Year,30 Years
NCT00352534,"Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor",Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor,ACTIVE_NOT_RECRUITING,Stage I Kidney Wilms Tumor|Stage II Kidney Wilms Tumor|Stage III Kidney Wilms Tumor,Radiation: 3-Dimensional Conformal Radiation Therapy|Radiation: 3-Dimensional Conformal Radiation Therapy|Radiation: 3-Dimensional Conformal Radiation Therapy,2006-07-14,2024-04-24,PHASE3,INTERVENTIONAL,ALL,,29 Years
NCT04858334,"APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation","APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation",RECRUITING,Pancreatic Acinar Cell Carcinoma|Pancreatic Adenosquamous Carcinoma|Pancreatic Squamous Cell Carcinoma|Resectable Pancreatic Acinar Cell Carcinoma|Resectable Pancreatic Adenocarcinoma|Resectable Pancreatic Adenosquamous Carcinoma|Resectable Pancreatic Carcinoma,Procedure: Biospecimen Collection|Procedure: Biospecimen Collection,2021-04-26,2024-09-26,PHASE2,INTERVENTIONAL,ALL,18 Years,
NCT03595124,A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC),A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups,ACTIVE_NOT_RECRUITING,Metastatic Renal Cell Carcinoma|Stage III Renal Cell Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8|TFE3-Rearranged Renal Cell Carcinoma|Unresectable Renal Cell Carcinoma,Drug: Axitinib|Drug: Axitinib|Biological: Nivolumab,2018-07-23,2024-09-26,PHASE2,INTERVENTIONAL,ALL,12 Months,
NCT04513717,"Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial",Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*),RECRUITING,Metastatic Malignant Neoplasm in the Bone|Prostate Adenocarcinoma|Stage III Prostate Cancer AJCC v8|Stage IIIA Prostate Cancer AJCC v8|Stage IIIB Prostate Cancer AJCC v8|Stage IIIC Prostate Cancer AJCC v8|Stage IVA Prostate Cancer AJCC v8,Drug: Bicalutamide|Drug: Bicalutamide|Drug: Bicalutamide|Drug: Apalutamide,2020-08-14,2024-02-07,PHASE3,INTERVENTIONAL,MALE,18 Years,
NCT05696717,Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy,"A Phase 3, Multi-center, Randomized Withdrawal and Long Term Extension Study of Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Participants With Multiple System Atrophy",RECRUITING,Symptomatic Neurogenic Orthostatic Hypotension|MSA - Multiple System Atrophy,Drug: Ampreloxetine|Drug: Ampreloxetine|Drug: Ampreloxetine,2023-01-25,2024-08-22,PHASE3,INTERVENTIONAL,ALL,30 Years,
NCT02166463,"Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma",A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults,ACTIVE_NOT_RECRUITING,Ann Arbor Stage IIB Hodgkin Lymphoma|Ann Arbor Stage IIIB Hodgkin Lymphoma|Ann Arbor Stage IVA Hodgkin Lymphoma|Ann Arbor Stage IVB Hodgkin Lymphoma|Childhood Hodgkin Lymphoma|Classic Hodgkin Lymphoma,Biological: Bleomycin Sulfate|Drug: Brentuximab Vedotin,2014-06-18,2024-08-09,PHASE3,INTERVENTIONAL,ALL,2 Years,22 Years
NCT04782024,A Study to Investigate the Effect of 7-Keto on Resting Metabolic Rate in Overweight Adults,"A Randomized, Double-Blind, Placebo Controlled Parallel Study to Investigate the Effect of 7-Keto on Resting Metabolic Rate in Overweight Adults",COMPLETED,Resting Metabolic Rate|Overweight Subjects,Dietary Supplement: Placebo|Dietary Supplement: 7-Keto 50mg|Dietary Supplement: 7-Keto 25mg,2021-03-04,2021-04-26,PHASE2,INTERVENTIONAL,ALL,20 Years,55 Years
NCT01673022,Determining the Sensitivity of Sentinel Lymph Nodes Identified With Robotic Fluorescence Imaging,Determining the Sensitivity of Sentinel Lymph Nodes Identified With Robotic Fluorescence Imaging for Detecting Metastatic Endometrial and Cervical Cancer,COMPLETED,Endometrial Cancer|Cervical Cancer,Drug: IC Green,2012-08-27,2018-07-24,NA,INTERVENTIONAL,FEMALE,18 Years,
NCT02963025,Protective Ventilation With High Versus Low PEEP During One-lung Ventilation for Thoracic Surgery,PROtective Ventilation With High Versus Low PEEP During One-lung Ventilation for THORacic Surgery PROTHOR: A Randomized Controlled Trial,ACTIVE_NOT_RECRUITING,One-Lung Ventilation,Procedure: PEEP level|Procedure: PEEP level,2016-11-15,2024-03-07,NA,INTERVENTIONAL,ALL,18 Years,
NCT04538625,Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer Therapy,"A Phase 3 Multicenter, Randomized, Double-blind Placebo-controlled Trial Evaluating Crofelemer for the Prophylaxis of Diarrhea in Adult Patients With Solid Tumors Receiving Targeted-cancer Therapies With or Without Standard Chemotherapy",COMPLETED,Cancer Therapy-Related Diarrhea|Chemotherapy-related Diarrhea|Adult Solid Tumor|Prophylaxis of Diarrhea|Symptomatic Relief of Diarrhea|Targeted Therapy-related Diarrhea,Drug: Placebo|Drug: Crofelemer 125 MG [Mytesi],2020-09-04,2024-07-26,PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT03914625,A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia,A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy),ACTIVE_NOT_RECRUITING,B Acute Lymphoblastic Leukemia|B Lymphoblastic Lymphoma|Down Syndrome,Drug: Asparaginase Erwinia chrysanthemi|Drug: Asparaginase Erwinia chrysanthemi|Drug: Asparaginase Erwinia chrysanthemi|Drug: Asparaginase Erwinia chrysanthemi|Drug: Asparaginase Erwinia chrysanthemi|Drug: Asparaginase Erwinia chrysanthemi|Drug: Asparaginase Erwinia chrysanthemi,2019-04-16,2024-08-21,PHASE3,INTERVENTIONAL,ALL,365 Days,31 Years
NCT00809926,8 Weeks Study to Evaluate the Efficacy and Safety of Valsartan in Combination With Aliskiren Compared to Valsartan Alone in Patients With Stage 2 Hypertension,"An 8-week Randomized, Double-Blind, Parallel Group, Multi-Center, Active Controlled Study to Evaluate the Efficacy and Safety of Valsartan Administered in Combination With Aliskiren (160/150 mg, 320/300 mg) Versus Valsartan Alone (160 mg, 320 mg) in Patients With Stage 2 Hypertension",COMPLETED,Stage 2 Hypertension,Drug: Valsartan/aliskiren|Drug: Valsartan,2008-12-17,2011-05-02,PHASE4,INTERVENTIONAL,ALL,18 Years,
NCT02761057,"Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed","A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)",ACTIVE_NOT_RECRUITING,Locally Advanced Papillary Renal Cell Carcinoma|Metastatic Papillary Renal Cell Carcinoma|Stage III Renal Cell Cancer AJCC v7|Stage IV Renal Cell Cancer AJCC v7|Type 1 Papillary Renal Cell Carcinoma|Type 2 Papillary Renal Cell Carcinoma|Unresectable Renal Cell Carcinoma,Procedure: Biospecimen Collection|Procedure: Biospecimen Collection|Procedure: Biospecimen Collection|Procedure: Biospecimen Collection,2016-05-04,2024-08-16,PHASE2,INTERVENTIONAL,ALL,18 Years,
NCT04322318,A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT,Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT),RECRUITING,Anaplastic Kidney Wilms Tumor|Recurrent Kidney Wilms Tumor|Stage II Kidney Wilms Tumor|Stage III Kidney Wilms Tumor|Stage IV Kidney Wilms Tumor,Procedure: Biopsy|Procedure: Biopsy,2020-03-26,2024-09-23,PHASE2,INTERVENTIONAL,ALL,,30 Years
NCT04166318,"Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study",A Randomized Phase II Study De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE),RECRUITING,Anal Basaloid Carcinoma|Anal Canal Cloacogenic Carcinoma|Anal Canal Squamous Cell Carcinoma|Anal Margin Squamous Cell Carcinoma|Stage I Anal Cancer AJCC v8|Stage IIA Anal Cancer AJCC v8,Drug: Capecitabine|Drug: Capecitabine,2019-11-18,2024-08-07,PHASE2,INTERVENTIONAL,ALL,18 Years,
NCT03944941,Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer,Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC),ACTIVE_NOT_RECRUITING,Skin Squamous Cell Carcinoma|Metastatic Skin Cancer,Drug: Avelumab|Drug: Avelumab,2019-05-10,2024-02-20,PHASE2,INTERVENTIONAL,ALL,18 Years,
NCT03387306,Serum Bilirubin Levels in Normal-tension Glaucoma,Reduced Serum Bilirubin Levels in Patients With Normal-tension Glaucoma,COMPLETED,"Normal Tension Glaucoma|Bilirubin; Defect, Excretion",|,2018-01-02,2018-01-02,,OBSERVATIONAL,ALL,18 Years,80 Years
NCT03955406,Low Flow Anesthesia Without Initial High Flow Phase,Comparison of Low Flow Anesthesia With and Without Initial High Flow Phase,COMPLETED,Low Flow Anesthesia|Volatile Anesthetic Consumption,Procedure: Conventional Low flow Anesthesia|Procedure: Low Flow Anesthesia with fixed fresh gas flow rate,2019-05-20,2019-07-10,NA,INTERVENTIONAL,ALL,18 Years,80 Years
NCT01231906,Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma,A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-Metastatic Ewing Sarcoma,ACTIVE_NOT_RECRUITING,Localized Extraskeletal Ewing Sarcoma|Peripheral Primitive Neuroectodermal Tumor of Bone|Peripheral Primitive Neuroectodermal Tumor of Soft Tissues,Drug: Cyclophosphamide|Drug: Cyclophosphamide,2010-11-01,2024-09-19,PHASE3,INTERVENTIONAL,ALL,,50 Years
NCT02890355,FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer,Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer,ACTIVE_NOT_RECRUITING,Metastatic Pancreatic Adenocarcinoma|Recurrent Pancreatic Carcinoma|Stage IV Pancreatic Cancer AJCC v6 and v7,Drug: Fluorouracil|Drug: Fluorouracil,2016-09-07,2024-09-26,PHASE2,INTERVENTIONAL,ALL,18 Years,
NCT03067181,"Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors",A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors,RECRUITING,Childhood Extracranial Germ Cell Tumor|Extragonadal Embryonal Carcinoma|Germ Cell Tumor|Malignant Germ Cell Tumor|Malignant Ovarian Teratoma|Stage I Ovarian Choriocarcinoma|Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7|Stage I Ovarian Teratoma AJCC v6 and v7|Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7|Stage I Testicular Choriocarcinoma AJCC v6 and v7|Stage I Testicular Embryonal Carcinoma AJCC v6 and v7|Stage I Testicular Seminoma AJCC v6 and v7|Stage I Testicular Yolk Sac Tumor AJCC v6 and v7|Stage II Ovarian Choriocarcinoma|Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7|Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7|Stage II Testicular Choriocarcinoma AJCC v6 and v7|Stage II Testicular Embryonal Carcinoma AJCC v6 and v7|Stage II Testicular Yolk Sac Tumor AJCC v6 and v7|Stage III Ovarian Choriocarcinoma|Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7|Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7|Stage III Testicular Choriocarcinoma AJCC v6 and v7|Stage III Testicular Embryonal Carcinoma AJCC v6 and v7|Stage III Testicular Yolk Sac Tumor AJCC v6 and v7|Stage IV Ovarian Choriocarcinoma|Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7|Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7|Testicular Mixed Choriocarcinoma and Embryonal Carcinoma|Testicular Mixed Choriocarcinoma and Teratoma|Testicular Mixed Choriocarcinoma and Yolk Sac Tumor,Procedure: Biopsy|Procedure: Biopsy|Procedure: Biopsy|Procedure: Biopsy|Other: Best Practice,2017-03-01,2024-09-23,PHASE3,INTERVENTIONAL,ALL,,
NCT00931710,Valsartan/Amlodipine As Compared to Losartan Treatment in Stage 2 Systolic Hypertension,"A 12-week Multicenter, Randomized, Double-blind, Parallel-group, Active-control Study to Evaluate the Antihypertensive Efficacy and Safety of Valsartan/Amlodipine-based Regimen Versus a Losartan-based Regimen in Patients With Stage 2 Systolic Hypertension",COMPLETED,Stage 2 Systolic Hypertension,"Drug: valsartan, amlodipine, HCTZ|Drug: Losartan, HCTZ followed by valsartan, amlodipine, HCTZ",2009-07-02,2011-03-07,PHASE4,INTERVENTIONAL,ALL,18 Years,
NCT01349881,"S0820, Adenoma and Second Primary Prevention Trial","A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)",ACTIVE_NOT_RECRUITING,Colorectal Neoplasms,Drug: Eflornithine placebo & sulindac placebo|Drug: eflornithine & sulindac placebo|Drug: Eflornithine placebo & sulindac|Drug: Eflornithine plus sulindac,2011-05-09,2024-03-20,PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT05483868,"A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer","A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) to Determine the Feasibility and Safety of Intratumoral Injection With or Without Intramural Injection in Subjects With Bladder Cancer",RECRUITING,Non-muscle-invasive Bladder Cancer|Muscle-Invasive Bladder Carcinoma,Drug: AU-011|Combination Product: AU-011 in Combination with Medical Laser Adminstration|Combination Product: AU-011 in Combination with Medical Laser Administration|Combination Product: AU-011 in Combination with Medical Laser Administration|Combination Product: AU-011 in Combination with Medical Laser Administration|Combination Product: AU-011 in Combination with Medical Laser Administration,2022-08-02,2024-06-12,PHASE1,INTERVENTIONAL,ALL,18 Years,
NCT04905069,Effectiveness of the SpaceOAR Vue System in Subjects With Prostate Cancer Being Treated With Stereotactic Body Radiotherapy,Effectiveness of the SpaceOAR Vue System in Subjects With Prostate Cancer Being Treated With Stereotactic Body Radiotherapy,RECRUITING,Prostate Cancer,|Device: SpaceOAR Vue System,2021-05-27,2024-09-23,NA,INTERVENTIONAL,MALE,18 Years,
NCT03269669,"Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma",Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma,ACTIVE_NOT_RECRUITING,Grade 1 Follicular Lymphoma|Grade 2 Follicular Lymphoma|Grade 3a Follicular Lymphoma|Recurrent Follicular Lymphoma|Refractory Follicular Lymphoma,Procedure: Biopsy|Procedure: Biopsy|Drug: Bendamustine Hydrochloride,2017-09-01,2024-09-26,PHASE2,INTERVENTIONAL,ALL,18 Years,
NCT04205968,Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers,Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel Adenocarcinoma,RECRUITING,Metastatic Small Intestinal Adenocarcinoma|Stage III Small Intestinal Adenocarcinoma AJCC v8|Stage IIIA Small Intestinal Adenocarcinoma AJCC v8|Stage IIIB Small Intestinal Adenocarcinoma AJCC v8|Stage IV Small Intestinal Adenocarcinoma AJCC v8,Drug: Paclitaxel|Drug: Fluorouracil,2019-12-20,2024-08-16,PHASE2,INTERVENTIONAL,ALL,18 Years,
NCT03654768,Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia,A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination With BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients With Molecular Evidence of Disease,ACTIVE_NOT_RECRUITING,"Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive",Drug: Bosutinib|Drug: Dasatinib,2018-08-31,2024-07-08,PHASE2,INTERVENTIONAL,ALL,18 Years,
NCT05077969,Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients,"A Virtual Phase 2 Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of the Combination of Famotidine and Celecoxib as a Post-exposure Prophylaxis (PEP) for Newly-infected COVID-19 Patients",TERMINATED,2019 Novel Coronavirus Disease|2019 Novel Coronavirus Infection|2019-nCoV Disease|2019-nCoV Infection|COVID-19|COVID-19 Pandemic|COVID-19 Virus Disease|COVID-19 Virus Infection|Covid19|Coronavirus Disease 2019|SARS-CoV2 Infection|SARS-CoV-2 Acute Respiratory Disease,Drug: Famotidine|Drug: Placebo,2021-10-14,2024-07-09,PHASE2,INTERVENTIONAL,ALL,18 Years,
NCT02066181,Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis,"A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)",COMPLETED,Desmoid Fibromatosis,Other: Laboratory Biomarker Analysis|Other: Laboratory Biomarker Analysis,2014-02-19,2023-06-07,PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT02196181,Dabrafenib and Trametinib for the Treatment of Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery,A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma,ACTIVE_NOT_RECRUITING,Stage III Cutaneous Melanoma AJCC v7|Stage IV Cutaneous Melanoma AJCC v6 and v7|Unresectable Melanoma,Procedure: Biospecimen Collection|Procedure: Biospecimen Collection,2014-07-21,2024-09-26,PHASE2,INTERVENTIONAL,ALL,18 Years,
NCT04036981,Muscle Selection for Botulinum Toxin A Injection in Poststroke Elbow Flexor Spasticity,The Effect of Muscle Selection for Botulinum Toxin A Injection on the Treatment Outcome in Poststroke Elbow Flexor Spasticity,COMPLETED,Muscle Spasticity,Drug: Botulinum toxin type A|Drug: Botulinum toxin type A|Drug: Botulinum toxin type A,2019-07-30,2021-06-23,,OBSERVATIONAL,ALL,18 Years,
NCT02523014,"Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients with Progressive Meningiomas",Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2/CDK Pathway Mutations,RECRUITING,Intracranial Meningioma|Recurrent Meningioma|NF2 Gene Mutation,Drug: Vismodegib|Drug: FAK Inhibitor GSK2256098|Drug: Capivasertib|Drug: Abemaciclib,2015-08-14,2024-09-19,PHASE2,INTERVENTIONAL,ALL,18 Years,
NCT02100514,Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events,"A 52 Week Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events",COMPLETED,Hyperlipidemia,Drug: Bococizumab (PF-04950615; RN316)|Other: Placebo,2014-04-01,2018-07-31,PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT05035212,"Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.","A PHASE 3 STUDY TO EVALUATE THE EFFICACY, IMMUNOGENICITY, AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN ADULTS",RECRUITING,Lower Respiratory Tract Illness,Biological: RSVpreF|Biological: Placebo|Biological: RSVpreF|Biological: Placebo|Biological: RSVpreF|Biological: Placebo|Biological: RSVpreF|Biological: RSVpreF|Biological: Placebo,2021-09-05,2024-09-19,PHASE3,INTERVENTIONAL,ALL,60 Years,
NCT03766295,Masitinib Plus Gemcitabine in Pancreatic Cancer,"A Prospective, Multicenter, Double-randomized, Double-blind, 2-parallel Groups, Phase 3 Study to Compare as First Line Therapy Efficacy and Safety of Masitinib in Combination With Gemcitabine, to Gemcitabine in Combination With Placebo, in the Treatment of Patients With Non Resectable Locally Advanced or Metastatic Pancreatic Cancer",COMPLETED,Locally Advanced or Metastatic Pancreatic Cancer,Drug: Masitinib|Drug: Gemcitabine,2018-12-06,2020-12-08,PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT03291769,Effects of Intraoperative Blood and Blood Product Consumption on Postoperative Results in Pediatric Cardiac Surgery,Effects of Intraoperative Blood Transfusion on Postoperative Results in Pediatric Cardiac Surgery,COMPLETED,"Blood Loss, Surgical|Pediatric Heart Surgery",,2017-09-25,2019-10-17,,OBSERVATIONAL,ALL,1 Day,16 Years
NCT04684368,A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT,A Phase 2 Trial of Chemotherapy Followed by Response-Based Whole Ventricular &Amp; Spinal Canal Irradiation (WVSCI) for Patients With Localized Non-Germinomatous Central Nervous System Germ Cell Tumor,RECRUITING,Central Nervous System Nongerminomatous Germ Cell Tumor|Choriocarcinoma|Embryonal Carcinoma|Immature Teratoma|Malignant Teratoma|Mixed Germ Cell Tumor|Pineal Region Germ Cell Tumor|Pineal Region Immature Teratoma|Pineal Region Yolk Sac Tumor|Suprasellar Germ Cell Tumor,Procedure: Biospecimen Collection|Procedure: Biospecimen Collection,2020-12-24,2024-09-23,PHASE2,INTERVENTIONAL,ALL,3 Years,29 Years
NCT02713646,Magnetic Resonance Imaging Study on Patients With Trigeminal Neuralgia,"Applied Research on Patients With Trigeminal Neuralgia by Multi-planar Reconstruction, Curved Planar Reconstruction and Magnetic Resonance Virtual Endoscopy",COMPLETED,Trigeminal Neuralgia,|,2016-03-21,2023-02-16,,OBSERVATIONAL,ALL,35 Years,70 Years
NCT01167712,"Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer","GOG-0262: A Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel in Combination With Carboplatin With or Without Concurrent and Consolidation Bevacizumab (NSC #704865) in the Treatment of Primary Stage II, III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer and ACRIN 6695: Perfusion CT Imaging to Evaluate Treatment Response in Patients Participating in GOG-0262",ACTIVE_NOT_RECRUITING,Fallopian Tube Endometrioid Adenocarcinoma|Fallopian Tube Mucinous Adenocarcinoma|Fallopian Tube Transitional Cell Carcinoma|Ovarian Brenner Tumor|Ovarian Clear Cell Adenocarcinofibroma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Adenocarcinoma|Ovarian Seromucinous Carcinoma|Ovarian Serous Adenocarcinoma|Ovarian Transitional Cell Carcinoma|Ovarian Undifferentiated Carcinoma|Primary Peritoneal Serous Adenocarcinoma|Stage IIA Fallopian Tube Cancer AJCC v6 and v7|Stage IIA Ovarian Cancer AJCC V6 and v7|Stage IIB Fallopian Tube Cancer AJCC v6 and v7|Stage IIB Ovarian Cancer AJCC v6 and v7|Stage IIC Fallopian Tube Cancer AJCC v6 and v7|Stage IIC Ovarian Cancer AJCC v6 and v7|Stage IIIA Fallopian Tube Cancer AJCC v7|Stage IIIA Ovarian Cancer AJCC v6 and v7|Stage IIIA Primary Peritoneal Cancer AJCC v7|Stage IIIB Fallopian Tube Cancer AJCC v7|Stage IIIB Ovarian Cancer AJCC v6 and v7|Stage IIIB Primary Peritoneal Cancer AJCC v7|Stage IIIC Fallopian Tube Cancer AJCC v7|Stage IIIC Ovarian Cancer AJCC v6 and v7|Stage IIIC Primary Peritoneal Cancer AJCC v7|Stage IV Fallopian Tube Cancer AJCC v6 and v7|Stage IV Ovarian Cancer AJCC v6 and v7|Stage IV Primary Peritoneal Cancer AJCC v7,Biological: Bevacizumab|Biological: Bevacizumab,2010-07-22,2024-08-16,PHASE3,INTERVENTIONAL,FEMALE,18 Years,
NCT02601469,Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque Psoriasis,"An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS (Taro Pharmaceuticals U.S.A., Inc.) in Patients With Plaque Psoriasis.",COMPLETED,Plaque Psoriasis,Drug: DSXS,2015-11-10,2018-12-07,PHASE2,INTERVENTIONAL,ALL,2 Years,
NCT05334069,Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection,Blinded Reference Set for Multicancer Early Detection Blood Tests,RECRUITING,Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Ann Arbor Stage I Lymphoma|Ann Arbor Stage II Lymphoma|Ann Arbor Stage III Lymphoma|Ann Arbor Stage IV Lymphoma|Chronic Lymphocytic Leukemia|Chronic Myeloid Leukemia|Gastroesophageal Junction Adenocarcinoma|Head and Neck Carcinoma|Hematopoietic and Lymphoid Cell Neoplasm|Invasive Breast Carcinoma|Kidney Carcinoma|Malignant Hepatobiliary Neoplasm|Malignant Solid Neoplasm|Melanoma|Muscle-Invasive Bladder Carcinoma|RISS Stage I Plasma Cell Myeloma|RISS Stage II Plasma Cell Myeloma|RISS Stage III Plasma Cell Myeloma|Sarcoma|Stage I Bladder Cancer AJCC v6 and v7|Stage I Breast Cancer AJCC v7|Stage I Colorectal Cancer AJCC v6 and v7|Stage I Esophageal Cancer AJCC V7|Stage I Gastric Cancer AJCC V7|Stage I Lung Cancer AJCC v7|Stage I Ovarian Cancer AJCC v6 and v7|Stage I Pancreatic Cancer AJCC v6 and v7|Stage I Prostate Cancer AJCC v7|Stage I Uterine Corpus Cancer AJCC v7|Stage II Bladder Cancer AJCC v6 and v7|Stage II Breast Cancer AJCC v6 and v7|Stage II Colorectal Cancer AJCC v7|Stage II Esophageal Cancer AJCC v7|Stage II Gastric Cancer AJCC v7|Stage II Lung Cancer AJCC v7|Stage II Ovarian Cancer AJCC v6 and v7|Stage II Pancreatic Cancer AJCC v6 and v7|Stage II Prostate Cancer AJCC v7|Stage II Uterine Corpus Cancer AJCC v7|Stage III Bladder Cancer AJCC v6 and v7|Stage III Breast Cancer AJCC v7|Stage III Colorectal Cancer AJCC v7|Stage III Esophageal Cancer AJCC v7|Stage III Gastric Cancer AJCC v7|Stage III Lung Cancer AJCC v7|Stage III Ovarian Cancer AJCC v6 and v7|Stage III Pancreatic Cancer AJCC v6 and v7|Stage III Prostate Cancer AJCC v7|Stage III Uterine Corpus Cancer AJCC v7|Stage IV Bladder Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7|Stage IV Colorectal Cancer AJCC v7|Stage IV Esophageal Cancer AJCC v7|Stage IV Gastric Cancer AJCC v7|Stage IV Lung Cancer AJCC v7|Stage IV Ovarian Cancer AJCC v6 and v7|Stage IV Pancreatic Cancer AJCC v6 and v7|Stage IV Prostate Cancer AJCC v7|Stage IV Uterine Corpus Cancer AJCC v7|Thyroid Gland Carcinoma,Other: Questionnaire Administration,2022-04-19,2024-08-02,,OBSERVATIONAL,ALL,40 Years,75 Years
NCT02340169,"Adrenal Suppression and Pharmacokinetics of Topicort® Spray, 0.25% in Pediatric Patients With Plaque Psoriasis","An Open Label, Safety Study to Assess the Potential for Adrenal Suppression and Pharmacokinetics Following Maximal Use Treatment With Topicort® (Desoximetasone) Topical Spray, 0.25% in Pediatric Patients With Plaque Psoriasis.",COMPLETED,Plaque Psoriasis,"Drug: Topicort® (desoximetasone) Topical Spray, 0.25%",2015-01-16,2023-03-28,PHASE4,INTERVENTIONAL,ALL,2 Years,17 Years
NCT02735655,Global State of Digestive Endoscopy Training Survey,The Global Status and the Unmet Needs for Training in Endoscopy; a World Endoscopy Organization Web Based Survey,UNKNOWN,Gastrointestinal Endoscopy Training,,2016-04-13,2016-05-02,,OBSERVATIONAL,ALL,18 Years,100 Years
NCT02961114,Use of Autologous Adipose-Derived Stem/Stromal Cells (AD-cSVF) in Symptomatic Benign Prostate Hypertrophy,Use of Autologous Adipose-Derived Stem/Stromal Cells In Symptomatic Benign Prostate Hypertrophy,WITHDRAWN,BPH|Nocturia|BPH With Urinary Obstruction|Prostatism|Prostate Inflammation,Procedure: Microcannula Harvest Adipose|Device: Centricyte 1000|Biological: IV Sterile Normal Saline,2016-11-10,2021-01-12,PHASE1|PHASE2,INTERVENTIONAL,MALE,30 Years,80 Years
NCT04242095,Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects,Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events,RECRUITING,Malignancy,Procedure: Biospecimen Collection,2020-01-27,2024-08-02,,OBSERVATIONAL,ALL,,
NCT03737981,"Testing The Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia",A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (&gt;/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL),ACTIVE_NOT_RECRUITING,Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma,Drug: Ibrutinib|Drug: Ibrutinib,2018-11-13,2024-09-26,PHASE3,INTERVENTIONAL,ALL,65 Years,
NCT03739814,"Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia",A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease,RECRUITING,"B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative|Recurrent B Acute Lymphoblastic Leukemia|Refractory B Acute Lymphoblastic Leukemia",Biological: Blinatumomab|Biological: Blinatumomab,2018-11-14,2024-09-26,PHASE2,INTERVENTIONAL,ALL,18 Years,
NCT01948050,Pilot Study of Transcranial Stimulation (tDCS)to Relieve Neuropathic Pain in Cancer Patients,Pilot Study on Safety and Efficacy of the Non-invasive Transcranial Stimulation (tDCS) to Relieve Neuropathic Pain in Cancer Patients,COMPLETED,Pain,Device: non-invasive transcranial direct current stimulation (tDCS)|Device: non-invasive transcranial direct current stimulation (tDCS),2013-09-23,2014-07-14,NA,INTERVENTIONAL,ALL,21 Years,
NCT04175912,Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver,A Phase 2 Study of Pevonedistat in Combination With Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma,ACTIVE_NOT_RECRUITING,Metastatic Cholangiocarcinoma|Metastatic Hepatocellular Carcinoma|Stage III Hepatocellular Carcinoma AJCC v8|Stage III Intrahepatic Cholangiocarcinoma AJCC v8|Stage IIIA Hepatocellular Carcinoma AJCC v8|Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8|Stage IIIB Hepatocellular Carcinoma AJCC v8|Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8|Stage IV Hepatocellular Carcinoma AJCC v8|Stage IV Intrahepatic Cholangiocarcinoma AJCC v8|Stage IVA Hepatocellular Carcinoma AJCC v8|Stage IVB Hepatocellular Carcinoma AJCC v8|Unresectable Cholangiocarcinoma|Unresectable Hepatocellular Carcinoma|Unresectable Intrahepatic Cholangiocarcinoma,Drug: Pevonedistat|Drug: Carboplatin,2019-11-25,2024-08-16,PHASE2,INTERVENTIONAL,ALL,18 Years,
NCT00433836,Effect of Valsartan Compared to Enalapril on Sitting Systolic Blood Pressure in Children With High Blood Pressure,"A Multicenter, Randomized, Double-blind, Parallel-group, Evaluation of 12 Weeks of Valsartan Compared to Enalapril on Sitting Systolic Blood Pressure in Children 6 to 17 Years of Age With Hypertension",COMPLETED,Hypertension,Drug: Valsartan|Drug: Valsartan|Drug: Valsartan|Drug: Enalapril|Drug: Enalapril|Drug: Enalapril,2007-02-12,2011-05-19,PHASE3,INTERVENTIONAL,ALL,6 Years,17 Years
NCT04266249,CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy,(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response,RECRUITING,Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Invasive Breast Carcinoma|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8,Drug: Docetaxel|Drug: Docetaxel,2020-02-12,2024-04-18,PHASE2,INTERVENTIONAL,ALL,18 Years,
NCT00736749,Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies,Umbrella Long-Term Follow-Up Protocol,RECRUITING,Hematopoietic Cell Transplantation Recipient|Leukemia|Solid Tumor,Procedure: Assessment of Therapy Complications,2008-08-18,2024-04-11,,OBSERVATIONAL,ALL,,
NCT04726241,The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study,Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias,RECRUITING,Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Acute Myeloid Leukemia Post Cytotoxic Therapy|Juvenile Myelomonocytic Leukemia|Mixed Phenotype Acute Leukemia|Myelodysplastic Syndrome|Myelodysplastic Syndrome Post Cytotoxic Therapy|Myeloid Leukemia Associated With Down Syndrome,Procedure: Biospecimen Collection,2021-01-27,2024-09-23,PHASE1|PHASE2,INTERVENTIONAL,ALL,,22 Years
NCT04504734,Bucillamine in Treatment of Patients With COVID-19,"Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Bucillamine in Patients With Mild-Moderate COVID-19",TERMINATED,Covid19,Drug: Bucillamine|Drug: Bucillamine|Drug: Placebo,2020-08-07,2023-07-07,PHASE3,INTERVENTIONAL,ALL,18 Years,80 Years
NCT03698019,A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma,A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma,ACTIVE_NOT_RECRUITING,Acral Lentiginous Melanoma|Clinical Stage III Cutaneous Melanoma AJCC v8|Clinical Stage IV Cutaneous Melanoma AJCC v8|Mucosal Melanoma,Procedure: Biospecimen Collection|Procedure: Biospecimen Collection,2018-10-05,2024-08-16,PHASE2,INTERVENTIONAL,ALL,18 Years,
NCT03371719,BIOMARKER TRIAL of APALUTAMIDE and RADIATION for RECURRENT PROSTATE CANCER,"A Phase II, Double-Blinded, Placebo Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-androgen Therapy With Apalutamide in Recurrent Prostate Cancer",ACTIVE_NOT_RECRUITING,PSA Progression|Stage III Prostate Adenocarcinoma|Stage IV Prostate Adenocarcinoma,Radiation: External Beam Radiation Therapy|Drug: Apalutamide,2017-12-13,2024-03-06,PHASE2,INTERVENTIONAL,MALE,18 Years,
NCT00904241,Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma,Neuroblastoma Biology Studies,RECRUITING,Ganglioneuroblastoma|Localized Resectable Neuroblastoma|Localized Unresectable Neuroblastoma|Regional Neuroblastoma|Stage 4 Neuroblastoma|Stage 4S Neuroblastoma,Other: Cytology Specimen Collection Procedure,2009-05-19,2024-04-16,,OBSERVATIONAL,ALL,,30 Years
NCT05439941,A Long-Term Extension Trial in Participants With Atopic Dermatitis Who Participated in Previous EDP1815 Trials,A Long-Term Extension Trial in Participants With Atopic Dermatitis Who Participated in Previous Phase 2 And 3 EDP1815 Trials,TERMINATED,Atopic Dermatitis,Drug: EDP1815|Drug: EDP1815|Drug: EDP1815,2022-06-30,2023-09-07,PHASE2,INTERVENTIONAL,ALL,18 Years,76 Years
NCT04334941,Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker,Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination With Talazoparib in Patients With SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC),ACTIVE_NOT_RECRUITING,Extensive Stage Lung Small Cell Carcinoma,Drug: Atezolizumab|Drug: Atezolizumab,2020-04-06,2024-08-16,PHASE2,INTERVENTIONAL,ALL,18 Years,
NCT00523549,The Effects of Systolic Blood Pressure Lowering on Diastolic Function Using Valsartan + Amlodipine in Patients With Hypertension and Diastolic Dysfunction,"A Multi-center, Prospective, Randomized, Open-label Study With Blinded Outcome Evaluation to Evaluate the Effects of Systolic Blood Pressure Lowering to Different Targets (Less Than 130 mmHg vs. Less Than 140 mmHg) on Diastolic Function Using Valsartan + Amlodipine in Patients With Hypertension and Diastolic Dysfunction",COMPLETED,Hypertension|Diastolic Dysfunction,Drug: valsartan|Drug: valsartan,2007-08-31,2012-04-23,PHASE4,INTERVENTIONAL,ALL,45 Years,
NCT02834013,Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors,ACTIVE_NOT_RECRUITING,"Acinar Cell Carcinoma|Adenoid Cystic Carcinoma|Adrenal Cortical Carcinoma|Adrenal Gland Pheochromocytoma|Anal Canal Neuroendocrine Carcinoma|Anal Canal Undifferentiated Carcinoma|Angiosarcoma|Apocrine Neoplasm|Appendix Mucinous Adenocarcinoma|Bartholin Gland Transitional Cell Carcinoma|Basal Cell Carcinoma|Bladder Adenocarcinoma|Breast Metaplastic Carcinoma|Cervical Adenocarcinoma|Cholangiocarcinoma|Chordoma|Colorectal Squamous Cell Carcinoma|Desmoid Fibromatosis|Endometrial Transitional Cell Carcinoma|Endometrioid Adenocarcinoma|Esophageal Neuroendocrine Carcinoma|Esophageal Undifferentiated Carcinoma|Extrahepatic Bile Duct Carcinoma|Extramammary Paget Disease|Fallopian Tube Adenocarcinoma|Fallopian Tube Transitional Cell Carcinoma|Fibromyxoid Tumor|Gallbladder Carcinoma|Gastric Neuroendocrine Carcinoma|Gastric Squamous Cell Carcinoma|Gastric Undifferentiated Carcinoma|Gastrointestinal Stromal Tumor|Gestational Trophoblastic Tumor|Giant Cell Carcinoma|Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type|Intestinal Neuroendocrine Carcinoma|Intrahepatic Cholangiocarcinoma|Lung Neuroendocrine Tumor|Lung Sarcomatoid Carcinoma|Major Salivary Gland Carcinoma|Malignant Odontogenic Neoplasm|Malignant Peripheral Nerve Sheath Tumor|Malignant Solid Neoplasm|Malignant Testicular Sex Cord-Stromal Tumor|Metastatic Malignant Neoplasm of Unknown Primary|Metastatic Pituitary Neuroendocrine Tumor|Minimally Invasive Lung Adenocarcinoma|Mixed Mesodermal (Mullerian) Tumor|Mucinous Adenocarcinoma|Mucinous Cystadenocarcinoma|Nasal Cavity Adenocarcinoma|Nasal Cavity Carcinoma|Nasopharyngeal Carcinoma|Nasopharyngeal Low Grade Papillary Adenocarcinoma|Nasopharyngeal Undifferentiated Carcinoma|Oral Cavity Carcinoma|Oropharyngeal Undifferentiated Carcinoma|Ovarian Adenocarcinoma|Ovarian Germ Cell Tumor|Ovarian Mucinous Adenocarcinoma|Ovarian Squamous Cell Carcinoma|Ovarian Transitional Cell Carcinoma|Pancreatic Acinar Cell Carcinoma|Pancreatic Neuroendocrine Carcinoma|Paraganglioma|Paranasal Sinus Adenocarcinoma|Paranasal Sinus Carcinoma|Parathyroid Gland Carcinoma|PEComa|Penile Squamous Cell Carcinoma|Peritoneal Mesothelial Neoplasm|Placental Choriocarcinoma|Primary Peritoneal High Grade Serous Adenocarcinoma|Pseudomyxoma Peritonei|Rare Disorder|Scrotal Squamous Cell Carcinoma|Seminal Vesicle Adenocarcinoma|Seminoma|Serous Cystadenocarcinoma|Small Intestinal Adenocarcinoma|Small Intestinal Squamous Cell Carcinoma|Spindle Cell Neoplasm|Teratoma With Somatic-Type Malignancy|Testicular Non-Seminomatous Germ Cell Tumor|Thyroid Gland Carcinoma|Tracheal Carcinoma|Transitional Cell Carcinoma|Ureter Adenocarcinoma|Ureter Squamous Cell Carcinoma|Urethral Adenocarcinoma|Urethral Squamous Cell Carcinoma|Vaginal Adenocarcinoma|Vaginal Squamous Cell Carcinoma, Not Otherwise Specified|Vulvar Carcinoma",Procedure: Biospecimen Collection|Procedure: Biospecimen Collection,2016-07-15,2024-09-26,PHASE2,INTERVENTIONAL,ALL,18 Years,
NCT04484818,"Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study",A Phase III Double Blinded Study of Early Intervention After RADICAl ProstaTEctomy With Androgen Deprivation Therapy With or Without Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE),ACTIVE_NOT_RECRUITING,Prostate Carcinoma,Drug: Goserelin Acetate|Drug: Darolutamide,2020-07-24,2024-07-03,PHASE3,INTERVENTIONAL,MALE,18 Years,
NCT02048813,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)",ACTIVE_NOT_RECRUITING,Anemia|Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma,Drug: Ibrutinib|Drug: Cyclophosphamide,2014-01-29,2024-09-26,PHASE3,INTERVENTIONAL,ALL,18 Years,70 Years
NCT02177318,Tiotropium in the Treatment of the Patients With Chronic Obstructive Pulmonary Disease,Drug Use Results Survey of Tiotropium Bromide,COMPLETED,"Pulmonary Disease, Chronic Obstructive",Drug: Spiriva (tiotropium bromide) inhalation capsules,2014-06-27,2014-06-27,,OBSERVATIONAL,ALL,,
NCT01013649,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery,A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma,ACTIVE_NOT_RECRUITING,Pancreatic Adenocarcinoma|Pancreatic Ductal Adenocarcinoma|Pancreatic Intraductal Papillary-Mucinous Neoplasm|Stage I Pancreatic Cancer AJCC v6 and v7|Stage II Pancreatic Cancer AJCC v6 and v7,Procedure: Biospecimen Collection|Procedure: Biospecimen Collection|Procedure: Biospecimen Collection|Radiation: 3-Dimensional Conformal Radiation Therapy,2009-11-16,2024-05-17,PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT06112613,Mobile Health for Adherence in Breast Cancer Patients,Improving Medication Adherence in Metastatic Breast Cancer Using a Connected Customized Treatment Platform (CONCURxP),RECRUITING,Anatomic Stage IV Breast Cancer AJCC v8|Breast Carcinoma|HER2-Negative Breast Carcinoma|Hormone Receptor-Positive Breast Carcinoma,Other: Electronic Health Record Review|Other: Electronic Health Record Review|Other: Interview,2023-11-01,2024-08-12,NA,INTERVENTIONAL,ALL,18 Years,
NCT01841736,Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors,Prospective Randomized Phase II Trial of Pazopanib (NSC #737754) Versus Placebo in Patients With Progressive Carcinoid Tumors,ACTIVE_NOT_RECRUITING,Foregut Neuroendocrine Tumor|Hindgut Neuroendocrine Tumor|Metastatic Digestive System Neuroendocrine Tumor G1|Metastatic Neuroendocrine Tumor|Midgut Neuroendocrine Tumor G1|Neuroendocrine Tumor G2|Recurrent Digestive System Neuroendocrine Tumor G1|Regional Digestive System Neuroendocrine Tumor G1,Procedure: Biospecimen Collection|Procedure: Biospecimen Collection,2013-04-26,2024-09-19,PHASE2,INTERVENTIONAL,ALL,18 Years,
NCT03244384,Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer,Phase III Randomized Adjuvant Study of Pembrolizumab in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation,ACTIVE_NOT_RECRUITING,Localized Renal Pelvis and Ureter Urothelial Carcinoma|Locally Advanced Bladder Urothelial Carcinoma|Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma|Locally Advanced Ureter Urothelial Carcinoma|Locally Advanced Urothelial Carcinoma|Stage II Bladder Urothelial Carcinoma AJCC v6 and v7|Stage II Renal Pelvis and Ureter Cancer AJCC v7|Stage II Ureter Cancer AJCC v7|Stage III Bladder Urothelial Carcinoma AJCC v6 and v7|Stage III Renal Pelvis and Ureter Cancer AJCC v7|Stage III Ureter Cancer AJCC v7,Procedure: Biospecimen Collection|Procedure: Biospecimen Collection,2017-08-09,2024-09-26,PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT04916002,A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer,"A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer",ACTIVE_NOT_RECRUITING,Merkel Cell Carcinoma|Cutaneous Squamous Cell Carcinoma|Basal Cell Carcinoma|Triple Negative Breast Cancer|Non-Small Cell Lung Cancer|Oropharynx Squamous Cell Carcinoma,Drug: vidutolimod|Drug: vidutolimod|Drug: vidutolimod|Drug: vidutolimod|Drug: vidutolimod|Drug: vidutolimod|Drug: vidutolimod|Drug: vidutolimod|Drug: vidutolimod,2021-06-07,2024-08-13,PHASE2,INTERVENTIONAL,ALL,18 Years,
NCT02873221,An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine,"A Multicenter, Randomized, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura",COMPLETED,"Migraine, With or Without Aura",Drug: Usual Care|Drug: Ubrogepant|Drug: Ubrogepant,2016-08-19,2019-08-28,PHASE3,INTERVENTIONAL,ALL,18 Years,76 Years
NCT03367702,Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer,Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer,ACTIVE_NOT_RECRUITING,Stage II Prostate Adenocarcinoma,Radiation: Intensity-Modulated Radiation Therapy (IMRT)|Radiation: Stereotactic Body Radiation Therapy (SBRT),2017-12-11,2024-02-07,PHASE3,INTERVENTIONAL,MALE,18 Years,
NCT04444921,EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients,A Randomized Phase III Study of Immune Checkpoint Inhibition With Chemotherapy in Treatment-Naive Metastatic Anal Cancer Patients,ACTIVE_NOT_RECRUITING,Anal Basaloid Squamous Cell Carcinoma|Anal Canal Cloacogenic Carcinoma|Metastatic Anal Squamous Cell Carcinoma|Recurrent Anal Squamous Cell Carcinoma|Stage III Anal Cancer AJCC v8|Stage IV Anal Cancer AJCC v8|Unresectable Anal Squamous Cell Carcinoma,Drug: Carboplatin|Drug: Carboplatin,2020-06-24,2024-09-26,PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT04611802,"A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2","A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years)",COMPLETED,SARS-CoV Infection|Covid19,Biological: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)|Other: Placebo (Initial Vaccination Period)|Biological: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period)|Biological: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination)|Biological: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Second Booster Vaccination)|Other: Placebo (Crossover Vaccination period),2020-11-02,2023-12-21,PHASE3,INTERVENTIONAL,ALL,12 Years,
NCT04960202,EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19,"AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2/3, DOUBLE-BLIND, 2-ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF-07321332/RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID-19 WHO ARE AT INCREASED RISK OF PROGRESSING TO SEVERE ILLNESS",COMPLETED,COVID-19,Drug: PF-07321332|Drug: Placebo,2021-07-13,2023-02-09,PHASE2|PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT04095364,"Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum",RECRUITING,Low Grade Fallopian Tube Serous Adenocarcinoma|Ovarian Low Grade Serous Adenocarcinoma|Primary Peritoneal Low Grade Serous Adenocarcinoma|Stage II Fallopian Tube Cancer AJCC v8|Stage II Ovarian Cancer AJCC v8|Stage II Primary Peritoneal Cancer AJCC v8|Stage III Fallopian Tube Cancer AJCC v8|Stage III Ovarian Cancer AJCC v8|Stage III Primary Peritoneal Cancer AJCC v8|Stage IV Fallopian Tube Cancer AJCC v8|Stage IV Ovarian Cancer AJCC v8|Stage IV Primary Peritoneal Cancer AJCC v8,Procedure: Biopsy|Procedure: Biopsy,2019-09-19,2024-05-02,PHASE3,INTERVENTIONAL,FEMALE,18 Years,
NCT04972721,SELECT-LIFE: A Research Study Looking at Long-term Effects of Semaglutide in People Who Took Part in the SELECT Cardiovascular Outcomes Trial,SELECT-LIFE (SELECT Follow-up Study to Evaluate Long-term Impact oF Anti-obEsity Medication),RECRUITING,Overweight|Obesity,Other: No treatment given,2021-07-22,2024-02-29,,OBSERVATIONAL,ALL,45 Years,
NCT01274338,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High-Risk Melanoma,ACTIVE_NOT_RECRUITING,Melanoma of Unknown Primary|Recurrent Melanoma|Stage IIIB Cutaneous Melanoma AJCC v7|Stage IIIC Cutaneous Melanoma AJCC v7|Stage IV Cutaneous Melanoma AJCC v6 and v7,Biological: Ipilimumab|Other: Quality-of-Life Assessment|Biological: Ipilimumab|Biological: Ipilimumab|Biological: Recombinant Interferon Alfa-2b|Biological: Ipilimumab,2011-01-11,2024-09-26,PHASE3,INTERVENTIONAL,ALL,12 Years,
NCT03257943,"A Bioequivalence Study, Comparing Two Formulations of Ivermectin Lotion, 0.5%","A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-group Study, Comparing Ivermectin Lotion, 0.5% in the Treatment of Subjects With Active Infestation With Head Lice and Their Ova",COMPLETED,Lice; Head Lice,"Drug: Ivermectin Lotion, 0.5%|Drug: SKLICE (ivermectin) Lotion, 0.5%|Drug: Vehicle of the Test product",2017-08-22,2018-05-18,PHASE1,INTERVENTIONAL,ALL,18 Years,
NCT01950390,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,A Randomized Phase II Trial of Ipilimumab With or Without Bevacizumab in Patients With Unresectable Stage III or Stage IV Melanoma,ACTIVE_NOT_RECRUITING,Stage IIIC Cutaneous Melanoma AJCC v7|Stage IV Cutaneous Melanoma AJCC v6 and v7|Unresectable Melanoma,Biological: Ipilimumab|Biological: Bevacizumab,2013-09-25,2024-09-25,PHASE2,INTERVENTIONAL,ALL,18 Years,
NCT00676143,Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients,"A Phase Iii, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Efficacy And Safety Trial Of Bapineuzumab (Aab 001, Eln115727) In Subjects With Mild To Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Carriers",TERMINATED,Alzheimer Disease,Drug: bapineuzumab|Drug: placebo,2008-05-12,2016-06-10,PHASE3,INTERVENTIONAL,ALL,50 Years,88 Years
NCT04177108,A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer,"A Phase III, Double-blind, Placebo-controlled, Randomized Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Patients With Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer",COMPLETED,Triple-Negative Breast Cancer,Drug: Atezolizumab|Drug: Ipatasertib|Drug: Paclitaxel|Drug: Atezolizumab|Drug: Atezolizumab,2019-11-26,2024-03-27,PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT06015308,A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo,"A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis",RECRUITING,Dermatitis Atopic,Drug: Amlitelimab|Drug: Placebo,2023-08-29,2024-09-25,PHASE2,INTERVENTIONAL,ALL,18 Years,
NCT02595008,Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Atopic Dermatitis,"An Open Label, Safety Study to Assess the Potential for Adrenal Suppression and Pharmacokinetics Following Maximal Use Treatment With DSXS in Patients With Atopic Dermatitis.",COMPLETED,"Dermatitis, Atopic",Drug: DSXS,2015-11-03,2018-12-07,PHASE2,INTERVENTIONAL,ALL,2 Years,
NCT05640908,Pelvic Fixation and Fusion During Multilevel Spinal Surgery,Pelvic Fixation and Fusion During Multilevel Spinal Surgery,RECRUITING,Spinal Fusion|Deformity of Spine,Device: iFuse Bedrock Granite Implant System,2022-12-07,2024-01-18,,OBSERVATIONAL,ALL,18 Years,
NCT01193608,Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease,"A Phase 1, Multicenter, Randomized, Double-blind, Placebo-controlled, Adaptive, Multiple Ascending Dose Study Of The Safety, Tolerability And Pharmacokinetics Of Aab-003 (Pf-05236812) In Subjects With Mild To Moderate Alzheimer's Disease",COMPLETED,Alzheimer's Disease,Drug: AAB-003 (PF-05236812)|Drug: AAB-003 (PF-05236812)|Drug: AAB-003 (PF-05236812)|Drug: AAB-003 (PF-05236812)|Drug: AAB-003 (PF-05236812)|Other: Placebo,2010-09-02,2017-02-23,PHASE1,INTERVENTIONAL,ALL,50 Years,89 Years
NCT05818150,GAE Using Embosphere Microspheres Vs Corticosteroid Injections for Treatment of Symptomatic Knee OA (MOTION),"Multicenter, PrOspective, Randomized, Controlled Trial Comparing GenIcular Artery EmbOlization Using Embosphere Microspheres to Corticosteroid INjections for the Treatment of Symptomatic Knee Osteoarthritis: MOTION Study",RECRUITING,Knee Osteoarthritis,Device: Embosphere Microspheres|Drug: Corticosteroid injection,2023-04-18,2024-08-30,NA,INTERVENTIONAL,ALL,21 Years,
NCT04281108,Efficacy and Safety APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2),"Fluticasone Propionate Oral Dispersible Tablet Formulation in Eosinophilic Esophagitis: A Two-Part, Randomized, Double-blind, Placebo-Controlled Study of APT-1011 With an Open-label Extension, in Adult Subjects With Eosinophilic Esophagitis",COMPLETED,Eosinophilic Esophagitis,Drug: APT-1011|Drug: Placebo oral tablet,2020-02-24,2023-06-12,PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT03909750,Use of Autologous Stem/Stromal Cells In Chronic Lung Disorders: Obstructive (COPD) & Restrictive (RLD),Use of Autologous Stem/Stromal Cells in Chronic Lung Disorders: Obstructive (COPD) and Restrictive (RLD),SUSPENDED,COPD|Respiratory Insufficiency,Procedure: Lipoaspiration|Procedure: AD-cSVF|Procedure: Normal Saline IV,2019-04-10,2022-03-16,PHASE1,INTERVENTIONAL,ALL,18 Years,
NCT04250350,Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis,"An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis",COMPLETED,Atopic Dermatitis,Biological: Lebrikizumab,2020-01-31,2023-02-24,PHASE3,INTERVENTIONAL,ALL,12 Years,17 Years
NCT03015350,Blood Levels of Sevoflurane and Desflurane,Blood Levels of Sevoflurane and Desflurane During One Lung Ventilation,COMPLETED,"Anesthetics, Inhalation",Drug: Sevoflurane|Drug: Sevoflurane|Drug: Desflurane|Drug: Desflurane,2017-01-10,2018-03-05,,OBSERVATIONAL,ALL,25 Years,65 Years
NCT04548752,"Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations",Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients With Germline BRCA1 or BRCA2 Mutations,RECRUITING,Metastatic Pancreatic Adenocarcinoma|Pancreatic Adenocarcinoma|Stage IV Pancreatic Cancer AJCC v8,Procedure: Biopsy|Procedure: Biopsy,2020-09-16,2024-09-26,PHASE2,INTERVENTIONAL,ALL,18 Years,
NCT02206334,"Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer",A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases,COMPLETED,Male Breast Carcinoma|Prostate Adenocarcinoma|Recurrent Breast Carcinoma|Recurrent Non-Small Cell Lung Carcinoma|Recurrent Prostate Carcinoma|Stage IV Breast Cancer|Stage IV Non-Small Cell Lung Cancer|Stage IV Prostate Cancer,Radiation: Stereotactic Body Radiation Therapy (SBRT),2014-08-01,2022-05-25,PHASE1,INTERVENTIONAL,ALL,18 Years,
NCT04316117,"Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study","FDG PET to Assess Therapeutic Response in Patients With Bone-Dominant Metastatic Breast Cancer, FEATURE",ACTIVE_NOT_RECRUITING,Anatomic Stage IV Breast Cancer AJCC v8|Hormone Receptor Positive Breast Carcinoma|Metastatic Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8,Procedure: Computed Tomography,2020-03-20,2024-04-18,PHASE2,INTERVENTIONAL,ALL,18 Years,
NCT04960696,Effect on Ocular Surface Symptoms of Online Education,An Evaluation of the Effect on Ocular Surface Symptoms of Online Education During the Pandemic,COMPLETED,Eye Diseases|Ocular Surface Disease|Dry Eye,Diagnostic Test: OSDI|Diagnostic Test: OSDI|Diagnostic Test: OSDI|Diagnostic Test: OSDI,2021-07-14,2021-07-14,,OBSERVATIONAL,ALL,6 Years,30 Years
NCT05596734,"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza","A PHASE 1/2 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID-19 AND INFLUENZA IN HEALTHY INDIVIDUALS",COMPLETED,"Influenza, Human|COVID-19",Biological: bivalent BNT162b2 (original/Omi BA.4/BA.5)|Biological: bivalent BNT162b2 (original/Omi BA.4/BA.5)|Biological: bivalent BNT162b2 (original/Omi BA.4/BA.5)|Biological: qIRV (22/23)|Biological: qIRV (22/23)|Biological: bivalent BNT162b2 (original/Omi BA.4/BA.5)|Biological: bivalent BNT162b2 (original/Omi BA.4/BA.5)|Biological: bivalent BNT162b2 (original/Omi BA.4/BA.5)|Biological: bivalent BNT162b2 (original/Omi BA.4/BA.5)|Biological: bivalent BNT162b2 (original/Omi BA.4/BA.5)|Biological: bivalent BNT162b2 (original/Omi BA.4/BA.5)|Biological: bivalent BNT162b2 (original/Omi BA.4/BA.5)|Biological: bivalent BNT162b2 (original/Omi BA.4/BA.5)|Biological: bivalent BNT162b2 (original/Omi BA.4/BA.5)|Biological: bivalent BNT162b2 (original/Omi BA.4/BA.5)|Biological: bivalent BNT162b2 (original/Omi BA.4/BA.5)|Biological: bivalent BNT162b2 (original/Omi BA.4/BA.5)|Biological: qIRV (22/23),2022-10-27,2024-06-04,PHASE1|PHASE2,INTERVENTIONAL,ALL,18 Years,
NCT03518034,A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men,Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy ResponSE in Hypogonadal Men (TRAVERSE) Study,COMPLETED,Hypogonadism|Cardiovascular Diseases,Drug: AndroGel®|Drug: Placebo,2018-05-08,2024-03-13,PHASE4,INTERVENTIONAL,MALE,45 Years,80 Years
NCT04518670,Success in Comaneci-assist Coils Embolization Surveillance Study (SUCCESS),Success in Comaneci-assist Coils Embolization Surveillance Study,ACTIVE_NOT_RECRUITING,Intracranial Aneurysm,,2020-08-19,2024-05-21,,OBSERVATIONAL,ALL,18 Years,85 Years
NCT04122170,Phase 2B Study to Evaluate the Efficacy of Bentracimab (PB2452) in Reversal of Ticagrelor in Subjects Aged 50-80 Years Old,"A Phase 2B, Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy of Bentracimab (PB2452) in Reversing Ticagrelor in Subjects Aged 50 to 80 Years Old",COMPLETED,Healthy,Drug: Ticagrelor Oral Tablet - Pre-Treatment|Drug: Ticagrelor Oral Tablet - Pre-Treatment,2019-10-10,2024-04-08,PHASE2,INTERVENTIONAL,ALL,50 Years,80 Years
NCT02618759,Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque Psoriasis,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque Psoriasis",COMPLETED,Plaque Psoriasis,Drug: DSXS|Drug: DSXS,2015-12-01,2018-12-10,PHASE3,INTERVENTIONAL,ALL,12 Years,
NCT02912559,Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair,Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair,ACTIVE_NOT_RECRUITING,Colon Adenocarcinoma|DNA Repair Disorder|Lynch Syndrome|Stage III Colon Cancer AJCC v8,Drug: Atezolizumab|Procedure: Biospecimen Collection,2016-09-23,2024-09-26,PHASE3,INTERVENTIONAL,ALL,12 Years,
NCT06312059,Goat or Cow Milk Based Infant Formula GMS,Growth Tolerance and Safety Study of Healthy Term Infants Consuming a Goat or Cow Milk Based Infant Formula,RECRUITING,Growth,"Other: Advance Infant Formula Powder|Other: ""Kendamil Cow milk test product|Other: ""Kendamil goat milk test product",2024-03-15,2024-05-09,PHASE2|PHASE3,INTERVENTIONAL,ALL,,14 Days
NCT00866775,Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs,"Double-Blind, Randomized, Historical Control Study of the Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs",COMPLETED,Epilepsy With Simple or Complex Partial Onset Seizures,Drug: Eslicarbazepine acetate|Drug: Eslicarbazepine acetate,2009-03-20,2016-03-11,PHASE3,INTERVENTIONAL,ALL,16 Years,70 Years
NCT04751370,Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer,A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma,SUSPENDED,Locally Advanced Rectal Adenocarcinoma|Stage II Rectal Cancer AJCC v8|Stage III Rectal Cancer AJCC v8,Procedure: Computed Tomography,2021-02-12,2024-08-13,PHASE2,INTERVENTIONAL,ALL,18 Years,
NCT05228275,"Evaluation of Immunologic Response Following COVID-19 Vaccination in Children, Adolescents, and Young Adults With Cancer","Prospective Cohort Study to Evaluate Immunologic Response Following COVID-19 Vaccination in Children, Adolescents and Young Adults With Cancer",RECRUITING,COVID-19 Infection|Hematopoietic and Lymphatic System Neoplasm|Malignant Solid Neoplasm,Procedure: Biospecimen Collection,2022-02-08,2024-08-26,,OBSERVATIONAL,ALL,6 Months,37 Years
NCT00413699,"Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis","A Long-term, Open-label Follow-up Study Of Tofacitinib (Cp-690,550) For Treatment Of Rheumatoid Arthritis",COMPLETED,"Arthritis, Rheumatoid","Drug: CP-690,550|Drug: CP-690,550",2006-12-20,2018-10-30,PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT01896999,Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma,"A Phase I Study With an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma",SUSPENDED,Recurrent Classic Hodgkin Lymphoma|Refractory Classic Hodgkin Lymphoma,Procedure: Biopsy|Procedure: Biopsy|Procedure: Biopsy|Procedure: Biopsy|Procedure: Biopsy,2013-07-11,2024-09-26,PHASE1|PHASE2,INTERVENTIONAL,ALL,12 Years,
NCT02642042,Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer,A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies,ACTIVE_NOT_RECRUITING,KRAS Gene Mutation|Recurrent Lung Non-Small Cell Carcinoma|Stage IV Lung Non-Small Cell Cancer AJCC v7,Drug: Docetaxel,2015-12-30,2024-09-26,PHASE2,INTERVENTIONAL,ALL,,
NCT04195399,"A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery","A Safety, Pharmacokinetic and Efficacy Study of a y-Secretase Inhibitor, Nirogacestat (PF-03084014), in Children and Adolescents With Progressive, Surgically Unresectable Desmoid Tumors",ACTIVE_NOT_RECRUITING,Desmoid Fibromatosis|Recurrent Desmoid Fibromatosis|Unresectable Desmoid Fibromatosis,Procedure: Biospecimen Collection,2019-12-11,2024-08-15,PHASE2,INTERVENTIONAL,ALL,12 Months,18 Years
NCT00718042,Evaluation of Chagas Blood Screening and Confirmatory Assays,Evaluation of ABBOTT PRISM Chagas Assay and Chagas Confirmatory Assay,COMPLETED,Healthy,Device: ABBOTT PRISM Chagas Assay and Chagas Confirmatory Assay|Device: ABBOTT PRISM Chagas Assay and Chagas Confirmatory Assay,2008-07-18,2012-03-07,NA,INTERVENTIONAL,ALL,18 Years,
NCT06136559,A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011),"A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011)",RECRUITING,Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma,Drug: Nemtabrutinib|Drug: Ibrutinib,2023-11-18,2024-09-27,PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT04248452,Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body,A Phase III Study of Consolidative Radiotherapy in Patients With Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA),RECRUITING,Clinical Stage IV Esophageal Adenocarcinoma AJCC v8|Clinical Stage IV Gastric Cancer AJCC v8|Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8|Clinical Stage IVA Gastric Cancer AJCC v8|Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8|Clinical Stage IVB Gastric Cancer AJCC v8|Metastatic Esophageal Adenocarcinoma|Metastatic Gastric Adenocarcinoma|Oligometastatic Esophageal Adenocarcinoma|Oligometastatic Gastric Adenocarcinoma|Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IV Gastric Cancer AJCC v8|Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8,Drug: Fluorouracil|Drug: Capecitabine|Drug: Fluorouracil|Drug: Fluorouracil|Drug: Capecitabine|Drug: Capecitabine,2020-01-30,2024-08-07,PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT05053152,Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer,"A Phase II Double-Blinded, Placebo-Controlled Trial of PROstate OligoMETastatic RadiotHErapy With or Without ANdrogen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG Promethean)",RECRUITING,Oligometastatic Prostate Carcinoma|Prostate Adenocarcinoma|Stage IVB Prostate Cancer AJCC v8,Drug: Placebo Administration|Other: Quality-of-Life Assessment,2021-09-22,2024-02-07,PHASE2,INTERVENTIONAL,MALE,18 Years,
NCT03777059,12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine,"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine (ADVANCE)",COMPLETED,Episodic Migraine,Drug: Placebo|Drug: Atogepant|Drug: Atogepant|Drug: Atogepant,2018-12-17,2021-07-09,PHASE3,INTERVENTIONAL,ALL,18 Years,80 Years
NCT05010759,Study of Focal Ablation of the Prostate With NanoTherm® Therapy System for Intermediate-Risk Prostate Cancer,"Stage 2B of: A Pivotal, Prospective, Three-Stage, Single-Arm Study of Focal Ablation of the Prostate With NanoTherm® Therapy System for a Limited-Volume, Clinically Localized, Intermediate-Risk Prostate Cancer",TERMINATED,Prostate Cancer,Device: NanoTherm Ablation,2021-08-18,2023-08-01,NA,INTERVENTIONAL,MALE,40 Years,85 Years
NCT05940870,A Prospective Post-marketing Observational Study Assessing the Safety and Efficacy of Nerivio for Migraine Prevention.,"A Prospective, Open-label, Post-marketing Observational Study Assessing the Safety and Efficacy of Nerivio for Migraine Prevention in Real-world Environment.",ACTIVE_NOT_RECRUITING,Migraine,Device: Nerivio,2023-07-11,2024-01-23,,OBSERVATIONAL,ALL,12 Years,
NCT03720470,Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy,"A PHASE 3 RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OF PF-04965842 AND DUPILUMAB IN COMPARISON WITH PLACEBO IN ADULT SUBJECTS ON BACKGROUND TOPICAL THERAPY, WITH MODERATE TO SEVERE ATOPIC DERMATITIS",COMPLETED,"Dermatitis|Dermatitis, Atopic|Eczema|Skin Diseases|Skin Diseases, Genetic|Genetic Diseases, Inborn|Skin Diseases, Eczematous|Hypersensitivity|Hypersensitivity, Immediate|Immune System Diseases",Drug: PF-04965842 100 mg|Drug: PF-04965842 200 mg|Drug: Dupilumab|Drug: PF-04965842 100 mg|Drug: PF-04965842 200 mg,2018-10-25,2021-01-19,PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT01351415,A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC),"An Open-label, Randomized, Phase IIIb Trial Evaluating the Efficacy and Safety of Standard of Care +/- Continuous Bevacizumab Treatment Beyond Progression of Disease (PD) in Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) After First Line Treatment With Bevacizumab Plus a Platinum Doublet-containing Chemotherapy",COMPLETED,Non-Squamous Non-Small Cell Lung Cancer,Drug: Bevacizumab|Drug: Docetaxel,2011-05-10,2017-09-18,PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT03811015,Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer,"A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC",SUSPENDED,Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8|Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8|Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8|Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8,Procedure: Biospecimen Collection|Procedure: Biospecimen Collection|Procedure: Biospecimen Collection,2019-01-22,2024-09-26,PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT03565185,Comparison Of Two Different Type Robot Assisted Gait Training In Rehabilitation Of Stroke,Comparison Of An Exoskeleton Device With An End-Effector Device In Robotic Gait Assesment Of Stroke,COMPLETED,Stroke,Other: robot-assisted gait training|Other: robot-assisted gait training|Other: placebo,2018-06-21,2020-05-13,NA,INTERVENTIONAL,ALL,18 Years,
NCT04994132,A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma,"A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy With Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) Plus VINO-CPO Maintenance in Patients With High Risk Rhabdomyosarcoma (HR-RMS)",ACTIVE_NOT_RECRUITING,Alveolar Rhabdomyosarcoma|Botryoid-Type Embryonal Rhabdomyosarcoma|Embryonal Rhabdomyosarcoma|Metastatic Embryonal Rhabdomyosarcoma|Metastatic Rhabdomyosarcoma|Solid Alveolar Rhabdomyosarcoma|Spindle Cell Rhabdomyosarcoma|Spindle Cell/Sclerosing Rhabdomyosarcoma,Procedure: Biospecimen Collection|Procedure: Biospecimen Collection,2021-08-06,2024-09-23,PHASE3,INTERVENTIONAL,ALL,,50 Years
NCT03468985,"Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer","A Randomized Phase II Trial of Nivolumab, Cabozantinib Plus Nivolumab, and Cabozantinib Plus Nivolumab Plus Ipilimumab in Patients With Previously Treated Non-Squamous NSCLC",COMPLETED,Metastatic Lung Non-Squamous Non-Small Cell Carcinoma|Recurrent Lung Non-Squamous Non-Small Cell Carcinoma|Stage IV Lung Non-Small Cell Cancer AJCC v7,Biological: Nivolumab|Drug: Cabozantinib|Drug: Cabozantinib|Drug: Cabozantinib,2018-03-19,2023-10-17,PHASE2,INTERVENTIONAL,ALL,18 Years,
NCT03199885,Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer,"A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer",ACTIVE_NOT_RECRUITING,Metastatic Breast Adenocarcinoma|Metastatic HER2-Positive Breast Carcinoma|Recurrent Breast Adenocarcinoma|Recurrent HER2-Positive Breast Carcinoma|Stage III Breast Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7|Unresectable Breast Carcinoma|Unresectable HER2-Positive Breast Carcinoma,Drug: Atezolizumab|Procedure: Biopsy,2017-06-27,2024-09-26,PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT02883049,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations,A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations,ACTIVE_NOT_RECRUITING,"B Acute Lymphoblastic Leukemia|B Acute Lymphoblastic Leukemia, BCR-ABL1-Like|Central Nervous System Leukemia|Testicular Leukemia",Drug: Cyclophosphamide|Drug: Cyclophosphamide|Drug: Cyclophosphamide|Drug: Cyclophosphamide|Drug: Cyclophosphamide|Drug: Cyclophosphamide|Drug: Clofarabine|Drug: Cyclophosphamide,2016-08-30,2024-08-21,PHASE3,INTERVENTIONAL,ALL,1 Year,31 Years
NCT03811002,"Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)",Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab,ACTIVE_NOT_RECRUITING,Limited Stage Lung Small Cell Carcinoma|Stage I Lung Cancer AJCC v8|Stage II Lung Cancer AJCC v8|Stage III Lung Cancer AJCC v8,Radiation: 3-Dimensional Conformal Radiation Therapy|Radiation: 3-Dimensional Conformal Radiation Therapy,2019-01-22,2024-09-25,PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT00498602,Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease,"Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimers Disease",COMPLETED,Alzheimer Disease,Biological: ACC-001 + QS-21|Biological: QS-21|Other: Diluent: Phosphate Buffered Saline|Biological: ACC-001,2007-07-10,2016-01-01,PHASE2,INTERVENTIONAL,ALL,50 Years,85 Years
NCT01196390,"Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer",A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma,COMPLETED,Esophageal Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma|Stage IB Esophageal Cancer AJCC v7|Stage IIA Esophageal Cancer AJCC v7|Stage IIB Esophageal Cancer AJCC v7|Stage IIIA Esophageal Cancer AJCC v7|Stage IIIB Esophageal Cancer AJCC v7,Drug: Carboplatin|Drug: Carboplatin,2010-09-08,2023-09-07,PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT02933502,Safety Study in Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical Product,"An Open-label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS 1538b Topical Product Applied Once-daily in Patients With Moderate to Severe Scalp Psoriasis",COMPLETED,Scalp Psoriasis,Drug: DSXS topical product,2016-10-14,2018-12-10,PHASE2,INTERVENTIONAL,ALL,12 Years,17 Years
NCT03597490,Multimodal Physical Therapy With Exercise in Partial-thickness Rotator Cuff Tears,Effectiveness of Multimodal Physical Therapy Combined With Exercise in Partial-thickness Rotator Cuff Tears: a Prospective Observational Study,TERMINATED,Partial Thickness Rotator Cuff Tear,Combination Product: Multimodal physical therapy with exercise,2018-07-24,2019-05-20,,OBSERVATIONAL,ALL,50 Years,
NCT04068103,Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery,Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA),ACTIVE_NOT_RECRUITING,Colon Adenocarcinoma|Stage IIA Colon Cancer AJCC v8,Other: Patient Observation|Drug: Capecitabine,2019-08-28,2024-09-04,PHASE2|PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT02194738,Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial),Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST),RECRUITING,Stage IB Lung Non-Small Cell Carcinoma AJCC v7|Stage II Lung Non-Small Cell Cancer AJCC v7|Stage IIA Lung Cancer AJCC v8|Stage IIB Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIA Lung Non-Small Cell Cancer AJCC v7|Stage IIIB Lung Cancer AJCC v8,Other: Cytology Specimen Collection Procedure|Other: Cytology Specimen Collection Procedure|Other: Cytology Specimen Collection Procedure|Other: Clinical Observation|Drug: Carboplatin|Drug: Carboplatin|Drug: Carboplatin|Drug: Crizotinib|Other: Clinical Observation|Procedure: Biospecimen Collection|Procedure: Biospecimen Collection,2014-07-18,2024-09-27,NA,INTERVENTIONAL,ALL,18 Years,
NCT03793179,Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer,"EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis",ACTIVE_NOT_RECRUITING,Lung Non-Squamous Non-Small Cell Carcinoma|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8|Stage IV Lung Cancer AJCC v8,Procedure: Biospecimen Collection|Procedure: Biospecimen Collection|Procedure: Biospecimen Collection,2019-01-04,2024-09-26,PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT03304379,Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip,"Phase 3 Randomized, Double-Blind, Multi-Dose, Placebo And NSAID Controlled Study To Evaluate The Efficacy And Safety Of Fasinumab In Patients With Pain Due To Osteoarthritis Of The Knee Or Hip",COMPLETED,"Osteoarthritis, Knee|Osteoarthritis, Hip",Drug: Fasinumab|Other: Diclofenac|Other: Celecoxib|Drug: Matching placebo,2017-10-09,2023-02-24,PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT05050084,Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score,Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE),RECRUITING,Prostate Adenocarcinoma,Radiation: Radiation Therapy|Drug: Bicalutamide|Drug: Bicalutamide|Drug: Buserelin,2021-09-20,2024-02-07,PHASE3,INTERVENTIONAL,MALE,18 Years,
NCT02724579,Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma,A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients,ACTIVE_NOT_RECRUITING,Medulloblastoma,Drug: Cisplatin,2016-03-31,2024-09-19,PHASE2,INTERVENTIONAL,ALL,3 Years,21 Years
NCT00769379,Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy,A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently With Radiation Therapy and Radiation Therapy Alone for Women With HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy,ACTIVE_NOT_RECRUITING,Breast Ductal Carcinoma In Situ,Other: Laboratory Biomarker Analysis|Other: Laboratory Biomarker Analysis,2008-10-09,2024-09-26,PHASE3,INTERVENTIONAL,FEMALE,18 Years,
NCT05343364,"A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Vonoprazan in Adolescents With Symptomatic Gastroesophageal Reflux Disease","A Phase 1, Randomized, Parallel-group, Open-label, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Vonoprazan (10 or 20 mg Once Daily) in Adolescents With Symptomatic Gastroesophageal Reflux Disease",COMPLETED,Gastroesophageal Reflux,Drug: Vonoprazan|Drug: Vonoprazan,2022-04-25,2024-06-03,PHASE1,INTERVENTIONAL,ALL,12 Years,17 Years
NCT01096290,Comparison of Lubiprostone and Placebo for the Relief of Constipation From Constipating Medications,Comparison of Lubiprostone and Placebo for the Relief of Constipation From Constipating Medications,TERMINATED,Constipation,Drug: lubiprostone|Drug: Matched placebo,2010-03-31,2020-11-20,PHASE4,INTERVENTIONAL,ALL,19 Years,
NCT04010279,Can we Improve Preoxygenation by Using Adjustable Pressure Limiting Valve (APL) ?,The Effects of Setting Adjustable Pressure Limiting Valve (APL) to 5 cmH2O on Preoxygenation,COMPLETED,Preoxygenation,"Procedure: preoxygenation with 100% O2, fresh gas flow rate 12 L/minute|Procedure: preoxygenation with 100% O2, fresh gas flow rate 12 L/minute|Procedure: preoxygenation with 100% O2, fresh gas flow rate 12 L/minute",2019-07-08,2019-11-13,NA,INTERVENTIONAL,ALL,18 Years,40 Years
NCT05677490,"mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma",Randomized Phase III Trial of mFOLFIRINOX vs. FOLFOX With Nivolumab for First-Line Treatment of Metastatic HER2- Gastroesophageal Adenocarcinoma,RECRUITING,Advanced Esophageal Adenocarcinoma|Advanced Gastric Adenocarcinoma|Advanced Gastroesophageal Junction Adenocarcinoma|Clinical Stage III Esophageal Adenocarcinoma AJCC v8|Clinical Stage III Gastric Cancer AJCC v8|Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IV Esophageal Adenocarcinoma AJCC v8|Clinical Stage IV Gastric Cancer AJCC v8|Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Metastatic Esophageal Adenocarcinoma|Metastatic Gastric Adenocarcinoma|Metastatic Gastroesophageal Junction Adenocarcinoma|Unresectable Esophageal Adenocarcinoma|Unresectable Gastric Adenocarcinoma|Unresectable Gastroesophageal Junction Adenocarcinoma,Drug: Fluorouracil|Drug: Fluorouracil,2023-01-10,2023-08-31,PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT02635009,Whole-Brain Radiation Therapy With or Without Hippocampal Avoidance in Limited Stage or Extensive Stage Small Cell Lung Cancer,Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer,ACTIVE_NOT_RECRUITING,Extensive Stage Small Cell Lung Carcinoma|Limited Stage Small Cell Lung Carcinoma,Radiation: Three-Dimensional Conformal Radiation Therapy|Radiation: Intensity-Modulated Radiation Therapy,2015-12-18,2024-07-17,PHASE2|PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT04681456,Skin Cancer Oncology Radiation Evidence Registry,Skin Cancer Oncology Radiation Evidence Registry,TERMINATED,Non-melanoma Skin Cancer,,2020-12-23,2021-05-14,,OBSERVATIONAL,ALL,18 Years,120 Years
NCT04435756,A Study of miRNA 371 in Patients With Germ Cell Tumors,A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients With Newly Diagnosed Germ Cell Tumors,RECRUITING,Germ Cell Tumor|Metachronous Malignant Neoplasm|Seminoma|Stage I Testicular Cancer AJCC v8|Stage IA Testicular Cancer AJCC v8|Stage IB Testicular Cancer AJCC v8|Stage IS Testicular Cancer AJCC v8,Other: Biomarker Analysis,2020-06-17,2023-12-12,,OBSERVATIONAL,ALL,18 Years,
NCT02837237,"Safety, Tolerability, and Pharmacokinetics of KBP-5074 Following Oral Administration in Chronic Kidney Disease","A Phase 1, Open-Label Study in Hemodialysis and Non-Hemodialysis Patients With Severe Chronic Kidney Disease to Evaluate the Safety, Tolerability, and Pharmacokinetics of KBP-5074 Following Oral Administration",COMPLETED,Chronic Kidney Disease,Drug: KBP-5074,2016-07-19,2024-03-15,PHASE1,INTERVENTIONAL,ALL,18 Years,75 Years
NCT04459715,"A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)","A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)",ACTIVE_NOT_RECRUITING,Squamous Cell Carcinoma of the Head and Neck,Drug: Xevinapant (Debio 1143)|Drug: Cisplatin,2020-07-07,2024-06-13,PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT00103285,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,Standard Risk B-precursor Acute Lymphoblastic Leukemia (ALL),COMPLETED,Acute Lymphoblastic Leukemia|Childhood B Acute Lymphoblastic Leukemia,Drug: Cytarabine|Drug: Cyclophosphamide|Radiation: 3-Dimensional Conformal Radiation Therapy|Radiation: 3-Dimensional Conformal Radiation Therapy|Radiation: 3-Dimensional Conformal Radiation Therapy|Radiation: 3-Dimensional Conformal Radiation Therapy|Radiation: 3-Dimensional Conformal Radiation Therapy|Radiation: 3-Dimensional Conformal Radiation Therapy,2005-02-08,2021-06-14,PHASE3,INTERVENTIONAL,ALL,1 Year,9 Years
NCT03959085,"Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy","A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy",RECRUITING,B Acute Lymphoblastic Leukemia|B Lymphoblastic Lymphoma|Central Nervous System Leukemia|Mixed Phenotype Acute Leukemia|Testicular Leukemia,Procedure: Biospecimen Collection|Procedure: Biospecimen Collection|Procedure: Biospecimen Collection|Procedure: Biospecimen Collection|Procedure: Biospecimen Collection,2019-05-22,2024-09-23,PHASE3,INTERVENTIONAL,ALL,1 Year,25 Years
NCT04342637,COVID-19 Endoscopy Survey,Gastrointestinal Endoscopy in the Era of COVID-19: a Multinational Survey,COMPLETED,COVID-19,Other: Practice details,2020-04-13,2020-05-20,,OBSERVATIONAL,ALL,30 Years,70 Years
NCT03228537,"Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma",A Feasibility Trial of Neoadjuvant Cisplatin-Pemetrexed With Atezolizumab in Combination and in Maintenance for Resectable Malignant Pleural Mesothelioma,ACTIVE_NOT_RECRUITING,Biphasic Mesothelioma|Epithelioid Mesothelioma|Stage I Pleural Malignant Mesothelioma AJCC v7|Stage IA Pleural Malignant Mesothelioma AJCC v7|Stage IB Pleural Malignant Mesothelioma AJCC v7|Stage II Pleural Malignant Mesothelioma AJCC v7|Stage III Pleural Malignant Mesothelioma AJCC v7,Drug: Atezolizumab,2017-07-25,2024-07-26,PHASE1,INTERVENTIONAL,ALL,18 Years,
NCT04340115,Study To Assess Frequency Of Serious Infections In Clinical Practice In Japan For Adult Participants With Rheumatoid Arthritis Receiving Oral RINVOQ Tablets,Special Drug Use - Results Survey Of Evaluating Safety And Effectiveness Of RINVOQ In Patients With Rheumatoid Arthritis,RECRUITING,Rheumatoid Arthritis (RA),,2020-04-09,2024-08-19,,OBSERVATIONAL,ALL,15 Years,
NCT01272037,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer","A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer",ACTIVE_NOT_RECRUITING,Breast Ductal Carcinoma In Situ|Invasive Breast Carcinoma|Multicentric Breast Carcinoma|Multifocal Breast Carcinoma|Synchronous Bilateral Breast Carcinoma,Drug: Anastrozole|Drug: Anastrozole,2011-01-07,2024-09-26,PHASE3,INTERVENTIONAL,FEMALE,18 Years,
NCT00072709,Study Evaluating TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis (ALS),"A Randomized, Double-Blind, Placebo-Controlled, Stratified, Parallel-Group, Multicenter, Dose-Ranging Study Evaluating Four Oral Doses of TCH346 (1.0, 2.5, 7.5 and 15 mg) Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis",COMPLETED,Amyotrophic Lateral Sclerosis,,2003-11-11,2011-11-24,PHASE2,INTERVENTIONAL,ALL,21 Years,80 Years
NCT02003209,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer","A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients With Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated With Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) With or Without Estrogen Deprivation",ACTIVE_NOT_RECRUITING,HER2-Positive Breast Carcinoma|Hormone Receptor-Positive Breast Carcinoma|Stage IB Breast Cancer AJCC v7|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7,Drug: Carboplatin|Drug: Aromatase Inhibition Therapy,2013-12-06,2024-09-26,PHASE3,INTERVENTIONAL,FEMALE,18 Years,
NCT05794906,A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies,"A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Darolutamide Plus Androgen Deprivation Therapy (ADT) Compared With Placebo Plus ADT in Patients With High-risk Biochemical Recurrence (BCR) of Prostate Cancer",RECRUITING,Biochemically Recurrent Prostate Cancer,"Drug: Darolutamide (BAY1841788, Nubeqa)|Other: Placebo matching darolutamide",2023-04-03,2024-09-19,PHASE3,INTERVENTIONAL,MALE,18 Years,
NCT06118099,Proof-of-concept Study Evaluating Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa,"A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Proof-of-concept Study Assessing the Efficacy and Safety of Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa",RECRUITING,Hidradenitis,Drug: Amlitelimab|Drug: Placebo,2023-11-07,2024-09-19,PHASE2,INTERVENTIONAL,ALL,18 Years,70 Years
NCT04546399,A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL),"A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse",SUSPENDED,Down Syndrome|Recurrent B Acute Lymphoblastic Leukemia,Biological: Blinatumomab|Biological: Blinatumomab|Biological: Blinatumomab|Biological: Blinatumomab|Biological: Blinatumomab|Radiation: 3-Dimensional Conformal Radiation Therapy|Radiation: 3-Dimensional Conformal Radiation Therapy,2020-09-14,2024-09-24,PHASE2,INTERVENTIONAL,ALL,1 Year,30 Years
NCT02324400,Pilot Study for the Evaluation of the Safety and Performance of the RenaSense System in Hospitalized Acute Decompensated Heart Failure Patients,,UNKNOWN,"Heart Decompensation|Heart Failure, Congestive|Renal Insufficiency",Device: RenaSense Stimulation|Device: RenaSense Sham Control,2014-12-24,2014-12-24,PHASE1|PHASE2,INTERVENTIONAL,FEMALE,18 Years,85 Years
NCT00588770,Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma,A Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer,ACTIVE_NOT_RECRUITING,Neck Squamous Cell Carcinoma of Unknown Primary|Recurrent Hypopharyngeal Squamous Cell Carcinoma|Recurrent Laryngeal Squamous Cell Carcinoma|Recurrent Laryngeal Verrucous Carcinoma|Recurrent Lip and Oral Cavity Squamous Cell Carcinoma|Recurrent Neck Squamous Cell Carcinoma of Unknown Primary|Recurrent Oral Cavity Verrucous Carcinoma|Recurrent Oropharyngeal Squamous Cell Carcinoma|Recurrent Salivary Gland Carcinoma|Recurrent Sinonasal Squamous Cell Carcinoma|Salivary Gland Squamous Cell Carcinoma|Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7|Stage IV Major Salivary Gland Cancer AJCC v7|Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7|Stage IVA Laryngeal Verrucous Carcinoma AJCC v7|Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7|Stage IVA Major Salivary Gland Cancer AJCC v7|Stage IVA Oral Cavity Cancer AJCC v6 and v7|Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7|Stage IVA Sinonasal Squamous Cell Carcinoma AJCC v7|Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7|Stage IVB Laryngeal Verrucous Carcinoma AJCC v7|Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7|Stage IVB Major Salivary Gland Cancer AJCC v7|Stage IVB Oral Cavity Cancer AJCC v6 and v7|Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7|Stage IVB Sinonasal Squamous Cell Carcinoma AJCC v7|Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7|Stage IVC Laryngeal Verrucous Carcinoma AJCC v7|Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7|Stage IVC Major Salivary Gland Cancer AJCC v7|Stage IVC Oral Cavity Cancer AJCC v6 and v7|Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7|Stage IVC Sinonasal Squamous Cell Carcinoma AJCC v7|Tongue Carcinoma,Drug: Cisplatin|Biological: Bevacizumab|Drug: Carboplatin|Biological: Bevacizumab|Drug: Cisplatin|Biological: Bevacizumab|Drug: Carboplatin|Biological: Bevacizumab,2008-01-09,2024-09-27,PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT04137107,Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer,"Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study",ACTIVE_NOT_RECRUITING,Stage II Colorectal Cancer AJCC v8|Stage III Colorectal Cancer AJCC v8,Drug: Oxaliplatin|Drug: Oxaliplatin|Drug: Oxaliplatin|Drug: Oxaliplatin|Drug: Oxaliplatin,2019-10-23,2024-07-31,PHASE2|PHASE3,INTERVENTIONAL,ALL,25 Years,
NCT02601209,Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma,A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) VS. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma,TERMINATED,High Grade Sarcoma|Metastatic Leiomyosarcoma|Metastatic Malignant Peripheral Nerve Sheath Tumor|Metastatic Synovial Sarcoma|Metastatic Undifferentiated Pleomorphic Sarcoma|Metastatic Unresectable Sarcoma|Myxofibrosarcoma|Recurrent Leiomyosarcoma|Recurrent Malignant Peripheral Nerve Sheath Tumor|Recurrent Synovial Sarcoma|Recurrent Undifferentiated Pleomorphic Sarcoma|Stage III Uterine Corpus Leiomyosarcoma AJCC v8|Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8|Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8|Stage IIIC Uterine Corpus Leiomyosarcoma AJCC v8|Stage IV Uterine Corpus Leiomyosarcoma AJCC v8|Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8|Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8|Unresectable Leiomyosarcoma,Drug: Sapanisertib|Drug: Pazopanib,2015-11-10,2022-08-23,PHASE1|PHASE2,INTERVENTIONAL,ALL,18 Years,
NCT04251052,A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer,A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk],RECRUITING,Ovarian Carcinoma,Procedure: Bilateral Salpingectomy|Procedure: Bilateral Salpingectomy with Oophorectomy,2020-01-31,2024-09-19,NA,INTERVENTIONAL,FEMALE,35 Years,50 Years
NCT05832151,A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Diabetic Gastroparesis",RECRUITING,Diabetic Gastroparesis,Drug: CIN-102 Dose 1|Drug: CIN-102 Dose 2|Drug: Placebo,2023-04-27,2024-09-05,PHASE2,INTERVENTIONAL,ALL,18 Years,
NCT02101853,Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia,Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL),ACTIVE_NOT_RECRUITING,Recurrent B Acute Lymphoblastic Leukemia,Procedure: Allogeneic Hematopoietic Stem Cell Transplantation|Procedure: Allogeneic Hematopoietic Stem Cell Transplantation|Drug: Asparaginase|Biological: Blinatumomab,2014-04-02,2024-07-24,PHASE3,INTERVENTIONAL,ALL,1 Year,31 Years
NCT04486053,Long-term Results of Pediatric Flexor Tendon Injuries,Effect of Hand Dominance on Functional Outcomes in Pediatric Patients With Flexor Tendon Injuries,COMPLETED,Hand Injuries|Flexor Tendon Injury,Other: Screening,2020-07-24,2021-03-17,,OBSERVATIONAL,ALL,6 Years,18 Years
NCT00008554,Comparison of GW433908 and Nelfinavir in HIV Patients Who Have Not Had Antiretroviral Therapy,"A Phase III, Randomised, Multicenter, Parallel, Open-Label Study to Compare the Efficacy, Safety, and Tolerability of GW433908 (1400 Mg Bid) and Nelfinavir (1250 Mg Bid) Over 48 Weeks in Antiretroviral Therapy Naive HIV-1 Infected Adults",UNKNOWN,HIV Infections,,2001-08-31,2005-06-24,PHASE3,INTERVENTIONAL,ALL,13 Years,
NCT04392154,Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin),A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin),ACTIVE_NOT_RECRUITING,Atopic Dermatitis,Biological: Lebrikizumab|Biological: Lebrikizumab|Biological: Lebrikizumab|Biological: Lebrikizumab|Biological: Lebrikizumab|Biological: Lebrikizumab|Biological: Lebrikizumab,2020-05-18,2024-09-05,PHASE3,INTERVENTIONAL,ALL,12 Years,
NCT05739383,A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.,"A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT)",RECRUITING,Primary Prevention of Atherosclerotic Cardiovascular Disease,Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL|Drug: Placebo in 1.5ml,2023-02-22,2024-08-06,PHASE3,INTERVENTIONAL,ALL,40 Years,79 Years
NCT04283097,"Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects","A Phase 1, Multicenter, Open-label, Multiple-ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of KPG-818 in Subjects With Hematological Malignancies",RECRUITING,Hematological Malignancies,Drug: KPG-818,2020-02-25,2024-03-29,PHASE1,INTERVENTIONAL,ALL,18 Years,
NCT00408005,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma,"Intensified Methotrexate, Nelarabine (Compound 506U78) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL) or T-cell Lymphoblastic Lymphoma",ACTIVE_NOT_RECRUITING,T Acute Lymphoblastic Leukemia|T Lymphoblastic Lymphoma,Drug: Cytarabine|Drug: Cyclophosphamide|Drug: Cyclophosphamide|Drug: Cyclophosphamide|Other: Laboratory Biomarker Analysis|Drug: Leucovorin Calcium|Drug: Cyclophosphamide|Drug: Cyclophosphamide|Drug: Asparaginase|Drug: Mercaptopurine|Drug: Cyclophosphamide|Drug: Cyclophosphamide|Other: Laboratory Biomarker Analysis|Drug: Methotrexate|Drug: Cyclophosphamide|Other: Laboratory Biomarker Analysis|Drug: Mercaptopurine,2006-12-05,2024-08-06,PHASE3,INTERVENTIONAL,ALL,1 Year,30 Years
NCT00959283,Study of Blood Samples From Newborns With Down Syndrome,Biology Study of Transient Myeloproliferative Disorder (TMD) in Children With Down Syndrome (DS),COMPLETED,Myeloid Proliferations Associated With Down Syndrome,Other: Diagnostic Laboratory Biomarker Analysis,2009-08-14,2023-10-03,,OBSERVATIONAL,ALL,,90 Days
NCT02506153,"Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery",A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma,ACTIVE_NOT_RECRUITING,Clinical Stage III Cutaneous Melanoma AJCC v8|Clinical Stage IV Cutaneous Melanoma AJCC v8|Metastatic Cutaneous Melanoma|Metastatic Mucosal Melanoma|Metastatic Non-Cutaneous Melanoma|Non-Cutaneous Melanoma|Recurrent Cutaneous Melanoma|Recurrent Mucosal Melanoma|Recurrent Non-Cutaneous Melanoma,Procedure: Biospecimen Collection|Procedure: Biospecimen Collection,2015-07-23,2024-09-25,PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT04242953,"Study to Determine Safety, Tolerability and Pharmacokinetics, of SCO-120 in Healthy Male and Post-menopausal Female Subjects","A Multipart Phase 1 Study to Determine Safety, Tolerability and Pharmacokinetics of SCO-120 in Healthy Male and Post-menopausal Female Subjects",COMPLETED,Healthy Volunteer Study,Drug: SCO-120|Drug: matching placebo,2020-01-27,2023-04-21,PHASE1,INTERVENTIONAL,ALL,18 Years,99 Years
NCT04533451,Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer,Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated With First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist's/Patient's Choice),ACTIVE_NOT_RECRUITING,Metastatic Lung Adenocarcinoma|Metastatic Lung Non-Small Cell Carcinoma|Recurrent Lung Adenocarcinoma|Recurrent Lung Non-Small Cell Carcinoma|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8,Drug: Pembrolizumab|Drug: Pembrolizumab,2020-08-31,2024-04-09,PHASE2,INTERVENTIONAL,ALL,70 Years,
NCT04698187,CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma,"A Multicenter, Open-label, Phase 2 Study of Intratumoral CMP-001 in Combination With Intravenous Nivolumab in Subjects With Refractory Unresectable or Metastatic Melanoma",COMPLETED,Melanoma|Advanced Melanoma|Metastatic Melanoma|Unresectable Melanoma,Drug: CMP-001,2021-01-06,2024-02-23,PHASE2,INTERVENTIONAL,ALL,18 Years,
NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC),COMPLETED,Advanced Adult Hepatocellular Carcinoma|Recurrent Hepatocellular Carcinoma|Stage III Hepatocellular Carcinoma AJCC v7|Stage IIIA Hepatocellular Carcinoma AJCC v7|Stage IIIB Hepatocellular Carcinoma AJCC v7|Stage IIIC Hepatocellular Carcinoma AJCC v7|Stage IV Hepatocellular Carcinoma AJCC v7|Stage IVA Hepatocellular Carcinoma AJCC v7|Stage IVB Hepatocellular Carcinoma AJCC v7|Unresectable Hepatocellular Carcinoma,Drug: Doxorubicin Hydrochloride|Other: Laboratory Biomarker Analysis,2009-11-18,2022-08-04,PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT03150693,Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia,A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL,SUSPENDED,B Acute Lymphoblastic Leukemia,Drug: Allopurinol|Drug: Allopurinol,2017-05-12,2024-08-02,PHASE3,INTERVENTIONAL,ALL,18 Years,39 Years
NCT04387656,"NCI COVID-19 in Cancer Patients, NCCAPS Study",NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study,ACTIVE_NOT_RECRUITING,COVID-19 Infection|Hematopoietic and Lymphatic System Neoplasm|Malignant Solid Neoplasm|Metastatic Malignant Solid Neoplasm,Procedure: Biospecimen Collection,2020-05-14,2024-09-26,,OBSERVATIONAL,ALL,,
NCT05205356,VIGOR: Virtual Genome Center for Infant Health,VIGOR: Virtual Genome Center for Infant Health,RECRUITING,Genetics Disease|Genetics/Birth Defects|Genetic Predisposition to Disease,|,2022-01-25,2024-06-24,,OBSERVATIONAL,ALL,0 Days,99 Years
NCT05668637,Evaluation and Further Development of an Artificial Intelligence-based Algorithm for Clinical Decision Support,Retrospective Use of Patient Treatment Data for the Evaluation and Further Development of an Artificial Intelligence-based Algorithm for Clinical Decision Support in Invasive Mechanical Ventilation of Intensive Care Patients,RECRUITING,Invasive Mechanical Ventilation,,2022-12-30,2024-03-29,,OBSERVATIONAL,ALL,18 Years,
NCT01169337,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,ACTIVE_NOT_RECRUITING,Light Chain Deposition Disease|Smoldering Multiple Myeloma,Drug: Lenalidomide|Other: Clinical Observation,2010-07-26,2024-09-26,PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT04094688,Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer,Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS),ACTIVE_NOT_RECRUITING,Colorectal Adenocarcinoma,Drug: Bevacizumab|Drug: Bevacizumab,2019-09-19,2024-02-26,PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT04379609,Effects of Temporomandibular Disorder on Masticatory Efficiency,Masticatory Efficiency Before and After Muscle-Related Temporomandibular Disorder Treatment,COMPLETED,Temporomandibular Disorder,Other: Masticatory efficiency|Other: Masticatory efficiency,2020-05-07,2020-05-08,,OBSERVATIONAL,ALL,18 Years,
NCT02921256,"Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer",A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer,COMPLETED,Rectal Adenocarcinoma|Stage II Rectal Cancer AJCC v7|Stage III Rectal Cancer AJCC v7,Drug: Capecitabine|Drug: Capecitabine|Drug: Capecitabine,2016-10-03,2024-04-24,PHASE2,INTERVENTIONAL,ALL,18 Years,
NCT03563209,Assesment of Post-stroke Elbow Flexor Spasticity in Different Forearm Positions,Assesment of Post-stroke Elbow Flexor Spasticity in Response to Passive Stretch in Different Forearm Positions,COMPLETED,Post-stroke Elbow Spasticity,,2018-06-20,2019-05-22,,OBSERVATIONAL,ALL,18 Years,80 Years
NCT01368588,Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer,Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial,ACTIVE_NOT_RECRUITING,Prostate Cancer,Radiation: radiation therapy|Radiation: Whole-pelvic radiotherapy (WPRT),2011-06-08,2024-09-19,PHASE3,INTERVENTIONAL,MALE,18 Years,
NCT05622188,The Detection of Heat Stress by Assessing Individual Body Responses to Heat (Heat Strain) in Young and Healthy Non-athlete Participants,HEAT Stress Detection From Personally STandARdized Heat Strain Measurements - The HEATSTAR Pilot Trial,COMPLETED,Heat Stress,Other: Elevated ambient heat,2022-11-18,2023-02-13,,OBSERVATIONAL,ALL,18 Years,40 Years
NCT03907488,Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma,"A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age &gt;/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma",ACTIVE_NOT_RECRUITING,Ann Arbor Stage III Hodgkin Lymphoma|Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma|Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma|Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma|Ann Arbor Stage IV Hodgkin Lymphoma|Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma|Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma|Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma|Classic Hodgkin Lymphoma|Lymphocyte-Rich Classic Hodgkin Lymphoma,Procedure: Biospecimen Collection|Procedure: Biospecimen Collection,2019-04-09,2024-09-26,PHASE3,INTERVENTIONAL,ALL,12 Years,
NCT06030778,HEALTHCARE STUDENTS' ATTITUDES TOWARDS PATIENTS WITH CHRONIC PAIN,HEALTHCARE STUDENTS' ATTITUDES TOWARDS PATIENTS WITH CHRONIC PAIN: VALIDITY AND RELIABILITY STUDY,COMPLETED,Attitude to the Patient With Chronic Pain|Attitude of Health Care Students,,2023-09-11,2023-09-13,,OBSERVATIONAL,ALL,,
NCT01546571,"Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients","A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence",TERMINATED,Melanoma,Biological: POL-103A without API|Biological: POL-103A,2012-03-07,2021-12-08,PHASE3,INTERVENTIONAL,ALL,18 Years,80 Years
NCT05634811,Safety Study of a Vaccine to Help Protect Against Lyme Disease in Healthy Children,"A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLINDED TRIAL TO EVALUATE THE SAFETY OF A 6-VALENT OspA-BASED LYME DISEASE VACCINE (VLA15) IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE",ACTIVE_NOT_RECRUITING,Lyme Disease,Biological: VLA15|Other: Normal Saline,2022-12-02,2024-05-22,PHASE3,INTERVENTIONAL,ALL,5 Years,17 Years
NCT02717611,A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy,A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy,ACTIVE_NOT_RECRUITING,Chronic Lymphocytic Leukemia,Drug: ACP-196 (acalabrutinib),2016-03-24,2024-08-01,PHASE2,INTERVENTIONAL,ALL,18 Years,
NCT05046678,miRNAs in Periodontal Disease,Effects of Smoking on Saliva MicroRNAs Before and After Non-Surgical Periodontal Therapy in Patients With Periodontal Disease,COMPLETED,Periodontal Diseases|Periodontitis|Gingivitis,Diagnostic Test: Smokers with periodontally healthy|Diagnostic Test: Control|Diagnostic Test: Control|Diagnostic Test: Control|Diagnostic Test: Control|Diagnostic Test: Control,2021-09-16,2021-09-16,,OBSERVATIONAL,ALL,25 Years,55 Years
NCT04310007,"Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer",A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients With Previously Treated Non-Squamous NSCLC,ACTIVE_NOT_RECRUITING,Metastatic Lung Non-Squamous Non-Small Cell Carcinoma|Recurrent Lung Non-Squamous Non-Small Cell Carcinoma|Stage IV Lung Cancer AJCC v8,Procedure: Biospecimen Collection|Procedure: Biospecimen Collection|Procedure: Biospecimen Collection|Procedure: Biospecimen Collection,2020-03-17,2024-09-26,PHASE2,INTERVENTIONAL,ALL,18 Years,
NCT05445778,"Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA)","Randomized, Multicenter, Open-label, Phase 3 Study of Mirvetuximab Soravtansine in Combination With Bevacizumab Versus Bevacizumab Alone as Maintenance Therapy for Patients With FRα-high Recurrent Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Who Have Not Progressed After Second Line Platinum-based Chemotherapy Plus Bevacizumab (GLORIOSA)",RECRUITING,Ovarian Cancer|Peritoneal Cancer|Fallopian Tube Cancer,Drug: Mirvetuximab soravtansine plus Bevacizumab|Drug: Bevacizumab,2022-07-06,2024-09-23,PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT03723928,S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer,Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored With Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients With Metastatic Hormone Receptor Positive Breast Cancer,RECRUITING,Anatomic Stage IV Breast Cancer AJCC v8|Estrogen Receptor Positive|HER2/Neu Negative|Progesterone Receptor Positive|Prognostic Stage IV Breast Cancer AJCC v8|Elevated CA15-3 or CEA or CA27-29,Other: Usual care disease monitoring|Other: Serum Tumor Marker directed disease monitoring,2018-10-30,2024-04-04,NA,INTERVENTIONAL,ALL,18 Years,
NCT02339571,"A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma",Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma,RECRUITING,Stage III Cutaneous Melanoma AJCC v7|Stage IV Cutaneous Melanoma AJCC v6 and v7,Procedure: Biospecimen Collection|Procedure: Biospecimen Collection,2015-01-15,2024-09-26,PHASE2|PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT02839707,"Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer",ACTIVE_NOT_RECRUITING,Fallopian Tube High Grade Serous Adenocarcinoma|Ovarian High Grade Serous Adenocarcinoma|Ovarian Seromucinous Carcinoma|Primary Peritoneal High Grade Serous Adenocarcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Fallopian Tube Clear Cell Adenocarcinoma|Recurrent Fallopian Tube Endometrioid Adenocarcinoma|Recurrent Fallopian Tube Undifferentiated Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Ovarian Clear Cell Adenocarcinoma|Recurrent Ovarian Endometrioid Adenocarcinoma|Recurrent Ovarian Undifferentiated Carcinoma|Recurrent Platinum-Resistant Fallopian Tube Carcinoma|Recurrent Platinum-Resistant Ovarian Carcinoma|Recurrent Platinum-Resistant Primary Peritoneal Carcinoma|Recurrent Primary Peritoneal Carcinoma|Recurrent Primary Peritoneal Clear Cell Adenocarcinoma|Recurrent Primary Peritoneal Endometrioid Adenocarcinoma|Recurrent Primary Peritoneal Undifferentiated Carcinoma,Drug: Atezolizumab|Drug: Atezolizumab|Biological: Bevacizumab,2016-07-21,2023-11-08,PHASE2|PHASE3,INTERVENTIONAL,FEMALE,18 Years,
NCT02932878,"An Open Label, Safety Study to Assess the Potential for Adrenal Suppression","An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS Topical Product in Patients With Plaque Psoriasis",COMPLETED,Plaque Psoriasis,Drug: DSXS topical,2016-10-13,2018-12-06,PHASE2,INTERVENTIONAL,ALL,2 Years,18 Years
NCT05407207,Therapeutic Plantar Electrical Stimulation Intervention During Hemodialysis to Improve Balance and Mobility,Therapeutic Plantar Electrical Stimulation Intervention During Hemodialysis to Improve Balance and Mobility,RECRUITING,Diabetes Mellitus|Hemodialysis Complication|Cardiovascular Complication|Quality of Life,Device: Tennant Biomodulator ®|Device: Tennant Biomodulator ®,2022-06-07,2022-06-07,NA,INTERVENTIONAL,ALL,40 Years,
NCT05247528,Safety And Tolerability Of Subcutaneous MANP In Difficult To Control/Resistant Hypertensive Subjects,"A Phase 1B, Multiple Ascending Dose Trial Examining The Safety And Tolerability Of Subcutaneous MANP In Difficult To Control/Resistant Hypertensive Subjects",COMPLETED,Resistant Hypertension|Difficult to Control Hypertension,Drug: Placebo|Drug: MANP,2022-02-21,2022-11-29,PHASE1,INTERVENTIONAL,ALL,18 Years,80 Years
NCT03466411,A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease,"A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease",ACTIVE_NOT_RECRUITING,Crohn's Disease,Drug: Guselkumab Dose 1|Drug: Guselkumab Dose 2|Drug: Guselkumab Dose 4|Drug: Ustekinumab|Drug: Ustekinumab|Drug: Guselkumab|Drug: Ustekinumab|Drug: Ustekinumab,2018-03-15,2024-09-19,PHASE2|PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT00446511,"Extension Study to Assess Long Term Safety, Tolerability, and Efficacy of Valsartan and Enalapril Combined and Alone in Children With Hypertension","An Extension to Study Protocol CVAL489K2302 to Evaluate the Long Term Safety, Tolerability and Efficacy of Valsartan in Children 6 to 17 Years of Age With Hypertension, Versus Enalapril Treatment for 14 Weeks, or Combined With Enalapril Versus Enalapril for 66 Weeks in Chronic Kidney Disease Patients.",COMPLETED,Hypertension,Drug: Valsartan|Drug: Enalapril|Drug: Valsartan|Drug: Enalapril,2007-03-13,2011-07-12,PHASE3,INTERVENTIONAL,ALL,6 Years,17 Years
NCT03233711,Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer,A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer,ACTIVE_NOT_RECRUITING,Anal Basaloid Squamous Cell Carcinoma|Anal Canal Cloacogenic Carcinoma|Anal Margin Squamous Cell Carcinoma|Stage IIB Anal Cancer AJCC v8|Stage III Anal Cancer AJCC v8,Procedure: Biopsy|Procedure: Biospecimen Collection,2017-07-31,2024-09-26,PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT03331263,Single Dose CHG Pharmacokinetic Study,Single Dose Pharmacokinetic Study to Assess the Systemic Exposure of Chlorhexidine From ReadyPrep® CHG (2% Chlorhexidine Gluconate Cloth),COMPLETED,Surgical Skin Preparation,Drug: Chlorhexidine Gluconate|Drug: Chlorhexidine Gluconate|,2017-11-06,2023-12-15,PHASE1,INTERVENTIONAL,ALL,18 Years,60 Years
NCT02567435,Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma,"A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)",ACTIVE_NOT_RECRUITING,Alveolar Rhabdomyosarcoma|Botryoid-Type Embryonal Rhabdomyosarcoma|Embryonal Rhabdomyosarcoma|Rhabdomyosarcoma|Sclerosing Rhabdomyosarcoma|Spindle Cell Rhabdomyosarcoma,Drug: Cyclophosphamide|Drug: Cyclophosphamide|Drug: Cyclophosphamide,2015-10-05,2024-04-23,PHASE3,INTERVENTIONAL,ALL,,40 Years
NCT03765918,Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689),"A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)",ACTIVE_NOT_RECRUITING,Head and Neck Neoplasms,Biological: Pembrolizumab 200 mg|Radiation: Radiotherapy 60 Gray/day,2018-12-05,2024-04-16,PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT03555318,Intervention by a Cardiologist and Geriatrician in Elderly Patients After Admission Due to Heart Failure.,Randomized Clinical Trial: Assessment of a Multidisciplinary Intervention by a Cardiologist and Geriatrician After Hospital Admission Due to Heart Failure in Elderly Patients.,COMPLETED,Heart Failure,Other: Combined ambulatory visit|Other: Ambulatory visit,2018-06-13,2020-11-06,NA,INTERVENTIONAL,ALL,75 Years,
NCT00739596,Blood Pressure Lowering of Aliskiren Hydrochlorothiazide (HCTZ) Versus Amlodipine in Stage 2 Hypertension in African Americans,"An 8 Week Prospective, Multicenter, Randomized, Double-Blind, Active Control, Parallel Group Study to Evaluate the Efficacy and Safety of Aliskiren HCTZ Versus Amlodipine in African American Patients With Stage 2 Hypertension",COMPLETED,Hypertension,Drug: Aliskiren Hydrochlorothiazide (HCTZ): 8 weeks|Drug: Amlodipine: 8 weeks,2008-08-22,2016-10-27,PHASE4,INTERVENTIONAL,ALL,18 Years,
NCT04579224,Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer,"A Phase III Randomized Trial of Eribulin (NSC #707389) With Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy",RECRUITING,Metastatic Bladder Urothelial Carcinoma|Metastatic Renal Pelvis Urothelial Carcinoma|Metastatic Ureter Urothelial Carcinoma|Metastatic Urethral Urothelial Carcinoma|Metastatic Urothelial Carcinoma|Refractory Bladder Urothelial Carcinoma|Refractory Renal Pelvis Urothelial Carcinoma|Refractory Ureter Urothelial Carcinoma|Refractory Urethral Urothelial Carcinoma|Refractory Urothelial Carcinoma|Stage IV Bladder Cancer AJCC v8|Stage IV Renal Pelvis and Ureter Cancer AJCC v8|Stage IV Renal Pelvis Cancer AJCC v8|Stage IV Ureter Cancer AJCC v8|Stage IV Urethral Cancer AJCC v8|Stage IVA Bladder Cancer AJCC v8|Stage IVB Bladder Cancer AJCC v8,Procedure: Biospecimen Collection|Procedure: Biospecimen Collection|Procedure: Biospecimen Collection,2020-10-08,2024-09-26,PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT05009524,The Interactive Physical and Cognitive Exercise System (v3) for Mild Cognitive Impairment (MCI),The Interactive Physical and Cognitive Exercise System (iPACES v3) to Benefit Brain Health in Mild Cognitive Impairment (MCI): A Randomized Clinical Trial of Neuro-exergaming Pedal-to-play (iPACES) vs Pedal-while-play (PACE),UNKNOWN,MCI|Mild Cognitive Impairment|Alzheimer Disease|Dementia,Device: iPACES (interactive Physical and Cognitive Exercise System)|Device: PACE (Physical and Cognitive Exercise),2021-08-17,2021-11-22,NA,INTERVENTIONAL,ALL,50 Years,
NCT04699097,The Effect of Azithromycin Use on Conduction System of Heart in COVID-19 Positive Children,Azitromycin Use in COVID-19 Positive Pediatric Patients; Effect on Ventricle Repolarization,COMPLETED,Azithromycin Adverse Reaction|Covid19|Long QT Syndrome,Drug: Azithromycin,2021-01-07,2021-01-07,,OBSERVATIONAL,ALL,1 Year,18 Years
NCT03915405,KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer,"An Open-label, Phase 1 Study of KHK2455 in Combination With Avelumab in Adult Subjects With Locally Advanced or Metastatic Urothelial Carcinoma",TERMINATED,Urothelial Carcinoma,Drug: KHK2455,2019-04-16,2024-04-25,PHASE1,INTERVENTIONAL,ALL,18 Years,
NCT03712605,"Testing Pembrolizumab Versus Observation in Patients With Merkel Cell Carcinoma After Surgery, STAMP Trial","STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial",ACTIVE_NOT_RECRUITING,Pathologic Stage I Cutaneous Merkel Cell Carcinoma AJCC v8|Pathologic Stage II Cutaneous Merkel Cell Carcinoma AJCC v8|Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8,Procedure: Biospecimen Collection|Other: Best Practice,2018-10-19,2024-09-26,PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT00787605,Aliskiren HCTZ Compared to Amlodipine in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus,An 8-week Study to Evaluate the Efficacy and Safety of Aliskiren HCTZ (300/25 mg) Compared to Amlodipine (10 mg) in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus,COMPLETED,Hypertension|Diabetes Mellitus,Drug: Amlodipine|Drug: Hydrochlorothiazide (HCTZ),2008-11-07,2016-10-27,PHASE4,INTERVENTIONAL,ALL,18 Years,
NCT00336505,Study Comparing the Safety and Efficacy of Cethromycin to Clarithromycin for the Treatment of Community-Acquired Pneumonia (CAP),"A Double-Blinded, Randomized, Parallel Group, Multi-Center, Multi-National Comparative Study of the Safety and Efficacy of Cethromycin 300 mg QD to Clarithromycin (BIAXIN® Filmtab®) 250 mg BID for the Treatment of Community-Acquired Pneumonia in Adults",COMPLETED,Pneumonia,Drug: Clarithromycin|Drug: Cethromycin,2006-06-13,2010-02-26,PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT01524705,FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR),FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR,COMPLETED,Type 2 Diabetes,Drug: Insulin Glargine|Drug: Insulin Glargine,2012-02-02,2023-12-29,PHASE4,INTERVENTIONAL,ALL,40 Years,75 Years
NCT02228798,Perioperative Anticoagulant Use for Surgery Evaluation Study,"Perioperative Anticoagulant Use (Dabigatran, Rivaroxaban, or Apixaban) for Elective Surgery/Procedure Evaluation in Patients With Atrial Fibrillation (AF).",COMPLETED,Atrial Fibrillation,||,2014-08-29,2019-06-28,,OBSERVATIONAL,ALL,18 Years,
NCT05108298,Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials,Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials,RECRUITING,"Breast Cancer, NOS|CNS Primary Tumor, NOS|Cervical Cancer, NOS|Colorectal Cancer, NOS|Leukemia, NOS|Lymphoma, NOS|Miscellaneous Neoplasm, NOS|Non-Rhabdomyosarcoma Soft Tissue Sarcoma, NOS|Testicular Nonseminomatous Germ Cell Tumor, NOS|Thyroid Cancer, NOS|Melanoma|Bone Cancer, NOS",Other: Questionnaires|Other: Questionnaires,2021-11-04,2024-08-12,NA,INTERVENTIONAL,ALL,18 Years,39 Years
NCT05174598,A Clinical Trial to Evaluate Efficacy and Safety of Two Different Formulations of Topical Calcipotriol in Patients With Mild to Moderate Plaque Psoriasis,"A Phase III, Multicentre, Randomized, Observer Blind, Parallel Group, Three Arms, Controlled Clinical Trial to Evaluate the Efficacy and Safety of Topically Applied Calcipotriol/AKVANO 50 μg/g Cutaneous Solution Against Calcipotriol Ointment 50 Micrograms/g, Sandoz and Placebo in Patients With Mild to Moderate Plaque Psoriasis",COMPLETED,Mild to Moderate Plaque Psoriasis,"Drug: Calcipotriol/AKVANO, 50 μg/g cutaneous solution|Drug: Calcipotriol Ointment 50 micrograms/g|Other: Placebo",2022-01-03,2022-03-03,PHASE3,INTERVENTIONAL,ALL,18 Years,65 Years
NCT03544398,Comparison of an Exoskeleten With an End-effector for Assisted Gait Training in Spinal Cord Injury,Comparison of Exoskeleten Assisted Gait Training With End-effector Assisted Gait Training in Spinal Cord Injury,UNKNOWN,Spinal Cord Injuries,Other: robot assisted gait training|Other: robot assisted gait training|Other: robot assisted gait training,2018-06-01,2020-05-18,NA,INTERVENTIONAL,ALL,18 Years,80 Years
NCT03817398,Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia,Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP),ACTIVE_NOT_RECRUITING,"Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive",Procedure: Biospecimen Collection,2019-01-25,2024-09-19,PHASE2,INTERVENTIONAL,ALL,,25 Years
NCT04836598,Bikini Scarless Laparoscopic Cholecystectomy for Morbid Obesity as a Day Case.,Bikini Scarless Laparoscopic Cholecystectomy for Morbid Obesity as a Day Case.,UNKNOWN,"Cholecystitis, Chronic",Other: laparoscopic cholecystectomy|Other: laparoscopic cholecystectomy,2021-04-08,2021-04-08,NA,INTERVENTIONAL,ALL,17 Years,65 Years
NCT04510597,"Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial",Phase III Trial of Immunotherapy-Based Combination Therapy With or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial),RECRUITING,Metastatic Clear Cell Renal Cell Carcinoma|Metastatic Renal Cell Carcinoma|Stage IV Renal Cell Cancer AJCC v8,Procedure: Cytoreductive Nephrectomy|Procedure: Cytoreductive Nephrectomy,2020-08-12,2024-08-16,PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT03627897,ESP Block in Pediatric Patients for Postoperative Analgesia,"Erector Spinae Plane Block for Postoperative Analgesia in Pediatric Patients Undergoing Cardiac Surgery: A Double-Blind, Randomized, Controlled Study",COMPLETED,"Opioid Use|Pain, Postoperative|Quality of Life",Drug: Bupivacain|Drug: saline,2018-08-14,2022-02-01,PHASE4,INTERVENTIONAL,ALL,2 Years,10 Years
NCT00656097,A Randomized Phase II Trial to Compare the Safety and Neutralizing Activity of CL184 in Combination With Rabies Vaccine vs. HRIG or Placebo in Combination With Rabies Vaccine in Healthy Adult Subjects,"A Randomized, Single-blind, Controlled, Monocentric Phase II Trial to Compare the Safety and Neutralizing Activity of Simulated Rabies Post-exposure Prophylaxis With CL184 in Combination With Rabies Vaccine vs. HRIG or Placebo in Combination With Rabies Vaccine in Healthy Adult Subjects",COMPLETED,Rabies,Biological: CL184|Biological: HRIG|Biological: Placebo matching CL184,2008-04-10,2011-09-21,PHASE2,INTERVENTIONAL,ALL,19 Years,65 Years
NCT05052697,"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Influenza","A PHASE 1/2 RANDOMIZED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA IN HEALTHY INDIVIDUALS",COMPLETED,"Influenza, Human",Biological: mIRV|Biological: mIRV|Biological: mIRV|Biological: mIRV|Biological: mIRV|Biological: mIRV|Biological: mIRV|Biological: mIRV|Biological: bIRV AB|Biological: bIRV AB|Biological: bIRV AB|Biological: bIRV AB|Biological: mIRV|Biological: qIRV|Biological: mIRV|Biological: qIRV|Biological: QIV|Biological: QIV|Biological: QIV|Biological: QIV|Biological: QIV|Biological: qIRV|Biological: qIRV|Biological: qIRV|Biological: bIRV AA|Biological: QIV|Biological: qIRV|Biological: qIRV,2021-09-22,2024-03-12,PHASE1|PHASE2,INTERVENTIONAL,ALL,18 Years,85 Years
NCT02500797,Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery,Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Patients With Metastatic or Unresectable Sarcoma,COMPLETED,Locally Advanced Bone Sarcoma|Locally Advanced Dedifferentiated Liposarcoma|Locally Advanced Gastrointestinal Stromal Tumor|Locally Advanced Soft Tissue Sarcoma|Metastatic Bone Sarcoma|Metastatic Liposarcoma|Metastatic Soft Tissue Sarcoma|Metastatic Undifferentiated Pleomorphic Sarcoma|Metastatic Unresectable Sarcoma|Pleomorphic Liposarcoma|Stage III Bone Sarcoma AJCC v7|Stage III Soft Tissue Sarcoma AJCC v7|Stage IV Bone Sarcoma AJCC v7|Stage IV Soft Tissue Sarcoma AJCC v7|Stage IVA Bone Sarcoma AJCC v7|Stage IVB Bone Sarcoma AJCC v7|Unresectable Bone Sarcoma|Unresectable Dedifferentiated Liposarcoma|Unresectable Liposarcoma|Unresectable Malignant Gastrointestinal Stromal Tumor|Unresectable Soft Tissue Sarcoma,Other: Laboratory Biomarker Analysis|Biological: Ipilimumab,2015-07-17,2023-10-17,PHASE2,INTERVENTIONAL,ALL,18 Years,
NCT00425997,Efficacy of Valsartan/Hydrochlorothiazide Versus Amlodipine and Hydrochlorothiazide in Patients Hypertension,"A 10-week Multicenter,Forced-titration Study Using 24-hr ABPM to Evaluate the Efficacy of Valsartan/Hydrochlorothiazide (HCTZ) Treatment Regimen vs Conventional Treatment Regimen With Amlodipine and Hydrochlorothiazide (HCTZ) in Patients With Stage 2 Hypertension",COMPLETED,Hypertension,,2007-01-24,2011-06-08,PHASE4,INTERVENTIONAL,ALL,18 Years,
NCT04626297,A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA),"A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis",COMPLETED,Atopic Dermatitis,Drug: Lebrikizumab|Drug: Placebo,2020-11-12,2023-10-17,PHASE3,INTERVENTIONAL,ALL,18 Years,55 Years
NCT04092283,Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer,Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC,ACTIVE_NOT_RECRUITING,Recurrent Lung Non-Small Cell Carcinoma|Stage III Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8|Unresectable Lung Non-Small Cell Carcinoma,Drug: Carboplatin|Drug: Carboplatin,2019-09-17,2024-09-26,PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT04852887,"De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)","A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer",RECRUITING,Stage I Breast Cancer,"Other: Radiation and Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)|Drug: Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)",2021-04-21,2024-09-04,PHASE3,INTERVENTIONAL,ALL,50 Years,70 Years
NCT05097287,Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma,"A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma",RECRUITING,Asthma,Drug: Dupilumab|Drug: Placebo,2021-10-28,2024-09-19,PHASE4,INTERVENTIONAL,ALL,18 Years,
NCT02586233,"Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke","A Phase 1b/2, Multi-Center, Double-Blind (Principal Investigators and Study Subjects Blinded, Sponsor Unblinded), Placebo-Controlled, Randomized, Single-Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke",COMPLETED,Acute Ischemic Stroke|Thrombotic Disease,Drug: DS-1040b|Drug: Placebo,2015-10-26,2020-09-09,PHASE1|PHASE2,INTERVENTIONAL,ALL,18 Years,
NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer,ACTIVE_NOT_RECRUITING,HER2/Neu Positive|Progesterone Receptor Positive|Recurrent Breast Carcinoma|Stage IA Breast Cancer AJCC v7|Stage IB Breast Cancer AJCC v7|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7,Drug: Cyclophosphamide|Drug: Cyclophosphamide,2011-01-12,2024-09-26,PHASE3,INTERVENTIONAL,FEMALE,18 Years,
NCT01708954,Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer,"A Randomized Phase II Trial of Erlotinib, Cabozantinib, or Erlotinib Plus Cabozantinib as 2nd or 3rd Line Therapy in Patients With EGFR Wild-Type NSCLC",ACTIVE_NOT_RECRUITING,Recurrent Lung Non-Small Cell Carcinoma|Stage IV Lung Non-Small Cell Cancer AJCC v7,Drug: Erlotinib Hydrochloride|Drug: Cabozantinib S-malate|Drug: Cabozantinib S-malate|Drug: Cabozantinib S-malate,2012-10-17,2024-09-26,PHASE2,INTERVENTIONAL,ALL,18 Years,
NCT03267433,Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission,A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission,RECRUITING,CD20 Positive|Mantle Cell Lymphoma,Procedure: Autologous Hematopoietic Stem Cell Transplantation|Other: Laboratory Biomarker Analysis,2017-08-30,2024-08-09,PHASE3,INTERVENTIONAL,ALL,18 Years,70 Years
NCT04432454,Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation,"An Open-label, Multicenter Study Evaluating the Safety of Lasofoxifene in Combination With Abemaciclib for the Treatment of Pre- and Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer and Have an ESR1 Mutation ( ELAINEII )",ACTIVE_NOT_RECRUITING,Metastatic Breast Cancer,Drug: Lasofoxifene and abemaciclib (VERZENIO (R)).,2020-06-16,2024-08-16,PHASE2,INTERVENTIONAL,FEMALE,18 Years,
NCT05810454,iPACES v3 MCI NIA Protocol Copied for iPACES v4 PD NINDS,Neuro-exergaming for the Prevention and Remediation of Decline Due to Parkinson's Disease: Clinical Trial of the Interactive Physical and Cognitive Exercise System (iPACES-PD),NOT_YET_RECRUITING,Parkinson's Disease|PD|Mild Cognitive Impairment|MCI,Device: iPACES (interactive Physical and Cognitive Exercise System)|Device: PACE (Physical and Cognitive Exercise),2023-04-12,2023-04-12,NA,INTERVENTIONAL,ALL,50 Years,
NCT05685433,A Real World Study of eCoin for Urgency Urinary Incontinence: Post Approval Evaluation (RECIPE),A Real World Study of eCoin for Urgency Urinary Incontinence: Post Approval Evaluation (RECIPE),RECRUITING,"Overactive Bladder|Urge Incontinence|Incontinence, Urinary|Urinary Urge Incontinence",Device: eCoin Tibial Nerve Stimulation,2023-01-17,2024-04-09,NA,INTERVENTIONAL,ALL,18 Years,
NCT05058833,Prognostic Impact of Cardiac Diastolic Function and Coronary Microvascular Function,Prospective Registry Evaluating Prognostic Impact of Cardiac Diastolic Function and Coronary Microvascular Function,UNKNOWN,Ischemic Heart Disease|Microvascular Coronary Artery Disease|Diastolic Dysfunction|Heart Failure With Preserved Ejection Fraction,Diagnostic Test: Echocardiography|Diagnostic Test: Echocardiography,2021-09-28,2022-09-09,,OBSERVATIONAL,ALL,,
NCT02311933,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer","A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women With Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer",ACTIVE_NOT_RECRUITING,Recurrent Breast Carcinoma|Stage III Breast Cancer AJCC v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7,Drug: Endoxifen Hydrochloride|Other: Laboratory Biomarker Analysis,2014-12-09,2024-08-16,PHASE2,INTERVENTIONAL,FEMALE,18 Years,
NCT01835145,Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery,Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma,COMPLETED,Recurrent Uveal Melanoma|Stage III Uveal Melanoma AJCC v7|Stage IIIA Uveal Melanoma AJCC v7|Stage IIIB Uveal Melanoma AJCC v7|Stage IIIC Uveal Melanoma AJCC v7|Stage IV Uveal Melanoma AJCC v7,Drug: Cabozantinib S-malate|Drug: Dacarbazine,2013-04-18,2022-08-04,PHASE2,INTERVENTIONAL,ALL,18 Years,
NCT04385147,Advanced Endoscopy During COVID-19,The Status of Advanced Endoscopy in the Era of COVID-19: a Multicenter Study,COMPLETED,"Cholangitis, Secondary Biliary|Cholangiocarcinoma|Obstructive Jaundice|Pancreas Cancer|COVID-19|SARS-CoV-2",Other: Endoscopic management according to standard of care|Other: Endoscopic management according to standard of care,2020-05-12,2020-07-08,,OBSERVATIONAL,ALL,,
NCT00009061,Comparison of GW433908/Ritonavir to Nelfinavir When Used With Abacavir and Lamivudine in Patients That Have Not Taken Antiretroviral Drugs,"A Randomized, Open-Label, Two Arm Trial to Compare the Safety and Antiviral Efficacy of GW433908/Ritonavir QD to Nelfinavir BID When Used in Combination With Abacavir and Lamivudine for 48 Weeks in Antiretroviral Therapy Naive HIV-1 Infected Subjects",UNKNOWN,HIV Infections,,2001-08-31,2005-06-24,PHASE3,INTERVENTIONAL,ALL,13 Years,
NCT03382561,Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer,Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) Alone or in Combination With Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC),ACTIVE_NOT_RECRUITING,Extensive Stage Lung Small Cell Carcinoma|Recurrent Lung Small Cell Carcinoma,Drug: Carboplatin|Drug: Carboplatin,2017-12-26,2024-09-26,PHASE2,INTERVENTIONAL,ALL,18 Years,
NCT02306161,Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma,"Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma",ACTIVE_NOT_RECRUITING,Metastatic Ewing Sarcoma|Metastatic Malignant Neoplasm in the Bone|Metastatic Malignant Neoplasm in the Bone Marrow|Metastatic Malignant Neoplasm in the Lung|Metastatic Peripheral Primitive Neuroectodermal Tumor of Bone|Peripheral Primitive Neuroectodermal Tumor of Soft Tissues,Drug: Cyclophosphamide|Drug: Cyclophosphamide,2014-12-03,2024-09-05,PHASE3,INTERVENTIONAL,ALL,,50 Years
NCT02933528,Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS,"An Open-Label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS in Patients With Moderate to Severe Scalp Psoriasis",COMPLETED,Psoriasis,Drug: DSXS Topical product,2016-10-14,2018-12-06,PHASE2,INTERVENTIONAL,ALL,18 Years,
NCT00397345,TroVax Renal Immunotherapy Survival Trial,"Randomised,Double-blind,Placebo-controlled,Parallel Group Study TroVax, Added to First-line Standard of Care, Prolongs Survival of Patients With Locally Advanced or Metastatic Clear Cell Renal Adenocarcinoma.",COMPLETED,Clear Cell Renal Carcinoma,Biological: Trovax|Biological: Placebo,2006-11-09,2020-10-19,PHASE3,INTERVENTIONAL,ALL,18 Years,
NCT06467747,The Efficacy of Music on Perioperative Pain Management,The Efficacy of Intraoperative Music Stimulation on Perioperative Pain Management,RECRUITING,Perioperative Pain Management,Other: Music|Other: Mute|,2024-06-21,2024-08-09,NA,INTERVENTIONAL,ALL,20 Years,80 Years
NCT03007147,Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia,International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones,ACTIVE_NOT_RECRUITING,Acute Lymphoblastic Leukemia|B Acute Lymphoblastic Leukemia|Mixed Phenotype Acute Leukemia|T Acute Lymphoblastic Leukemia,Drug: Calaspargase Pegol|Drug: Calaspargase Pegol|Procedure: Allogeneic Hematopoietic Stem Cell Transplantation,2017-01-02,2024-09-23,PHASE3,INTERVENTIONAL,ALL,1 Year,21 Years
